An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
Tumors or cancer of the LUNG.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
Tumors or cancer of the LIVER.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)
Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.
A malignant epithelial tumor with a glandular organization.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
A cell line derived from cultured tumor cells.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)
A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)
A sarcoma characterized by the presence of small cells, cells measuring 9-14 micrometers with a faint or indistinct rim of cytoplasm and an oval-to-elongated nucleus with relatively dense chromatin. (From Segen, Dictionary of Modern Medicine, 1992)
Tumors or cancer of the THYROID GLAND.
Tumors or cancer of the human BREAST.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Tumors or cancer of the NASOPHARYNX.
DNA present in neoplastic tissue.
Tumors or cancer of the ESOPHAGUS.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Neuropeptide and gut hormone that helps regulate GASTRIC ACID secretion and motor function. Once released from nerves in the antrum of the STOMACH, the neuropeptide stimulates release of GASTRIN from the GASTRIN-SECRETING CELLS.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
Tumors or cancer of the URINARY BLADDER.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
A hydro-lyase that catalyzes the dehydration of 2-phosphoglycerate to form PHOSPHOENOLPYRUVATE. Several different isoforms of this enzyme exist, each with its own tissue specificity.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer of the BRONCHI.
In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products.
A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)
Antibodies produced by a single clone of cells.
Tumors or cancer of the SKIN.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Tumors or cancer of the MOUTH.
Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Tumors or cancer of the STOMACH.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
Tumors or cancer of the COLON.
A tetradecapeptide originally obtained from the skins of toads Bombina bombina and B. variegata. It is also an endogenous neurotransmitter in many animals including mammals. Bombesin affects vascular and other smooth muscle, gastric secretion, and renal circulation and function.
A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)
A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.
Transplantation between animals of different species.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.
Tumors or cancer of the UTERINE CERVIX.
A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification.
Elements of limited time intervals, contributing to particular results or situations.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
Tumors or cancer of the gallbladder.
RNA present in neoplastic tissue.
A group of acidic proteins that are major components of SECRETORY GRANULES in the endocrine and neuroendocrine cells. They play important roles in the aggregation, packaging, sorting, and processing of secretory protein prior to secretion. They are cleaved to release biologically active peptides. There are various types of granins, usually classified by their sources.
Cell surface proteins that bind bombesin or closely related peptides with high affinity and trigger intracellular changes influencing the behavior of cells. Gastrin- releasing peptide (GRP); GRP 18-27 (neuromedin C), and neuromedin B are endogenous ligands of bombesin receptors in mammals.
The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.
Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
Established cell cultures that have the potential to propagate indefinitely.
A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)
An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
The malignant stem cells of TERATOCARCINOMAS, which resemble pluripotent stem cells of the BLASTOCYST INNER CELL MASS. The EC cells can be grown in vitro, and experimentally induced to differentiate. They are used as a model system for studying early embryonic cell differentiation.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.
A MARVEL domain-containing protein found in the presynaptic vesicles of NEURONS and NEUROENDOCRINE CELLS. It is commonly used as an immunocytochemical marker for neuroendocrine differentiation.
A thyroid neoplasm of mixed papillary and follicular arrangement. Its biological behavior and prognosis is the same as that of a papillary adenocarcinoma of the thyroid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1271)
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
A rare aggressive variant of chondrosarcoma, characterized by a biphasic histologic pattern of small compact cells intermixed with islands of cartilaginous matrix. Mesenchymal chondrosarcomas have a predilection for flat bones; long tubular bones are rarely affected. They tend to occur in the younger age group and are highly metastatic. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1456)
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
A protein-tyrosine kinase receptor that is specific for STEM CELL FACTOR. This interaction is crucial for the development of hematopoietic, gonadal, and pigment stem cells. Genetic mutations that disrupt the expression of PROTO-ONCOGENE PROTEINS C-KIT are associated with PIEBALDISM, while overexpression or constitutive activation of the c-kit protein-tyrosine kinase is associated with tumorigenesis.
The first alpha-globulins to appear in mammalian sera during FETAL DEVELOPMENT and the dominant serum proteins in early embryonic life.
Tumors or cancer of the TONGUE.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
Neoplasms composed of more than one type of neoplastic tissue.
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.
Cancer or tumors of the URETER which may cause obstruction leading to hydroureter, HYDRONEPHROSIS, and PYELONEPHRITIS. HEMATURIA is a common symptom.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
An autoimmune disease characterized by weakness and fatigability of proximal muscles, particularly of the pelvic girdle, lower extremities, trunk, and shoulder girdle. There is relative sparing of extraocular and bulbar muscles. CARCINOMA, SMALL CELL of the lung is a frequently associated condition, although other malignancies and autoimmune diseases may be associated. Muscular weakness results from impaired impulse transmission at the NEUROMUSCULAR JUNCTION. Presynaptic calcium channel dysfunction leads to a reduced amount of acetylcholine being released in response to stimulation of the nerve. (From Adams et al., Principles of Neurology, 6th ed, pp 1471)
Tumors or cancer of the SALIVARY GLANDS.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.
A type II keratin found associated with KERATIN-19 in ductal epithelia and gastrointestinal epithelia.
The relationship between the dose of an administered drug and the response of the organism to the drug.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
Biochemical identification of mutational changes in a nucleotide sequence.
The epithelial lining of the URINARY TRACT.
A type of chromogranin which was first isolated from CHROMAFFIN CELLS of the ADRENAL MEDULLA but is also found in other tissues and in many species including human, bovine, rat, mouse, and others. It is an acidic protein with 431 to 445 amino acid residues. It contains fragments that inhibit vasoconstriction or release of hormones and neurotransmitter, while other fragments exert antimicrobial actions.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
One of the AROMATIC-L-AMINO-ACID DECARBOXYLASES, this enzyme is responsible for the conversion of DOPA to DOPAMINE. It is of clinical importance in the treatment of Parkinson's disease.
Diagnosis of the type and, when feasible, the cause of a pathologic process by means of microscopic study of cells in an exudate or other form of body fluid. (Stedman, 26th ed)
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
A type I keratin found associated with KERATIN-7 in ductal epithelia and gastrointestinal epithelia.
Neoplasms of the SQUAMOUS EPITHELIAL CELLS. The concept does not refer to neoplasms located in tissue composed of squamous elements.
Calcium-dependent cell adhesion proteins. They are important in the formation of ADHERENS JUNCTIONS between cells. Cadherins are classified by their distinct immunological and tissue specificities, either by letters (E- for epithelial, N- for neural, and P- for placental cadherins) or by numbers (cadherin-12 or N-cadherin 2 for brain-cadherin). Cadherins promote cell adhesion via a homophilic mechanism as in the construction of tissues and of the whole animal body.
The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.
Tumors or cancer of the RECTUM.
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
An organoplatinum compound that possesses antineoplastic activity.
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
A type II keratin found associated with KERATIN-16 or KERATIN-17 in rapidly proliferating squamous epithelial tissue. Mutations in gene for keratin-6A and keratin-6B have been associated with PACHYONYCHIA CONGENITA, TYPE 1 and PACHYONYCHIA CONGENITA, TYPE 2 respectively.
Administration of antineoplastic agents together with an embolizing vehicle. This allows slow release of the agent as well as obstruction of the blood supply to the neoplasm.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.
Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus.
Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.
Tumors or cancer located in bone tissue or specific BONES.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
A skin carcinoma that histologically exhibits both basal and squamous elements. (From Dorland, 27th ed)
Cells with the capacity to take up and decarboxylate the amine precursors DIHYDROXYPHENYLALANINE or 5-HYDROXYTRYPTOPHAN. This is a property of endocrine cells of neural and non-neural origin. APUDOMA is a general term collectively applied to tumors associated with APUD cells.
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.
Metastases in which the tissue of origin is unknown.
Surgical removal of the thyroid gland. (Dorland, 28th ed)
The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.
Variation in a population's DNA sequence that is detected by determining alterations in the conformation of denatured DNA fragments. Denatured DNA fragments are allowed to renature under conditions that prevent the formation of double-stranded DNA and allow secondary structure to form in single stranded fragments. These fragments are then run through polyacrylamide gels to detect variations in the secondary structure that is manifested as an alteration in migration through the gels.
A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
A technique that localizes specific nucleic acid sequences within intact chromosomes, eukaryotic cells, or bacterial cells through the use of specific nucleic acid-labeled probes.
In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES.

Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression. (1/2496)

Based on an increased frequency of early death (death within the first treatment cycle) in our two latest randomized trials of combination chemotherapy in small-cell lung cancer (SCLC), we wanted to identify patients at risk of early non-toxic death (ENTD) and early toxic death (ETD). Data were stored in a database and logistic regression analyses were performed to identify predictive factors for early death. During the first cycle, 118 out of 937 patients (12.6%) died. In 38 patients (4%), the cause of death was sepsis. Significant risk factors were age, performance status (PS), lactate dehydrogenase (LDH) and treatment with epipodophyllotoxins and platinum in the first cycle (EP). Risk factors for ENTD were age, PS and LDH. Extensive stage had a hazard ratio of 1.9 (P = 0.07). Risk factors for ETD were EP, PS and LDH, whereas age and stage were not. For EP, the hazard ratio was as high as 6.7 (P = 0.0001). We introduced a simple prognostic algorithm including performance status, LDH and age. Using a prognostic algorithm to exclude poor-risk patients from trials, we could minimize early death, improve long-term survival and increase the survival differences between different regimens. We suggest that other groups evaluate our algorithm and exclude poor prognosis patients from trials of dose intensification.  (+info)

Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. (2/2496)

The assessment of symptom palliation is an essential component of many treatment comparisons in clinical trials, yet an extensive literature search revealed no consensus as to its precise definition, which could embrace relief of symptoms, time to their onset, duration, degree, as well as symptom control and prevention. In an attempt to assess the importance of these aspects and to compare different methods of analysis, we used one symptom (cough) from a patient self-assessment questionnaire (the Rotterdam Symptom Checklist) in a large (>300 patient) multicentre randomized clinical trial (conducted by the Medical Research Council Lung Cancer Working Party) of palliative chemotherapy in small-cell lung cancer. The regimens compared were a two-drug regimen (2D) and a four-drug regimen (4D). No differences were seen between the regimens in time of onset of palliation or its duration. The degree of palliation was strongly related to the initial severity: 90% of the patients with moderate or severe cough at baseline reported improvement, compared with only 53% of those with mild cough. Analyses using different landmark time points gave conflicting results: the 4D regimen was superior at 1 month and at 3 months, whereas at 2 months the 2D regimen appeared superior. When improvement at any time up to 3 months was considered, the 4D regimen showed a significant benefit (4D 79%, 2D 60%, P = 0.02). These findings emphasize the need for caution in interpreting results, and the importance of working towards a standard definition of symptom palliation. The current lack of specified criteria makes analysis and interpretation of trial results difficult, and comparison across trials impossible. A standard definition of palliation for use in the analysis of clinical trials data is proposed, which takes into account aspects of onset, duration and degree of palliation, and symptom improvement, control and prevention.  (+info)

Coexpression of transcripts encoding EPHB receptor protein tyrosine kinases and their ephrin-B ligands in human small cell lung carcinoma. (3/2496)

The EPH family is the largest subfamily of receptor protein tyrosine kinases, consisting of the EPHA and EPHB subgroups. Ephrin-B1, ephrin-B2, and ephrin-B3 are ligands of the EPHB subgroup and are encoded by the EFNB1, EFNB2, and EFNB3 genes, respectively. We have shown previously that EPHB2 transcripts are expressed in six small cell lung carcinoma (SCLC) cell lines. In this study, we examined the expression of EPHB1, EPHB2, EPHB3, EPHB4, and EPHB6 in 4 SCLC tumor specimens and 14 cell lines including 3 cell lines derived from these tumor specimens. To investigate whether potential autocrine loops of EPHB receptors and ephrin-B ligands exist in SCLC, the expression of EFNB1, EFNB2, and EFNB3 was also examined. Our data show that transcripts encoding multiple members of the EPHB subgroup and the ephrin-B subgroup are coexpressed in SCLC cell lines and tumors. These results suggest that the EPHB subgroup receptor kinases may modulate the biological behavior of SCLC through autocrine and/or juxtacrine activation by ephrin-B ligands that are expressed in the same or neighboring cells.  (+info)

Combined modality therapy of lung cancer. (4/2496)

Combined modality therapy for lung cancer was first demonstrated to be successful in limited-stage small cell lung cancer. Concurrent administration of chemotherapy with chest and elective brain irradiation appears to produce the best results, with cisplatin/etoposide as the core chemotherapy. Using such programs, 2-year survival in the 40% range and 5-year survivals in excess of 20% may be expected, based on the results of multiple studies. Attempts to improve on these results through the use of altered schemes of chest irradiation or the delivery of high-dose consolidation chemotherapy are ongoing but to date have not been shown to affect survival significantly. We remain at a plateau in the effectiveness of combined modality therapy for small cell lung cancer, with little evidence that it impacts survival at all in extensive-stage disease. The incorporation of new agents in combination chemotherapy regimens, more "specific" immunotherapy directed at tumor-associated antigens, and the potential adjunctive use of broad-spectrum neuropeptide antagonists offer promise for the future. In non-small cell lung cancer, the sequential use of platinum-based chemotherapy and chest irradiation appears superior in survival to standard, daily fractionated radiation therapy used alone, with long-term survival increased from 5-10% to 15-20%. Concurrent administration of chemotherapy with cisplatin/etoposide and chest irradiation produces 2-year survival in the range of 30%, about twice that would be expected for radiation therapy alone, but has not been compared to it in the setting of a randomized trial. Low-dose cisplatin on a daily basis has been combined as a "sensitizer" with chest irradiation, producing initial results that appeared encouraging. However, these have not been reproduced in subsequent, randomized trials. Another approach to combined modalities has been to give chemotherapy or chemotherapy/radiation therapy as induction, followed by surgical resection, with or without subsequent additional treatment. Most patients (80-85%) can be resected, with encouraging survival at 2 and 3 years in the Southwest Oncology Group experience (37 and 26%, respectively). However, toxicity is greater, and such an approach is associated with an overall mortality risk in the range of 10%. A current intergroup study attempts to define the role of surgery in this setting. The major recent development that is likely to influence the future of combined modality therapy for this disease is the advent of multiple new chemotherapeutic agents, such as the taxanes, gemcitabine, vinorelbine, and the topoisomerase-I inhibitors, which have activity in stage IV disease. The immediate challenge is how to combine these agents with platinum analogues, radiation, and surgery. Aiding this process may be the use of molecular biological "markers" that may predict the chance of success or failure with a given systemic agent. The next decade is likely to see substantial improvements in the outcome of treatment for patients with stages I-III non-small cell lung cancer, based on the systemic exploration of combined modalities.  (+info)

Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin. (5/2496)

We conducted a phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin. Fostriecin was administered intravenously over 60 min on days 1-5 at 4-week intervals. Dose was escalated from 2 mg m(-2) day(-1) to 20 mg m(-2) day(-1) in 20 patients. Drug pharmacokinetics was analysed with high performance liquid chromatography with UV-detection. Plasma collected during drug administration was tested in vitro for growth inhibition of a teniposide-resistant small-cell lung cancer (SCLC) cell line. The predominant toxicities were elevated liver transaminases (maximum common toxicity criteria (CTC) grade 4) and serum creatinine (maximum CTC grade 2). These showed only a limited increase with increasing doses, often recovered during drug administration and were fully reversible. Duration of elevated alanine-amino transferase (ALT) was dose-limiting in one patient at 20 mg m(-2). Other frequent toxicities were grade 1-2 nausea/vomiting, fever and mild fatigue. Mean fostriecin plasma half-life was 0.36 h (initial; 95% CI, 0-0.76 h) and 1.51 h (terminal; 95% CI, 0.41-2.61 h). A metabolite, most probably dephosphorylated fostriecin, was detected in plasma and urine. No tumour responses were observed, but the plasma concentrations reached in the patients were insufficient to induce significant growth inhibition in vitro. The maximum tolerated dose (MTD) has not been reached, because drug supply was stopped at the 20 mg m(-2) dose level. However, further escalation seems possible and is warranted to achieve potentially effective drug levels. Fostriecin has a short plasma half-life and longer duration of infusion should be considered.  (+info)

Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study. (6/2496)

A combination chemotherapy of irinotecan (CPT-11) and cisplatin (CDDP) has been reported to be active for lung cancer. In the previous trial, however, diarrhoea and leucopenia became the major obstacle for sufficient dose escalation of CPT-11 to improve the treatment outcome. We conducted a phase I study to investigate whether the fractionated administration of CDDP and CPT-11 at escalated dose was feasible and could improve the treatment outcome. Twenty-four previously untreated patients with unresectable non-small-cell lung cancer (NSCLC) or extensive disease of small-cell lung cancer (SCLC) were eligible. Both CDDP and CPT-11 were given on days 1 and 8, and repeated every 4 weeks. The dose of CDDP was fixed at 60 mg m(-2) and given by 1-h infusion before CPT-11 administration. The starting dose of CPT-11 was 40 mg m(-2), and the dose was escalated by an increase of 10 mg m(-2). The maximally tolerated dose of CPT-11 was determined as 60 mg m(-2) because grade 4 haematological or grade 3 or 4 non-haematological toxicities developed in six patients out of 11 patients evaluated. Diarrhoea became a dose-limiting toxicity. The objective response rates were 76% for NSCLC and 100% for SCLC. The recommended dose of CPT-11 and CDDP in a phase II study will be 50 mg m(-2) and 60 mg m(-2) respectively.  (+info)

Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma. (7/2496)

Patients with stiff man syndrome and breast cancer develop anti-amphiphysin I antibodies that primarily recognise the C terminus of the protein. Anti-amphiphysin I antibodies have also been identified in a few patients with paraneoplastic neurological disorders (PND) and small cell lung cancer (SCLC). The frequency of anti-amphiphysin I antibodies in patients with SCLC and PND was analysed and the epitope specificity of these antibodies was characterised. Anti-amphiphysin I antibodies were evaluated by immunohistochemistry on human and rat cerebellum and immunoblots of rat brain homogenates. Serum samples included 134 patients with PND and anti-Hu antibodies (83% had SCLC), 44 with SCLC and PND without anti-Hu-antibodies, 63 with PND and either Yo, Ri, or Tr antibodies, 146 with SCLC without PND, and 104 with non-PND. Positive serum samples were confirmed with immunoblots of recombinant human amphiphysin I and immunoreacted with five overlapping peptide fragments covering the full length of the molecule. Serum samples positive for anti-amphiphysin I antibodies included those from seven (2.9%) patients with PND and two (1.4%) with SCLC without PND. Six of the seven anti-amphiphysin I antibody positive patients with PND had SCLC (three with Hu-antibodies), and one had anti-Hu-antibodies but no detectable tumour. The PND included encephalomyelitis/sensory neuropathy (five patients), cerebellar degeneration (one), and opsoclonus (one). All anti-amphiphysin I antibodies reacted with the C terminus of amphiphysin I, but seven also recognised other fragments of the molecule. In conclusion, anti-amphiphysin I antibodies are present at low frequency in patients with SCLC irrespective of the presence of an associated PND. All anti-amphiphysin I antibody positive serum samples have in common reactivity with the C terminus of the protein.  (+info)

Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. (8/2496)

PURPOSE: To evaluate the efficacy of paclitaxel and carboplatin (PC) in small-cell lung cancer (SCLC) patients resistant to cyclophosphamide, doxorubicin, and etoposide (CDE). PATIENTS AND METHODS: We performed a phase II study with PC in SCLC patients who relapsed within 3 months after first-line treatment with CDE. Paclitaxel administration (175 mg/m2 by a 3-hour intravenous infusion) was followed by a 30-minute infusion of carboplatin (area under the curve 7; Chatelut formula) once every 3 weeks for five cycles. Dexamethasone, clemastine, and ranitidine were standard premedication before every cycle. RESULTS: Included were 35 patients (median age, 59 years; 16 with limited disease and 19 with extensive disease; Eastern Cooperative Oncology Group performance status of < or = 1; median time off treatment 6 weeks) who were previously treated with CDE (n = 33), oral etoposide (n = 2), and reinduction CDE (n = 15); only one patient had received three CDE treatments of five cycles. The CDE regimen was followed by local thoracic radiotherapy in seven patients. Hematologic toxicity of grade 3 or 4, for leukopenia was 27% and 6%, for thrombocytopenia 21% and 13%, and for anemia 17% and 0%, respectively, for a total of 132 cycles. Two patients had neutropenic fever; no toxic death occurred. Nonhematologic toxicity was paresthesia CTC grade 3, diarrhea grade 4, and myalgia grade 3 in one patient each. Reversible paresthesia (CTC grade 1 and 2) in toes and fingers was reported in 69% of patients. Thirty-four patients were assessable for response: complete response in two patients, partial response in 23 patients, stable disease in eight patients, and progressive disease in one patient (response rate, 73.5%; 95% confidence interval, 59% to 88%). One patient was found to have atypical carcinoid at pathologic review and was excluded. Median time to progression was 21 weeks (range, 3 to 40 weeks). Median survival was 31 weeks (range, 6 to 112 weeks). One-year survival was 9%. CONCLUSION: Second-line PC in CDE-resistant SCLC patients yields a high response rate and seems non-cross-resistant to CDE. Toxicity was mild in these poor-prognosis patients.  (+info)

Epidemiology:

* Incidence: Small cell carcinoma (SCC) accounts for approximately 10%-15% of all skin cancers, but it is more common in certain populations such as fair-skinned individuals and those with a history of sun exposure.
* Prevalence: The prevalence of SCC is difficult to determine due to its rarity, but it is believed to be more common in certain geographic regions such as Australia and New Zealand.

Clinical features:

* Appearance: Small cell carcinoma usually appears as a firm, shiny nodule or plaque on sun-exposed areas of the skin, such as the face, ears, lips, and hands. It can also occur in other parts of the body, including the mucous membranes.
* Color: The color of SCC can range from pink to red to purple, and it may be covered with a crust or scab.
* Dimensions: SCC usually measures between 1-5 cm in diameter, but it can be larger in some cases.
* Surface: The surface of SCC may be smooth or rough, and it may have a "pearly" appearance due to the presence of small, white, and shiny nodules called "heidlebergs."

Differential diagnosis:

* Other types of skin cancer, such as basal cell carcinoma and squamous cell carcinoma.
* Other diseases that can cause similar symptoms and appearance, such as psoriasis, eczema, and actinic keratosis.

Treatment:

* Surgical excision: Small cell carcinoma is usually treated with surgical excision, which involves removing the tumor and some surrounding tissue.
* Radiation therapy: In some cases, radiation therapy may be used after surgical excision to ensure that all cancer cells are eliminated.
* Topical treatments: For more superficial SCC, topical treatments such as imiquimod cream or podofilox solution may be effective.

Prognosis:

* The prognosis for small cell carcinoma is generally good if it is detected and treated early.
* However, if left untreated, SCC can invade surrounding tissues and organs, leading to serious complications and potentially fatal outcomes.

Complications:

* Invasion of surrounding tissues and organs.
* Spread of cancer cells to other parts of the body (metastasis).
* Scarring and disfigurement.
* Infection and inflammation.

There are several subtypes of carcinoma, including:

1. Adenocarcinoma: This type of carcinoma originates in glandular cells, which produce fluids or mucus. Examples include breast cancer, prostate cancer, and colon cancer.
2. Squamous cell carcinoma: This type of carcinoma originates in squamous cells, which are found on the surface layers of skin and mucous membranes. Examples include head and neck cancers, cervical cancer, and anal cancer.
3. Basal cell carcinoma: This type of carcinoma originates in the deepest layer of skin, called the basal layer. It is the most common type of skin cancer and tends to grow slowly.
4. Neuroendocrine carcinoma: This type of carcinoma originates in cells that produce hormones and neurotransmitters. Examples include lung cancer, pancreatic cancer, and thyroid cancer.
5. Small cell carcinoma: This type of carcinoma is a highly aggressive form of lung cancer that spreads quickly to other parts of the body.

The signs and symptoms of carcinoma depend on the location and stage of the cancer. Some common symptoms include:

* A lump or mass
* Pain
* Skin changes, such as a new mole or a change in the color or texture of the skin
* Changes in bowel or bladder habits
* Abnormal bleeding

The diagnosis of carcinoma typically involves a combination of imaging tests, such as X-rays, CT scans, MRI scans, and PET scans, and a biopsy, which involves removing a small sample of tissue for examination under a microscope. Treatment options for carcinoma depend on the location and stage of the cancer and may include surgery, radiation therapy, chemotherapy, or a combination of these.

In conclusion, carcinoma is a type of cancer that originates in epithelial cells and can occur in various parts of the body. Early detection and treatment are important for improving outcomes.

References:

1. American Cancer Society. (2022). Carcinoma. Retrieved from
2. Mayo Clinic. (2022). Carcinoma. Retrieved from
3. MedlinePlus. (2022). Carcinoma. Retrieved from

SCLC typically starts in the bronchi of the lungs and can spread quickly to other parts of the body, such as the brain, liver, and bones. It is often found in later stages and is associated with a poorer prognosis than non-small cell lung cancer (NSCLC).

There are two main types of SCLC:

1. Limited-stage SCLC: This type of SCLC is limited to one lung and has not spread to other parts of the body.
2. Extensive-stage SCLC: This type of SCLC has spread beyond one lung and may have spread to other parts of the body.

Symptoms of SCLC include:

* Coughing
* Chest pain
* Shortness of breath
* Weight loss
* Fatigue

Diagnosis of SCLC is typically made through a combination of imaging tests, such as chest X-rays, CT scans, and PET scans, and a biopsy to confirm the presence of cancer cells. Treatment options for SCLC include:

1. Chemotherapy: This is the primary treatment for SCLC and may be used alone or in combination with radiation therapy.
2. Radiation therapy: This may be used alone or in combination with chemotherapy to treat SCLC.
3. Surgery: In some cases, surgery may be possible to remove the tumor and affected tissue.
4. Clinical trials: These may be available for patients with SCLC to access new and innovative treatments.

Overall, SCLC is a highly aggressive form of lung cancer that requires prompt and accurate diagnosis and treatment to improve outcomes.

SCC typically appears as a firm, flat, or raised bump on the skin, and may be pink, red, or scaly. The cancer cells are usually well-differentiated, meaning they resemble normal squamous cells, but they can grow rapidly and invade surrounding tissues if left untreated.

SCC is more common in fair-skinned individuals and those who spend a lot of time in the sun, as UV radiation can damage the skin cells and increase the risk of cancer. The cancer can also spread to other parts of the body, such as lymph nodes or organs, and can be life-threatening if not treated promptly and effectively.

Treatment for SCC usually involves surgery to remove the cancerous tissue, and may also include radiation therapy or chemotherapy to kill any remaining cancer cells. Early detection and treatment are important to improve outcomes for patients with SCC.

There are several types of lung neoplasms, including:

1. Adenocarcinoma: This is the most common type of lung cancer, accounting for approximately 40% of all lung cancers. It is a malignant tumor that originates in the glands of the respiratory tract and can be found in any part of the lung.
2. Squamous cell carcinoma: This type of lung cancer accounts for approximately 25% of all lung cancers and is more common in men than women. It is a malignant tumor that originates in the squamous cells lining the airways of the lungs.
3. Small cell lung cancer (SCLC): This is a highly aggressive form of lung cancer that accounts for approximately 15% of all lung cancers. It is often found in the central parts of the lungs and can spread quickly to other parts of the body.
4. Large cell carcinoma: This is a rare type of lung cancer that accounts for only about 5% of all lung cancers. It is a malignant tumor that originates in the large cells of the respiratory tract and can be found in any part of the lung.
5. Bronchioalveolar carcinoma (BAC): This is a rare type of lung cancer that originates in the cells lining the airways and alveoli of the lungs. It is more common in women than men and tends to affect older individuals.
6. Lymphangioleiomyomatosis (LAM): This is a rare, progressive, and often fatal lung disease that primarily affects women of childbearing age. It is characterized by the growth of smooth muscle-like cells in the lungs and can lead to cysts, lung collapse, and respiratory failure.
7. Hamartoma: This is a benign tumor that originates in the tissue of the lungs and is usually found in children. It is characterized by an overgrowth of normal lung tissue and can be treated with surgery.
8. Secondary lung cancer: This type of cancer occurs when cancer cells from another part of the body spread to the lungs through the bloodstream or lymphatic system. It is more common in people who have a history of smoking or exposure to other carcinogens.
9. Metastatic cancer: This type of cancer occurs when cancer cells from another part of the body spread to the lungs through the bloodstream or lymphatic system. It is more common in people who have a history of smoking or exposure to other carcinogens.
10. Mesothelioma: This is a rare and aggressive form of cancer that originates in the lining of the lungs or abdomen. It is caused by asbestos exposure and can be treated with surgery, chemotherapy, and radiation therapy.

Lung diseases can also be classified based on their cause, such as:

1. Infectious diseases: These are caused by bacteria, viruses, or other microorganisms and can include pneumonia, tuberculosis, and bronchitis.
2. Autoimmune diseases: These are caused by an overactive immune system and can include conditions such as sarcoidosis and idiopathic pulmonary fibrosis.
3. Genetic diseases: These are caused by inherited mutations in genes that affect the lungs and can include cystic fibrosis and primary ciliary dyskinesia.
4. Environmental diseases: These are caused by exposure to harmful substances such as tobacco smoke, air pollution, and asbestos.
5. Radiological diseases: These are caused by exposure to ionizing radiation and can include conditions such as radiographic breast cancer and lung cancer.
6. Vascular diseases: These are caused by problems with the blood vessels in the lungs and can include conditions such as pulmonary embolism and pulmonary hypertension.
7. Tumors: These can be benign or malignant and can include conditions such as lung metastases and lung cancer.
8. Trauma: This can include injuries to the chest or lungs caused by accidents or other forms of trauma.
9. Congenital diseases: These are present at birth and can include conditions such as bronchopulmonary foregut malformations and congenital cystic adenomatoid malformation.

Each type of lung disease has its own set of symptoms, diagnosis, and treatment options. It is important to seek medical attention if you experience any persistent or severe respiratory symptoms, as early diagnosis and treatment can improve outcomes and quality of life.

There are several risk factors for developing HCC, including:

* Cirrhosis, which can be caused by heavy alcohol consumption, viral hepatitis (such as hepatitis B and C), or fatty liver disease
* Family history of liver disease
* Chronic obstructive pulmonary disease (COPD)
* Diabetes
* Obesity

HCC can be challenging to diagnose, as the symptoms are non-specific and can be similar to those of other conditions. However, some common symptoms of HCC include:

* Yellowing of the skin and eyes (jaundice)
* Fatigue
* Loss of appetite
* Abdominal pain or discomfort
* Weight loss

If HCC is suspected, a doctor may perform several tests to confirm the diagnosis, including:

* Imaging tests, such as ultrasound, CT scan, or MRI, to look for tumors in the liver
* Blood tests to check for liver function and detect certain substances that are produced by the liver
* Biopsy, which involves removing a small sample of tissue from the liver to examine under a microscope

Once HCC is diagnosed, treatment options will depend on several factors, including the stage and location of the cancer, the patient's overall health, and their personal preferences. Treatment options may include:

* Surgery to remove the tumor or parts of the liver
* Ablation, which involves destroying the cancer cells using heat or cold
* Chemoembolization, which involves injecting chemotherapy drugs into the hepatic artery to reach the cancer cells
* Targeted therapy, which uses drugs or other substances to target specific molecules that are involved in the growth and spread of the cancer

Overall, the prognosis for HCC is poor, with a 5-year survival rate of approximately 20%. However, early detection and treatment can improve outcomes. It is important for individuals at high risk for HCC to be monitored regularly by a healthcare provider, and to seek medical attention if they experience any symptoms.

Also known as CIS.

Definition:
A type of cancer that arises from cells of the neuroendocrine system, which are cells that produce hormones and neurotransmitters. These tumors can occur in various parts of the body, such as the lungs, digestive tract, and pancreas. They tend to grow slowly and can produce excess hormones or neurotransmitters, leading to a variety of symptoms. Carcinoma, neuroendocrine tumors are relatively rare but are becoming more commonly diagnosed.

Synonyms:

* Neuroendocrine carcinoma
* Neuroendocrine tumor
* Carcinoid tumor

Note: The term "carcinoma" refers to a type of cancer that arises from epithelial cells, while the term "neuroendocrine" refers to the fact that these tumors originate in cells of the neuroendocrine system.

Translation:

English: Neuroendocrine carcinoma
German: Neuroendokrines Karzinom
French: Tumeur carcinoïde neuroendocrine
Spanish: Carcinoma neuendocrino
Italian: Carcinoma neuroendocrino

Liver neoplasms, also known as liver tumors or hepatic tumors, are abnormal growths of tissue in the liver. These growths can be benign (non-cancerous) or malignant (cancerous). Malignant liver tumors can be primary, meaning they originate in the liver, or metastatic, meaning they spread to the liver from another part of the body.

There are several types of liver neoplasms, including:

1. Hepatocellular carcinoma (HCC): This is the most common type of primary liver cancer and arises from the main cells of the liver (hepatocytes). HCC is often associated with cirrhosis and can be caused by viral hepatitis or alcohol abuse.
2. Cholangiocarcinoma: This type of cancer arises from the cells lining the bile ducts within the liver (cholangiocytes). Cholangiocarcinoma is rare and often diagnosed at an advanced stage.
3. Hemangiosarcoma: This is a rare type of cancer that originates in the blood vessels of the liver. It is most commonly seen in dogs but can also occur in humans.
4. Fibromas: These are benign tumors that arise from the connective tissue of the liver (fibrocytes). Fibromas are usually small and do not spread to other parts of the body.
5. Adenomas: These are benign tumors that arise from the glandular cells of the liver (hepatocytes). Adenomas are usually small and do not spread to other parts of the body.

The symptoms of liver neoplasms vary depending on their size, location, and whether they are benign or malignant. Common symptoms include abdominal pain, fatigue, weight loss, and jaundice (yellowing of the skin and eyes). Diagnosis is typically made through a combination of imaging tests such as CT scans, MRI scans, and ultrasound, and a biopsy to confirm the presence of cancer cells.

Treatment options for liver neoplasms depend on the type, size, location, and stage of the tumor, as well as the patient's overall health. Surgery may be an option for some patients with small, localized tumors, while others may require chemotherapy or radiation therapy to shrink the tumor before surgery can be performed. In some cases, liver transplantation may be necessary.

Prognosis for liver neoplasms varies depending on the type and stage of the cancer. In general, early detection and treatment improve the prognosis, while advanced-stage disease is associated with a poorer prognosis.

The exact cause of ductal carcinoma is unknown, but certain risk factors such as family history, genetics, hormone replacement therapy, obesity, and delayed childbearing have been linked to its development. Early detection through mammography and breast self-examination can improve survival rates, which are generally high for women diagnosed with this type of cancer if caught early. Treatment typically involves surgery to remove the tumor (lumpectomy or mastectomy), followed by radiation therapy and/or chemotherapy.

BCC usually appears as a flesh-colored or pink bump, often with small blood vessels on the surface. It may also be flat and scaly, or have a waxy appearance. In rare cases, BCC can grow deep into the skin and cause damage to surrounding tissue.

Although BCC is not as aggressive as other types of skin cancer, such as melanoma, it can still cause significant damage if left untreated. Treatment options for BCC include topical creams, surgical excision, and Mohs microscopic surgery.

Preventative measures against BCC include protecting the skin from the sun, using sunscreen with a high SPF, and avoiding prolonged exposure to UV radiation. Early detection and treatment are key in managing this condition.

The risk factors for developing bronchogenic carcinoma include smoking, exposure to secondhand smoke, exposure to radon gas, asbestos, and certain industrial chemicals, as well as a family history of lung cancer. Symptoms of bronchogenic carcinoma can include coughing, chest pain, difficulty breathing, fatigue, weight loss, and coughing up blood.

Bronchogenic carcinoma is diagnosed through a combination of imaging tests such as chest x-rays, computed tomography (CT) scans, and positron emission tomography (PET) scans, as well as biopsy. Treatment options for bronchogenic carcinoma can include surgery, radiation therapy, chemotherapy, or a combination of these. The prognosis for bronchogenic carcinoma is generally poor, with a five-year survival rate of about 18%.

Prevention is the best approach to managing bronchogenic carcinoma, and this includes quitting smoking, avoiding exposure to secondhand smoke and other risk factors, and getting regular screenings if you are at high risk. Early detection and treatment can improve survival rates for patients with bronchogenic carcinoma, so it is important to seek medical attention if symptoms persist or worsen over time.

Adenocarcinoma is a term used to describe a variety of different types of cancer that arise in glandular tissue, including:

1. Colorectal adenocarcinoma (cancer of the colon or rectum)
2. Breast adenocarcinoma (cancer of the breast)
3. Prostate adenocarcinoma (cancer of the prostate gland)
4. Pancreatic adenocarcinoma (cancer of the pancreas)
5. Lung adenocarcinoma (cancer of the lung)
6. Thyroid adenocarcinoma (cancer of the thyroid gland)
7. Skin adenocarcinoma (cancer of the skin)

The symptoms of adenocarcinoma depend on the location of the cancer and can include:

1. Blood in the stool or urine
2. Abdominal pain or discomfort
3. Changes in bowel habits
4. Unusual vaginal bleeding (in the case of endometrial adenocarcinoma)
5. A lump or thickening in the breast or elsewhere
6. Weight loss
7. Fatigue
8. Coughing up blood (in the case of lung adenocarcinoma)

The diagnosis of adenocarcinoma is typically made through a combination of imaging tests, such as CT scans, MRI scans, and PET scans, and a biopsy, which involves removing a sample of tissue from the affected area and examining it under a microscope for cancer cells.

Treatment options for adenocarcinoma depend on the location of the cancer and can include:

1. Surgery to remove the tumor
2. Chemotherapy, which involves using drugs to kill cancer cells
3. Radiation therapy, which involves using high-energy X-rays or other particles to kill cancer cells
4. Targeted therapy, which involves using drugs that target specific molecules on cancer cells to kill them
5. Immunotherapy, which involves using drugs that stimulate the immune system to fight cancer cells.

The prognosis for adenocarcinoma is generally good if the cancer is detected and treated early, but it can be more challenging to treat if the cancer has spread to other parts of the body.

Adenocarcinoma is the most common subtype of NSCLC and is characterized by malignant cells that have glandular or secretory properties. Squamous cell carcinoma is less common and is characterized by malignant cells that resemble squamous epithelium. Large cell carcinoma is a rare subtype and is characterized by large, poorly differentiated cells.

The main risk factor for developing NSCLC is tobacco smoking, which is responsible for approximately 80-90% of all cases. Other risk factors include exposure to secondhand smoke, radon gas, asbestos, and certain chemicals in the workplace or environment.

Symptoms of NSCLC can include coughing, chest pain, shortness of breath, and fatigue. The diagnosis is typically made through a combination of imaging studies such as CT scans, PET scans, and biopsy. Treatment options for NSCLC can include surgery, chemotherapy, radiation therapy, or a combination of these. The prognosis for NSCLC depends on several factors, including the stage of the cancer, the patient's overall health, and the effectiveness of treatment.

Overall, NSCLC is a common and aggressive form of lung cancer that can be treated with a variety of therapies. Early detection and treatment are critical for improving outcomes in patients with this diagnosis.

Transitional cell carcinoma typically affects older adults, with the average age at diagnosis being around 70 years. Men are more likely to be affected than women, and the risk of developing TCC increases with age and exposure to certain environmental factors such as smoking and exposure to certain chemicals.

The symptoms of TCC can vary depending on the location and stage of the cancer, but may include:

* Blood in the urine (hematuria)
* Painful urination
* Frequent urination
* Pain in the lower abdomen or back

If left untreated, TCC can spread to other parts of the body, including the lymph nodes, liver, and bones. Treatment options for TCC may include surgery, chemotherapy, and immunotherapy, and the prognosis depends on the stage and location of the cancer at the time of diagnosis.

Preventive measures to reduce the risk of developing TCC include maintaining a healthy diet and lifestyle, avoiding smoking and excessive alcohol consumption, and regular screening for bladder cancer. Early detection and treatment can improve the prognosis for patients with TCC.

Also known as: Large cell carcinoma (LCC), malignant large cell carcinoma, and giant cell carcinoma.

Intraductal carcinoma may or may not cause symptoms, and is usually detected by a mammogram. Treatment often involves surgery to remove the cancerous cells from the milk ducts. If left untreated, intraductal carcinoma may progress to more advanced breast cancer in some cases.

Intraductal carcinoma accounts for 20% of all breast cancers diagnosed each year in the United States, according to estimates from the American Cancer Society. The condition affects women of all ages, but is most common in postmenopausal women.

This cancer is known for its aggressive behavior and early metastasis to regional lymph nodes, bones, and distant organs such as the liver and lungs. The prognosis is generally poor, with a 5-year survival rate of about 50%. The treatment options include surgery, radiation therapy, and chemotherapy, and the choice of treatment depends on the stage and location of the tumor.

Adenoid cystic carcinoma is also known as adenoid cystic cancer, cylindromatosis, or basaloid squamous cell carcinoma. It is a rare malignancy that requires specialized knowledge and management by head and neck surgeons and oncologists.

MCC typically affects older adults, with most cases occurring in people over the age of 60. The disease is more common in fair-skinned individuals, especially those who have had prolonged exposure to the sun. MCC can occur anywhere on the body, but it is most commonly found on the face, neck, and arms.

The symptoms of MCC can vary depending on the location and size of the tumor, but they may include:

* A firm, shiny nodule or lump on the skin
* Painless lumps or swelling in the affected area
* Redness, scaliness, or oozing of the skin around the nodule
* Itching or burning sensations in the affected area

If MCC is suspected, a biopsy will be performed to confirm the diagnosis. Treatment for MCC typically involves surgery to remove the tumor and any affected tissue. In some cases, radiation therapy or chemotherapy may also be recommended to kill any remaining cancer cells.

The prognosis for MCC is generally poor, as it tends to be an aggressive disease that can spread quickly to other parts of the body. However, early detection and treatment can improve the chances of a successful outcome.

1. Tumor size and location: Larger tumors that have spread to nearby tissues or organs are generally considered more invasive than smaller tumors that are confined to the original site.
2. Cellular growth patterns: The way in which cancer cells grow and divide can also contribute to the overall invasiveness of a neoplasm. For example, cells that grow in a disorganized or chaotic manner may be more likely to invade surrounding tissues.
3. Mitotic index: The mitotic index is a measure of how quickly the cancer cells are dividing. A higher mitotic index is generally associated with more aggressive and invasive cancers.
4. Necrosis: Necrosis, or the death of cells, can be an indication of the level of invasiveness of a neoplasm. The presence of significant necrosis in a tumor is often a sign that the cancer has invaded surrounding tissues and organs.
5. Lymphovascular invasion: Cancer cells that have invaded lymphatic vessels or blood vessels are considered more invasive than those that have not.
6. Perineural invasion: Cancer cells that have invaded nerve fibers are also considered more invasive.
7. Histological grade: The histological grade of a neoplasm is a measure of how abnormal the cancer cells look under a microscope. Higher-grade cancers are generally considered more aggressive and invasive than lower-grade cancers.
8. Immunohistochemical markers: Certain immunohistochemical markers, such as Ki-67, can be used to evaluate the proliferative activity of cancer cells. Higher levels of these markers are generally associated with more aggressive and invasive cancers.

Overall, the degree of neoplasm invasiveness is an important factor in determining the likelihood of the cancer spreading to other parts of the body (metastasizing) and in determining the appropriate treatment strategy for the patient.

Characteristics of Medullary Carcinoma:

1. Location: Medullary carcinoma typically arises in the inner substance of the breast, near the milk ducts and blood vessels.
2. Growth pattern: The cancer cells grow in a nodular or sheet-like pattern, with a clear boundary between the tumor and the surrounding normal tissue.
3. Cellular features: The cancer cells are typically large and polygonal, with prominent nucleoli and a pale, pinkish cytoplasm.
4. Lymphocytic infiltration: There is often a significant amount of lymphocytic infiltration surrounding the tumor, which can give it a "spiculated" or "heterogeneous" appearance.
5. Grade: Medullary carcinoma is generally a low-grade cancer, meaning that the cells are slow-growing and less aggressive than those of other types of breast cancer.
6. Hormone receptors: Medullary carcinoma is often hormone receptor-positive, meaning that the cancer cells have estrogen or progesterone receptors on their surface.
7. Her2 status: The cancer cells are typically Her2-negative, meaning that they do not overexpress the Her2 protein.

Prognosis and Treatment of Medullary Carcinoma:

The prognosis for medullary carcinoma is generally good, as it tends to be a slow-growing and less aggressive type of breast cancer. The 5-year survival rate for medullary carcinoma is around 80-90%.

Treatment for medullary carcinoma typically involves surgery, such as a lumpectomy or mastectomy, followed by radiation therapy and/or hormone therapy. Chemotherapy is sometimes used in addition to these treatments, especially if the cancer has spread to the lymph nodes or other parts of the body.

It's important for women with medullary carcinoma to work closely with their healthcare team to develop a personalized treatment plan that takes into account their unique needs and circumstances. With appropriate treatment, many women with medullary carcinoma can achieve long-term survival and a good quality of life.

Carcinoma, lobular (also known as lobular carcinoma in situ or LCIS) is a type of cancer that originates in the milk-producing glands (lobules) of the breast. It is a precancerous condition that can progress to invasive breast cancer if left untreated.

Precancerous changes occur within the lobules, leading to an abnormal growth of cells that can eventually break through the basement membrane and invade surrounding tissues. The risk of developing invasive breast cancer is increased in individuals with LCIS, especially if there are multiple areas of involvement.

Diagnosis is typically made through a combination of clinical breast examination, mammography, and histopathological analysis of a biopsy sample. Treatment options for LCIS include close surveillance, surgery, or radiation therapy, depending on the extent of the condition and the individual patient's risk factors.

Medical Specialty:

The medical specialty that deals with carcinoma, lobular is breast surgical oncology. Breast surgical oncologists are trained to diagnose and treat all types of breast cancer, including ductal and lobular carcinomas. They work in collaboration with other healthcare professionals, such as radiation oncologists and medical oncologists, to develop a comprehensive treatment plan for each patient.

Other relevant information:

* Lobular carcinoma in situ (LCIS) is a precancerous condition that affects the milk-producing glands (lobules) of the breast.
* It is estimated that 10-15% of all breast cancers are derived from LCIS.
* Women with a history of LCIS have a higher risk of developing invasive breast cancer in the future.
* The exact cause of LCIS is not fully understood, but it is thought to be linked to hormonal and genetic factors.

Small cell sarcoma typically affects the extremities (arms or legs) and can cause symptoms such as pain, swelling, and limited mobility. The diagnosis of small cell sarcoma is based on a combination of imaging studies (such as X-rays, CT scans, or MRI) and a biopsy, where a sample of tissue is removed and examined under a microscope for cancer cells.

Treatment for small cell sarcoma usually involves a combination of surgery, chemotherapy, and radiation therapy. The prognosis for this type of cancer depends on the stage and location of the tumor, as well as the effectiveness of treatment.

There are several types of thyroid neoplasms, including:

1. Thyroid nodules: These are abnormal growths or lumps that can develop in the thyroid gland. Most thyroid nodules are benign (non-cancerous), but some can be malignant (cancerous).
2. Thyroid cancer: This is a type of cancer that develops in the thyroid gland. There are several types of thyroid cancer, including papillary, follicular, and medullary thyroid cancer.
3. Thyroid adenomas: These are benign tumors that develop in the thyroid gland. They are usually non-cancerous and do not spread to other parts of the body.
4. Thyroid cysts: These are fluid-filled sacs that can develop in the thyroid gland. They are usually benign and do not cause any symptoms.

Thyroid neoplasms can be caused by a variety of factors, including genetic mutations, exposure to radiation, and certain medical conditions, such as thyroiditis (inflammation of the thyroid gland).

Symptoms of thyroid neoplasms can include:

* A lump or swelling in the neck
* Pain in the neck or throat
* Difficulty swallowing or breathing
* Hoarseness or voice changes
* Weight loss or fatigue

Diagnosis of thyroid neoplasms usually involves a combination of physical examination, imaging tests (such as ultrasound or CT scans), and biopsies. Treatment depends on the type and severity of the neoplasm, and can include surgery, radiation therapy, and medications.

There are different types of Breast Neoplasms such as:

1. Fibroadenomas: These are benign tumors that are made up of glandular and fibrous tissues. They are usually small and round, with a smooth surface, and can be moved easily under the skin.

2. Cysts: These are fluid-filled sacs that can develop in both breast tissue and milk ducts. They are usually benign and can disappear on their own or be drained surgically.

3. Ductal Carcinoma In Situ (DCIS): This is a precancerous condition where abnormal cells grow inside the milk ducts. If left untreated, it can progress to invasive breast cancer.

4. Invasive Ductal Carcinoma (IDC): This is the most common type of breast cancer and starts in the milk ducts but grows out of them and invades surrounding tissue.

5. Invasive Lobular Carcinoma (ILC): It originates in the milk-producing glands (lobules) and grows out of them, invading nearby tissue.

Breast Neoplasms can cause various symptoms such as a lump or thickening in the breast or underarm area, skin changes like redness or dimpling, change in size or shape of one or both breasts, discharge from the nipple, and changes in the texture or color of the skin.

Treatment options for Breast Neoplasms may include surgery such as lumpectomy, mastectomy, or breast-conserving surgery, radiation therapy which uses high-energy beams to kill cancer cells, chemotherapy using drugs to kill cancer cells, targeted therapy which uses drugs or other substances to identify and attack cancer cells while minimizing harm to normal cells, hormone therapy, immunotherapy, and clinical trials.

It is important to note that not all Breast Neoplasms are cancerous; some are benign (non-cancerous) tumors that do not spread or grow.

Most nasopharyngeal neoplasms are rare and tend to affect children and young adults more frequently than older adults. The most common types of nasopharyngeal neoplasms include:

1. Nasopharyngeal carcinoma (NPC): This is the most common type of malignant nasopharyngeal neoplasm and tends to affect young adults in Southeast Asia more frequently than other populations.
2. Adenoid cystic carcinoma: This is a rare, slow-growing tumor that usually affects the nasopharynx and salivary glands.
3. Metastatic squamous cell carcinoma: This is a type of cancer that originates in another part of the body (usually the head and neck) and spreads to the nasopharynx.
4. Lymphoma: This is a type of cancer that affects the immune system and can occur in the nasopharynx.
5. Benign tumors: These include benign growths such as papillomas, fibromas, and meningiomas.

Symptoms of nasopharyngeal neoplasms can vary depending on the size and location of the tumor but may include:

* Difficulty swallowing
* Nosebleeds
* Headaches
* Facial pain or numbness
* Trouble breathing through the nose
* Hoarseness or voice changes
* Enlarged lymph nodes in the neck

Diagnosis of nasopharyngeal neoplasms usually involves a combination of imaging tests such as CT or MRI scans, endoscopy (insertion of a flexible tube with a camera into the nose and throat), and biopsy (removal of a small sample of tissue for examination under a microscope).

Treatment of nasopharyngeal neoplasms depends on the type, size, location, and stage of the tumor but may include:

* Surgery to remove the tumor
* Radiation therapy to kill cancer cells
* Chemotherapy to kill cancer cells
* Targeted therapy to attack specific molecules on cancer cells

Prognosis for nasopharyngeal neoplasms varies depending on the type and stage of the tumor but in general, early detection and treatment improve the chances of a successful outcome.

Types of Esophageal Neoplasms:

1. Barrett's Esophagus: This is a precancerous condition that occurs when the cells lining the esophagus undergo abnormal changes, increasing the risk of developing esophageal cancer.
2. Adenocarcinoma: This is the most common type of esophageal cancer, accounting for approximately 70% of all cases. It originates in the glands that line the esophagus.
3. Squamous Cell Carcinoma: This type of cancer accounts for about 20% of all esophageal cancers and originates in the squamous cells that line the esophagus.
4. Other rare types: Other rare types of esophageal neoplasms include lymphomas, sarcomas, and carcinoid tumors.

Causes and Risk Factors:

1. Gastroesophageal reflux disease (GERD): Long-standing GERD can lead to the development of Barrett's esophagus, which is a precancerous condition that increases the risk of developing esophageal cancer.
2. Obesity: Excess body weight is associated with an increased risk of developing esophageal cancer.
3. Diet: A diet high in processed meats and low in fruits and vegetables may increase the risk of developing esophageal cancer.
4. Alcohol consumption: Heavy alcohol consumption is a known risk factor for esophageal cancer.
5. Smoking: Cigarette smoking is a major risk factor for esophageal cancer.
6. Family history: Having a family history of esophageal cancer or other cancers may increase an individual's risk.
7. Age: The risk of developing esophageal cancer increases with age, with most cases occurring in people over the age of 50.
8. Other medical conditions: Certain medical conditions, such as achalasia, may increase the risk of developing esophageal cancer.

Symptoms and Diagnosis:

1. Dysphagia (difficulty swallowing): This is the most common symptom of esophageal cancer, and can be caused by a narrowing or blockage of the esophagus due to the tumor.
2. Chest pain or discomfort: Pain in the chest or upper back can be a symptom of esophageal cancer.
3. Weight loss: Losing weight without trying can be a symptom of esophageal cancer.
4. Coughing or hoarseness: If the tumor is obstructing the airway, it can cause coughing or hoarseness.
5. Fatigue: Feeling tired or weak can be a symptom of esophageal cancer.
6. Diagnosis: A diagnosis of esophageal cancer is typically made through a combination of endoscopy, imaging tests (such as CT scans), and biopsies.

Treatment Options:

1. Surgery: Surgery is the primary treatment for esophageal cancer, and can involve removing the tumor and some surrounding tissue, or removing the entire esophagus and replacing it with a section of stomach or intestine.
2. Chemotherapy: Chemotherapy involves using drugs to kill cancer cells, and is often used in combination with surgery to treat esophageal cancer.
3. Radiation therapy: Radiation therapy uses high-energy X-rays to kill cancer cells, and can be used alone or in combination with surgery or chemotherapy.
4. Targeted therapy: Targeted therapy drugs are designed to target specific molecules that are involved in the growth and spread of cancer cells, and can be used in combination with other treatments.

Prognosis and Survival Rate:

1. The prognosis for esophageal cancer is generally poor, with a five-year survival rate of around 20%.
2. Factors that can improve the prognosis include early detection, small tumor size, and absence of spread to lymph nodes or other organs.
3. The overall survival rate for esophageal cancer has not improved much over the past few decades, but advances in treatment have led to a slight increase in survival time for some patients.

Lifestyle Changes and Prevention:

1. Avoiding tobacco and alcohol: Tobacco and alcohol are major risk factors for esophageal cancer, so avoiding them can help reduce the risk of developing the disease.
2. Maintaining a healthy diet: Eating a balanced diet that is high in fruits, vegetables, and whole grains can help protect against esophageal cancer.
3. Managing obesity: Obesity is a risk factor for esophageal cancer, so maintaining a healthy weight through diet and exercise can help reduce the risk of developing the disease.
4. Reducing exposure to pollutants: Exposure to certain chemicals and pollutants, such as pesticides and asbestos, has been linked to an increased risk of esophageal cancer. Avoiding these substances can help reduce the risk of developing the disease.
5. Getting regular screening: Regular screening for Barrett's esophagus, a precancerous condition that can develop in people with gastroesophageal reflux disease (GERD), can help detect and treat esophageal cancer early, when it is most treatable.

Current Research and Future Directions:

1. Targeted therapies: Researchers are working on developing targeted therapies that can specifically target the genetic mutations that drive the growth of esophageal cancer cells. These therapies may be more effective and have fewer side effects than traditional chemotherapy.
2. Immunotherapy: Immunotherapy, which uses the body's immune system to fight cancer, is being studied as a potential treatment for esophageal cancer. Researchers are working on developing vaccines and other immunotherapies that can help the body recognize and attack cancer cells.
3. Precision medicine: With the help of advanced genomics and precision medicine, researchers are working to identify specific genetic mutations that drive the growth of esophageal cancer in each patient. This information can be used to develop personalized treatment plans that are tailored to the individual patient's needs.
4. Early detection: Researchers are working on developing new methods for early detection of esophageal cancer, such as using machine learning algorithms to analyze medical images and detect signs of cancer at an early stage.
5. Lifestyle modifications: Studies have shown that lifestyle modifications, such as quitting smoking and maintaining a healthy diet, can help reduce the risk of developing esophageal cancer. Researchers are working on understanding the specific mechanisms by which these modifications can help prevent the disease.

In conclusion, esophageal cancer is a complex and aggressive disease that is often diagnosed at an advanced stage. However, with advances in technology, research, and treatment options, there is hope for improving outcomes for patients with this disease. By understanding the risk factors, early detection methods, and current treatments, as well as ongoing research and future directions, we can work towards a future where esophageal cancer is more manageable and less deadly.

Lymphatic metastasis occurs when cancer cells enter the lymphatic vessels and are carried through the lymphatic system to other parts of the body. This can happen through several mechanisms, including:

1. Direct invasion: Cancer cells can invade the nearby lymphatic vessels and spread through them.
2. Lymphatic vessel embolization: Cancer cells can block the flow of lymphatic fluid and cause the formation of a clot-like structure, which can trap cancer cells and allow them to grow.
3. Lymphatic vessel invasion: Cancer cells can infiltrate the walls of lymphatic vessels and spread through them.

Lymphatic metastasis is a common mechanism for the spread of cancer, particularly in the breast, melanoma, and other cancers that have a high risk of lymphatic invasion. The presence of lymphatic metastasis in a patient's body can indicate a more aggressive cancer and a poorer prognosis.

Treatment for lymphatic metastasis typically involves a combination of surgery, chemotherapy, and radiation therapy. Surgery may be used to remove any affected lymph nodes or other tumors that have spread through the lymphatic system. Chemotherapy may be used to kill any remaining cancer cells, while radiation therapy may be used to shrink the tumors and relieve symptoms.

In summary, lymphatic metastasis is a common mechanism for the spread of cancer through the body, particularly in cancers that originate in organs with a high lymphatic drainage. Treatment typically involves a combination of surgery, chemotherapy, and radiation therapy to remove or shrink the tumors and relieve symptoms.

These tumors can be benign or malignant, and their growth and behavior vary depending on the type of cancer. Malignant tumors can invade the surrounding tissues and spread to other parts of the body through the bloodstream or lymphatic system, causing serious complications and potentially life-threatening consequences.

The risk factors for developing urinary bladder neoplasms include smoking, exposure to certain chemicals, recurrent bladder infections, and a family history of bladder cancer. The symptoms of these tumors can include blood in the urine, pain during urination, frequent urination, and abdominal pain.

Diagnosis of urinary bladder neoplasms is typically made through a combination of imaging tests such as ultrasound, computed tomography (CT) scan or magnetic resonance imaging (MRI), and cystoscopy, which involves inserting a flexible tube with a camera into the bladder to visualize the tumor.

Treatment options for urinary bladder neoplasms depend on the type of cancer, stage, and location of the tumor. Treatment may include surgery to remove the tumor, chemotherapy, radiation therapy, or a combination of these modalities. Early detection and treatment can improve the prognosis for patients with urinary bladder neoplasms.

The cancer cells of this type are thought to arise from abnormalities in the cells that line the ducts of the salivary glands. These abnormal cells grow and divide uncontrollably, forming a mass that can obstruct the flow of saliva and cause symptoms such as pain, swelling, and difficulty eating or speaking.

Mucoepidermoid carcinoma is typically diagnosed with a combination of imaging studies, such as CT scans, MRI, and PET scans, and a biopsy, where a sample of tissue is removed from the tumor and examined under a microscope for cancer cells. Treatment typically involves surgery to remove the tumor, followed by radiation therapy and/or chemotherapy to kill any remaining cancer cells.

Prognosis for this type of cancer is generally good if it is diagnosed early and treated promptly, but it can be challenging to treat if it has spread to other parts of the body.

Neoplastic metastasis can occur in any type of cancer but are more common in solid tumors such as carcinomas (breast, lung, colon). It is important for cancer diagnosis and prognosis because metastasis indicates that the cancer has spread beyond its original site and may be more difficult to treat.

Metastases can appear at any distant location but commonly found sites include the liver, lungs, bones, brain, and lymph nodes. The presence of metastases indicates a higher stage of cancer which is associated with lower survival rates compared to localized cancer.

Example Sentences:

The patient was diagnosed with adenosquamous carcinoma of the lung and underwent surgical resection.

The pathology report revealed that the tumor was an adenosquamous carcinoma, which is a rare type of lung cancer.

Note: Adenosquamous carcinoma is a rare subtype of non-small cell lung cancer (NSCLC), accounting for approximately 1-3% of all lung cancers. It has a more aggressive clinical course and poorer prognosis compared to other types of NSCLC.

Multiple primary neoplasms can arise in different organs or tissues throughout the body, such as the breast, colon, prostate, lung, or skin. Each tumor is considered a separate entity, with its own unique characteristics, including size, location, and aggressiveness. Treatment for multiple primary neoplasms typically involves surgery, chemotherapy, radiation therapy, or a combination of these modalities.

The diagnosis of multiple primary neoplasms can be challenging due to the overlapping symptoms and radiological findings between the different tumors. Therefore, it is essential to have a thorough clinical evaluation and diagnostic workup to rule out other possible causes of the symptoms and confirm the presence of multiple primary neoplasms.

Multiple primary neoplasms are more common than previously thought, with an estimated prevalence of 2% to 5% in some populations. The prognosis for patients with multiple primary neoplasms varies depending on the location, size, and aggressiveness of each tumor, as well as the patient's overall health status.

It is important to note that multiple primary neoplasms are not the same as metastatic cancer, in which a single primary tumor spreads to other parts of the body. Multiple primary neoplasms are distinct tumors that arise independently from different primary sites within the body.

This definition of 'Neoplasm Recurrence, Local' is from the Healthcare Professionals edition of the Merriam-Webster Medical Dictionary, copyright © 2007 by Merriam-Webster, Inc.

Some common types of head and neck neoplasms include:

1. Oral cavity cancer: Cancer that develops in the mouth, tongue, lips, or floor of the mouth.
2. Oropharyngeal cancer: Cancer that develops in the throat, including the base of the tongue, soft palate, and tonsils.
3. Hypopharyngeal cancer: Cancer that develops in the lower part of the throat, near the esophagus.
4. Laryngeal cancer: Cancer that develops in the voice box (larynx).
5. Paranasal sinus cancer: Cancer that develops in the air-filled cavities around the eyes and nose.
6. Salivary gland cancer: Cancer that develops in the salivary glands, which produce saliva to moisten food and keep the mouth lubricated.
7. Thyroid gland cancer: Cancer that develops in the butterfly-shaped gland in the neck that regulates metabolism and growth.

The risk factors for developing head and neck neoplasms include tobacco use, heavy alcohol consumption, human papillomavirus (HPV) infection, poor diet, and exposure to environmental carcinogens such as asbestos or radiation. Symptoms of head and neck neoplasms can vary depending on the location and size of the tumor, but may include a lump or swelling, pain, difficulty swallowing, bleeding, and changes in voice or breathing.

Diagnosis of head and neck neoplasms typically involves a combination of physical examination, imaging tests such as CT scans or MRI, and biopsy to confirm the presence of cancer cells. Treatment options can include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, depending on the type, location, and stage of the cancer.

Overall, head and neck neoplasms can have a significant impact on quality of life, and early detection and treatment are important for improving outcomes. If you suspect any changes in your head or neck, it is essential to consult with a healthcare professional for an accurate diagnosis and appropriate treatment.

Benign ovarian neoplasms include:

1. Serous cystadenoma: A fluid-filled sac that develops on the surface of the ovary.
2. Mucinous cystadenoma: A tumor that is filled with mucin, a type of protein.
3. Endometrioid tumors: Tumors that are similar to endometrial tissue (the lining of the uterus).
4. Theca cell tumors: Tumors that develop in the supportive tissue of the ovary called theca cells.

Malignant ovarian neoplasms include:

1. Epithelial ovarian cancer (EOC): The most common type of ovarian cancer, which arises from the surface epithelium of the ovary.
2. Germ cell tumors: Tumors that develop from germ cells, which are the cells that give rise to eggs.
3. Stromal sarcomas: Tumors that develop in the supportive tissue of the ovary.

Ovarian neoplasms can cause symptoms such as pelvic pain, abnormal bleeding, and abdominal swelling. They can also be detected through pelvic examination, imaging tests such as ultrasound and CT scan, and biopsy. Treatment options for ovarian neoplasms depend on the type, stage, and location of the tumor, and may include surgery, chemotherapy, and radiation therapy.

Types of Bronchial Neoplasms:

1. Adenocarcinoma: This is the most common type of lung cancer and accounts for approximately 40% of all lung cancers. It originates in the glandular cells that line the bronchi.
2. Squamous Cell Carcinoma: This type of lung cancer originates in the squamous cells that line the bronchi. It is the second most common type of lung cancer, accounting for approximately 25% of all lung cancers.
3. Small Cell Lung Cancer (SCLC): This type of lung cancer is highly aggressive and accounts for approximately 10% of all lung cancers. It originates in the small cells that line the bronchi.
4. Large Cell Carcinoma: This type of lung cancer is rare and accounts for approximately 5% of all lung cancers. It originates in the large cells that line the bronchi.
5. Bronchioloalveolar Carcinoma (BAC): This type of lung cancer originates in the small air sacs (alveoli) and is rare, accounting for approximately 2% of all lung cancers.
6. Lymphoma: This type of cancer originates in the immune system cells that line the bronchi. It is rare, accounting for approximately 1% of all lung cancers.
7. Carcinoid Tumors: These are rare types of lung cancer that originate in the neuroendocrine cells that line the bronchi. They are typically slow-growing and less aggressive than other types of lung cancer.
8. Secondary Cancers: These are cancers that have spread to the lungs from other parts of the body, such as breast cancer or colon cancer.

Diagnosis of Bronchial Neoplasms:

1. Medical History and Physical Examination: A thorough medical history and physical examination are essential for diagnosing bronchial neoplasms. The doctor will ask questions about the patient's symptoms, risk factors, and medical history.
2. Chest X-Ray: A chest X-ray is often the first diagnostic test performed to evaluate the lungs for any abnormalities.
3. Computed Tomography (CT) Scan: A CT scan is a more detailed imaging test that uses X-rays and computer technology to produce cross-sectional images of the lungs. It can help identify the size, location, and extent of the tumor.
4. Positron Emission Tomography (PET) Scan: A PET scan is a diagnostic test that uses small amounts of radioactive material to visualize the metabolic activity of the cells in the lungs. It can help identify the presence of cancerous cells and determine the effectiveness of treatment.
5. Biopsy: A biopsy involves taking a sample of tissue from the lung and examining it under a microscope for cancerous cells. It is a definitive diagnostic test for bronchial neoplasms.
6. Bronchoscopy: Bronchoscopy is a procedure in which a thin, flexible tube with a camera on the end is inserted through the nose or mouth and guided to the lungs. It can help identify any abnormalities in the airways and obtain a biopsy sample.
7. Magnetic Resonance Imaging (MRI): An MRI uses magnetic fields and radio waves to produce detailed images of the lungs and surrounding tissues. It is not as commonly used for diagnosing bronchial neoplasms as other imaging tests, but it may be recommended in certain cases.
8. Ultrasound: An ultrasound uses high-frequency sound waves to produce images of the lungs and surrounding tissues. It is not typically used as a diagnostic test for bronchial neoplasms, but it may be used to evaluate the spread of cancer to other parts of the body.

It's important to note that the specific diagnostic tests and procedures used will depend on the individual case and the suspicion of malignancy. Your doctor will discuss the best course of action with you based on your symptoms, medical history, and test results.

The term "paraneoplastic" refers to the fact that these conditions are parallel to, or associated with, neoplasms (abnormal growths) in the body. The exact cause of paraneoplastic syndromes is not fully understood, but they are believed to be related to the immune system's response to cancer cells.

Some common features of paraneoplastic syndromes include:

1. Autoantibodies: The immune system produces antibodies that attack the body's own tissues and organs.
2. Inflammation: The immune system causes inflammation in various parts of the body.
3. Nerve damage: Paraneoplastic syndromes can affect the nerves, leading to symptoms such as numbness, weakness, and pain.
4. Muscle weakness: Some paraneoplastic syndromes can cause muscle weakness and wasting.
5. Skin rashes: Some patients with paraneoplastic syndromes may develop skin rashes or lesions.
6. Eye problems: Paraneoplastic syndromes can affect the eyes, leading to symptoms such as double vision, blindness, and eye pain.
7. Endocrine dysfunction: Some paraneoplastic syndromes can disrupt the normal functioning of the endocrine system, leading to hormonal imbalances.

Examples of paraneoplastic syndromes include:

1. Lambert-Eaton myasthenic syndrome (LEMS): This is a rare autoimmune disorder that affects the nerves and muscles, leading to muscle weakness and fatigue. It is often associated with small cell lung cancer.
2. Anti-NMDA receptor encephalitis: This is a severe autoimmune disorder that affects the brain and can cause symptoms such as seizures, confusion, and memory loss. It is often associated with ovarian teratoma.
3. Paraneoplastic cerebellar degeneration (PCD): This is a rare condition that affects the cerebellum and can cause symptoms such as coordination problems, balance difficulties, and difficulty with movement. It is often associated with lung cancer or other types of cancer.
4. Stiff-person syndrome: This is a rare autoimmune disorder that affects the central nervous system and can cause symptoms such as muscle stiffness, spasms, and autonomy dysfunction. It is often associated with ovarian teratoma.
5. Polymyositis: This is a rare inflammatory condition that affects the muscles and can cause muscle weakness and wasting. It is often associated with cancer, particularly lung cancer.
6. Dercum's disease: This is a rare condition that affects the adipose tissue and can cause symptoms such as pain, swelling, and limited mobility. It is often associated with cancer, particularly breast cancer.
7. Multiple myeloma: This is a type of cancer that affects the plasma cells in the bone marrow and can cause symptoms such as bone pain, fatigue, and weakness. It is often associated with ovarian teratoma.
8. Painless thyroiditis: This is a rare condition that affects the thyroid gland and can cause symptoms such as thyroid gland inflammation, fatigue, and weight gain. It is often associated with cancer, particularly breast cancer.
9. Ovarian cysts: These are fluid-filled sacs that form on the ovaries and can cause symptoms such as pelvic pain, bloating, and irregular menstrual periods. They are often associated with ovarian teratoma.
10. Endometriosis: This is a condition in which tissue similar to the lining of the uterus grows outside of the uterus and can cause symptoms such as pelvic pain, heavy menstrual bleeding, and infertility. It is often associated with ovarian teratoma.

It's important to note that these conditions are rare and not all cases of ovarian teratoma are associated with them. If you suspect you may have ovarian teratoma, it's important to talk to your healthcare provider for proper diagnosis and treatment.

Embryonal carcinoma is thought to be caused by genetic mutations that occur during fetal development. These mutations can disrupt the normal growth and development of cells, leading to the formation of abnormal tissue and eventually cancer.

Symptoms of embryonal carcinoma vary depending on the location of the tumor. They may include skin lesions, seizures, developmental delays, and gastrointestinal problems. Diagnosis is typically made through a combination of imaging tests such as ultrasound, CT scans, and MRI scans, as well as biopsy to confirm the presence of cancer cells.

Treatment for embryonal carcinoma usually involves surgery to remove the tumor, as well as chemotherapy and/or radiation therapy to destroy any remaining cancer cells. In some cases, bone marrow or stem cell transplantation may be necessary. Prognosis for this disease is generally poor, as it is often diagnosed at a late stage and can be difficult to treat effectively.

Embryonal carcinoma is different from other types of cancer in that it arises from embryonic tissue rather than adult tissue. It is also characterized by the presence of immature cells, which are not found in more advanced cancers. Overall, embryonal carcinoma is a rare and aggressive form of cancer that requires specialized treatment and management.

There are several types of skin neoplasms, including:

1. Basal cell carcinoma (BCC): This is the most common type of skin cancer, and it usually appears as a small, fleshy bump or a flat, scaly patch. BCC is highly treatable, but if left untreated, it can grow and invade surrounding tissue.
2. Squamous cell carcinoma (SCC): This type of skin cancer is less common than BCC but more aggressive. It typically appears as a firm, flat, or raised bump on sun-exposed areas. SCC can spread to other parts of the body if left untreated.
3. Melanoma: This is the most serious type of skin cancer, accounting for only 1% of all skin neoplasms but responsible for the majority of skin cancer deaths. Melanoma can appear as a new or changing mole, and it's essential to recognize the ABCDE signs (Asymmetry, Border irregularity, Color variation, Diameter >6mm, Evolving size, shape, or color) to detect it early.
4. Sebaceous gland carcinoma: This rare type of skin cancer originates in the oil-producing glands of the skin and can appear as a firm, painless nodule on the forehead, nose, or other oily areas.
5. Merkel cell carcinoma: This is a rare and aggressive skin cancer that typically appears as a firm, shiny bump on the skin. It's more common in older adults and those with a history of sun exposure.
6. Cutaneous lymphoma: This type of cancer affects the immune system and can appear as a rash, nodules, or tumors on the skin.
7. Kaposi sarcoma: This is a rare type of skin cancer that affects people with weakened immune systems, such as those with HIV/AIDS. It typically appears as a flat, red or purple lesion on the skin.

While skin cancers are generally curable when detected early, it's important to be aware of your skin and notice any changes or unusual spots, especially if you have a history of sun exposure or other risk factors. If you suspect anything suspicious, see a dermatologist for an evaluation and potential biopsy. Remember, prevention is key to avoiding the harmful effects of UV radiation and reducing your risk of developing skin cancer.

Types of mouth neoplasms include:

1. Oral squamous cell carcinoma (OSCC): This is the most common type of mouth cancer, accounting for about 90% of all cases. It usually occurs on the tongue, lips, or floor of the mouth.
2. Verrucous carcinoma: This type of cancer is slow-growing and typically affects the gums or the outer surface of the tongue.
3. Adenoid cystic carcinoma: This type of cancer is rare and usually affects the salivary glands. It can infiltrate surrounding tissues and cause significant destruction of nearby structures.
4. Mucoepidermoid carcinoma: This type of cancer is relatively rare and occurs most commonly on the tongue or the floor of the mouth. It can be benign or malignant, and its behavior varies depending on the type.
5. Melanotic neuroectodermal tumor: This is a rare type of cancer that affects the melanocytes (pigment-producing cells) in the mouth. It typically occurs in the tongue or the lips.

Symptoms of mouth neoplasms can include:

* A sore or ulcer that does not heal
* A lump or mass in the mouth
* Bleeding or pain in the mouth
* Difficulty swallowing or speaking
* Numbness or tingling in the mouth

Diagnosis of mouth neoplasms typically involves a combination of physical examination, imaging studies (such as X-rays or CT scans), and biopsy. Treatment options vary depending on the type and severity of the cancer, but may include surgery, radiation therapy, chemotherapy, or a combination of these. Early detection and treatment are important for improving outcomes in patients with mouth neoplasms.

There are several types of stomach neoplasms, including:

1. Adenocarcinoma: This is the most common type of stomach cancer, accounting for approximately 90% of all cases. It begins in the glandular cells that line the stomach and can spread to other parts of the body.
2. Squamous cell carcinoma: This type of cancer begins in the squamous cells that cover the outer layer of the stomach. It is less common than adenocarcinoma but more likely to be found in the upper part of the stomach.
3. Gastric mixed adenocarcinomasquamous cell carcinoma: This type of cancer is a combination of adenocarcinoma and squamous cell carcinoma.
4. Lymphoma: This is a cancer of the immune system that can occur in the stomach. It is less common than other types of stomach cancer but can be more aggressive.
5. Carcinomas of the stomach: These are malignant tumors that arise from the epithelial cells lining the stomach. They can be subdivided into adenocarcinoma, squamous cell carcinoma, and others.
6. Gastric brunner's gland adenoma: This is a rare type of benign tumor that arises from the Brunner's glands in the stomach.
7. Gastric polyps: These are growths that occur on the lining of the stomach and can be either benign or malignant.

The symptoms of stomach neoplasms vary depending on the location, size, and type of tumor. Common symptoms include abdominal pain, nausea, vomiting, weight loss, and difficulty swallowing. Diagnosis is usually made through a combination of endoscopy, imaging studies (such as CT or PET scans), and biopsy. Treatment depends on the type and stage of the tumor and may include surgery, chemotherapy, radiation therapy, or a combination of these. The prognosis for stomach neoplasms varies depending on the type and stage of the tumor, but early detection and treatment can improve outcomes.

Adrenocortical carcinoma can be subdivided into three main types based on their histological features:

1. Typical adrenocortical carcinoma: This is the most common type and accounts for about 70% of all cases. It is characterized by a large, irregular tumor that grows in the cortex of the adrenal gland.
2. Adenomatous adrenocortical carcinoma: This type is less aggressive than typical adrenocortical carcinoma and accounts for about 20% of cases. It is characterized by a small, well-circumscribed tumor that grows in the cortex of the adrenal gland.
3. Adrenocortical sarcoma: This is the least common type and accounts for about 10% of cases. It is characterized by a rare, malignant tumor that grows in the cortex of the adrenal gland.

Adrenocortical carcinoma can cause a variety of symptoms, including abdominal pain, weight loss, fatigue, and skin changes. The diagnosis is typically made through a combination of imaging studies, such as CT scans and MRI, and tissue biopsy. Treatment options include surgery, chemotherapy, and radiation therapy, and the prognosis depends on the stage and aggressiveness of the tumor.

Overall, adrenocortical carcinoma is a rare and aggressive cancer that requires prompt diagnosis and treatment to improve patient outcomes.

There are several types of colonic neoplasms, including:

1. Adenomas: These are benign growths that are usually precursors to colorectal cancer.
2. Carcinomas: These are malignant tumors that arise from the epithelial lining of the colon.
3. Sarcomas: These are rare malignant tumors that arise from the connective tissue of the colon.
4. Lymphomas: These are cancers of the immune system that can affect the colon.

Colonic neoplasms can cause a variety of symptoms, including bleeding, abdominal pain, and changes in bowel habits. They are often diagnosed through a combination of medical imaging tests (such as colonoscopy or CT scan) and biopsy. Treatment for colonic neoplasms depends on the type and stage of the tumor, and may include surgery, chemotherapy, and/or radiation therapy.

Overall, colonic neoplasms are a common condition that can have serious consequences if left untreated. It is important for individuals to be aware of their risk factors and to undergo regular screening for colon cancer to help detect and treat any abnormal growths or tumors in the colon.

Carcinoma verrucous is a type of squamous cell carcinoma that appears as a rough, bumpy, cauliflower-like lesion on the skin or mucous membranes. It is typically found in the oral cavity, lips, tongue, and penis. The tumor grows slowly, and the surface may be covered with a crust or scab that bleeds easily. Carcinoma verrucous tends to occur in older men, particularly those who smoke or drink excessively.

The exact cause of carcinoma verrucous is not known, but it is believed to be linked to exposure to certain viruses, such as human papillomavirus (HPV), and environmental factors, such as smoking and excessive alcohol consumption. The risk of developing carcinoma verrucous may also be increased by chronic inflammation, immunosuppression, and a diet low in fruits and vegetables.

The symptoms of carcinoma verrucous can vary depending on the location of the tumor. In the oral cavity, it may cause painless ulcers or bleeding gums, while in the penis, it may cause difficulty urinating or painful sexual activity. The diagnosis is made by a biopsy, which involves removing a small sample of tissue from the affected area and examining it under a microscope for cancer cells.

Carcinoma verrucous tends to grow slowly, and the prognosis is generally good if the tumor is completely removed before it spreads to other parts of the body. However, local recurrence is common, and the cancer can be difficult to treat once it has spread. The five-year survival rate for carcinoma verrucous is approximately 80%.

Carcinoma verrucous is often treated with surgery, and in some cases, radiation therapy or chemotherapy may also be recommended. Early detection and treatment are important to improve the chances of successful treatment and long-term survival.

A rare type of carcinoma that develops in the gastrointestinal tract (GI tract) such as stomach, small intestine, or large intestine is known as signet ring cell carcinoma. This cancerous tumor is characterized by its appearance under a microscope, which displays cells arranged in a signet ring pattern.

These cells have a distinctive round nucleus and prominent nucleoli that give them a characteristic signet ring appearance. Signet ring cell carcinomas tend to grow slowly, and they do not typically cause any symptoms until they reach an advanced stage.

Signet ring cell carcinoma can be difficult to diagnose because it often looks like other types of noncancerous conditions, such as inflammation or infection. To diagnose this condition, a healthcare provider will need to perform tests such as endoscopy, imaging studies (such as CT scan or MRI), and biopsy.

Treatment options for signet ring cell carcinoma include surgery to remove the tumor, chemotherapy, radiation therapy, or a combination of these. Treatment decisions depend on the stage of the cancer, location, and other factors such as patient's overall health status and personal preferences.

In summary, signet ring cell carcinoma is a rare type of gastrointestinal tract cancer characterized by its distinctive signet ring appearance under a microscope. It tends to grow slowly and can be difficult to diagnose until it reaches an advanced stage. Treatment options include surgery, chemotherapy, radiation therapy, or combination of these depending on the stage of the cancer and other factors.

Sources:
American Cancer Society. (2022). Signet Ring Cell Carcinoma of the Stomach. Retrieved from
National Cancer Institute. (2022). Signet Ring Cell Carcinoma of the Gastrointestinal Tract. Retrieved from

Precancerous changes in the uterine cervix are called dysplasias, and they can be detected by a Pap smear, which is a routine screening test for women. If dysplasia is found, it can be treated with cryotherapy (freezing), laser therapy, or cone biopsy, which removes the affected cells.

Cervical cancer is rare in developed countries where Pap screening is widely available, but it remains a common cancer in developing countries where access to healthcare and screening is limited. The human papillomavirus (HPV) vaccine has been shown to be effective in preventing cervical precancerous changes and cancer.

Cervical cancer can be treated with surgery, radiation therapy, or chemotherapy, depending on the stage and location of the cancer. The prognosis for early-stage cervical cancer is good, but advanced-stage cancer can be difficult to treat and may have a poor prognosis.

The following are some types of uterine cervical neoplasms:

1. Adenocarcinoma in situ (AIS): This is a precancerous condition that occurs when glandular cells on the surface of the cervix become abnormal and grow out of control.
2. Cervical intraepithelial neoplasia (CIN): This is a precancerous condition that occurs when abnormal cells are found on the surface of the cervix. There are several types of CIN, ranging from mild to severe.
3. Squamous cell carcinoma: This is the most common type of cervical cancer and arises from the squamous cells that line the cervix.
4. Adnexal carcinoma: This is a rare type of cervical cancer that arises from the glands or ducts near the cervix.
5. Small cell carcinoma: This is a rare and aggressive type of cervical cancer that grows rapidly and can spread quickly to other parts of the body.
6. Micropapillary uterine carcinoma: This is a rare type of cervical cancer that grows in a finger-like shape and can be difficult to diagnose.
7. Clear cell carcinoma: This is a rare type of cervical cancer that arises from clear cells and can be more aggressive than other types of cervical cancer.
8. Adenocarcinoma: This is a type of cervical cancer that arises from glandular cells and can be less aggressive than squamous cell carcinoma.
9. Sarcoma: This is a rare type of cervical cancer that arises from the connective tissue of the cervix.

The treatment options for uterine cervical neoplasms depend on the stage and location of the cancer, as well as the patient's overall health and preferences. The following are some common treatments for uterine cervical neoplasms:

1. Hysterectomy: This is a surgical procedure to remove the uterus and may be recommended for early-stage cancers or precancerous changes.
2. Cryotherapy: This is a minimally invasive procedure that uses liquid nitrogen to freeze and destroy abnormal cells in the cervix.
3. Laser therapy: This is a minimally invasive procedure that uses a laser to remove or destroy abnormal cells in the cervix.
4. Cone biopsy: This is a surgical procedure to remove a small cone-shaped sample of tissue from the cervix to diagnose and treat early-stage cancers or precancerous changes.
5. Radiation therapy: This is a non-surgical treatment that uses high-energy rays to kill cancer cells and may be recommended for more advanced cancers or when the cancer has spread to other parts of the body.
6. Chemotherapy: This is a non-surgical treatment that uses drugs to kill cancer cells and may be recommended for more advanced cancers or when the cancer has spread to other parts of the body.
7. Immunotherapy: This is a non-surgical treatment that uses drugs to stimulate the immune system to fight cancer cells and may be recommended for more advanced cancers or when other treatments have failed.
8. Targeted therapy: This is a non-surgical treatment that uses drugs to target specific genes or proteins that contribute to cancer growth and development and may be recommended for more advanced cancers or when other treatments have failed.

It is important to note that the choice of treatment will depend on the stage and location of the cancer, as well as the patient's overall health and preferences. Patients should discuss their treatment options with their doctor and develop a personalized plan that is right for them.

Types of Gallbladder Neoplasms:

1. Adenoma: A benign tumor that grows in the gallbladder wall and can become malignant over time if left untreated.
2. Cholangiocarcinoma: A rare and aggressive malignant tumor that arises in the gallbladder or bile ducts.
3. Gallbladder cancer: A general term used to describe any type of cancer that develops in the gallbladder, including adenocarcinoma, squamous cell carcinoma, and other rare types.

Causes and Risk Factors:

1. Genetics: A family history of gallbladder disease or certain genetic conditions can increase the risk of developing gallbladder neoplasms.
2. Chronic inflammation: Long-standing inflammation in the gallbladder, such as that caused by gallstones or chronic bile duct obstruction, can increase the risk of developing cancer.
3. Obesity: Being overweight or obese may increase the risk of developing gallbladder neoplasms.
4. Age: The risk of developing gallbladder neoplasms increases with age, with most cases occurring in people over the age of 50.

Symptoms and Diagnosis:

1. Abdominal pain: Pain in the upper right abdomen is a common symptom of gallbladder neoplasms.
2. Jaundice: Yellowing of the skin and eyes can occur if the cancer blocks the bile ducts.
3. Weight loss: Unexplained weight loss can be a symptom of some types of gallbladder neoplasms.
4. Fatigue: Feeling tired or weak can be a symptom of some types of gallbladder neoplasms.

Diagnosis is typically made through a combination of imaging tests such as CT scans, MRI scans, and PET scans, and a biopsy to confirm the presence of cancer cells.

Treatment:

1. Surgery: Surgery is the primary treatment for gallbladder neoplasms. The type of surgery depends on the stage and location of the cancer.
2. Chemotherapy: Chemotherapy may be used in combination with surgery to treat advanced or aggressive cancers.
3. Radiation therapy: Radiation therapy may be used in combination with surgery to treat advanced or aggressive cancers.
4. Watchful waiting: For early-stage cancers, a wait-and-watch approach may be taken, where the patient is monitored regularly with imaging tests to see if the cancer progresses.

Prognosis:
The prognosis for gallbladder neoplasms depends on the stage and location of the cancer at the time of diagnosis. In general, the earlier the cancer is detected and treated, the better the prognosis. For early-stage cancers, the 5-year survival rate is high, while for advanced cancers, the prognosis is poor.

Complications:

1. Bile duct injury: During surgery, there is a risk of damaging the bile ducts, which can lead to complications such as bile leakage or bleeding.
2. Infection: There is a risk of infection after surgery, which can be serious and may require hospitalization.
3. Pancreatitis: Gallbladder cancer can cause inflammation of the pancreas, leading to pancreatitis.
4. Jaundice: Cancer of the gallbladder can block the bile ducts, leading to jaundice and other complications.
5. Spread of cancer: Gallbladder cancer can spread to other parts of the body, such as the liver or lymph nodes, which can reduce the chances of a cure.

The most common types of laryngeal neoplasms include:

1. Vocal cord nodules and polyps: These are benign growths that develop on the vocal cords due to overuse, misuse, or trauma.
2. Laryngeal papillomatosis: This is a condition where warts grow on the vocal cords, often caused by the human papillomavirus (HPV).
3. Adenoid cystic carcinoma: This is a rare type of cancer that develops in the salivary glands near the larynx.
4. Squamous cell carcinoma: This is the most common type of cancer that develops in the larynx, often due to smoking or heavy alcohol consumption.
5. Verrucous carcinoma: This is a rare type of cancer that develops on the vocal cords and is often associated with chronic inflammation.
6. Lymphoma: This is a type of cancer that affects the immune system, and can develop in the larynx.
7. Melanoma: This is a rare type of cancer that develops from pigment-producing cells called melanocytes.

Symptoms of laryngeal neoplasms can include hoarseness or difficulty speaking, breathing difficulties, and ear pain. Diagnosis is typically made through a combination of physical examination, imaging tests such as CT scans or MRI, and biopsy. Treatment options vary depending on the type and severity of the neoplasm, but may include surgery, radiation therapy, or chemotherapy.

Disease progression can be classified into several types based on the pattern of worsening:

1. Chronic progressive disease: In this type, the disease worsens steadily over time, with a gradual increase in symptoms and decline in function. Examples include rheumatoid arthritis, osteoarthritis, and Parkinson's disease.
2. Acute progressive disease: This type of disease worsens rapidly over a short period, often followed by periods of stability. Examples include sepsis, acute myocardial infarction (heart attack), and stroke.
3. Cyclical disease: In this type, the disease follows a cycle of worsening and improvement, with periodic exacerbations and remissions. Examples include multiple sclerosis, lupus, and rheumatoid arthritis.
4. Recurrent disease: This type is characterized by episodes of worsening followed by periods of recovery. Examples include migraine headaches, asthma, and appendicitis.
5. Catastrophic disease: In this type, the disease progresses rapidly and unpredictably, with a poor prognosis. Examples include cancer, AIDS, and organ failure.

Disease progression can be influenced by various factors, including:

1. Genetics: Some diseases are inherited and may have a predetermined course of progression.
2. Lifestyle: Factors such as smoking, lack of exercise, and poor diet can contribute to disease progression.
3. Environmental factors: Exposure to toxins, allergens, and other environmental stressors can influence disease progression.
4. Medical treatment: The effectiveness of medical treatment can impact disease progression, either by slowing or halting the disease process or by causing unintended side effects.
5. Co-morbidities: The presence of multiple diseases or conditions can interact and affect each other's progression.

Understanding the type and factors influencing disease progression is essential for developing effective treatment plans and improving patient outcomes.

Examples of precancerous conditions include:

1. Dysplasia: This is a condition where abnormal cells are present in the tissue, but have not yet invaded surrounding tissues. Dysplasia can be found in organs such as the cervix, colon, and breast.
2. Carcinoma in situ (CIS): This is a condition where cancer cells are present in the tissue, but have not yet invaded surrounding tissues. CIS is often found in organs such as the breast, prostate, and cervix.
3. Atypical hyperplasia: This is a condition where abnormal cells are present in the tissue, but they are not yet cancerous. Atypical hyperplasia can be found in organs such as the breast and uterus.
4. Lobular carcinoma in situ (LCIS): This is a condition where cancer cells are present in the milk-producing glands of the breasts, but have not yet invaded surrounding tissues. LCIS is often found in both breasts and can increase the risk of developing breast cancer.
5. Adenomas: These are small growths on the surface of the colon that can become malignant over time if left untreated.
6. Leukoplakia: This is a condition where thick, white patches develop on the tongue or inside the mouth. Leukoplakia can be a precancerous condition and may increase the risk of developing oral cancer.
7. Oral subsquamous carcinoma: This is a type of precancerous lesion that develops in the mouth and can progress to squamous cell carcinoma if left untreated.
8. Cervical intraepithelial neoplasia (CIN): This is a condition where abnormal cells are present on the surface of the cervix, but have not yet invaded surrounding tissues. CIN can progress to cancer over time if left untreated.
9. Vulvar intraepithelial neoplasia (VIN): This is a condition where abnormal cells are present on the vulva, but have not yet invaded surrounding tissues. VIN can progress to cancer over time if left untreated.
10. Penile intraepithelial neoplasia (PIN): This is a condition where abnormal cells are present on the penis, but have not yet invaded surrounding tissues. PIN can progress to cancer over time if left untreated.

It is important to note that not all precancerous conditions will develop into cancer, and some may resolve on their own without treatment. However, it is important to follow up with a healthcare provider to monitor any changes and determine the best course of treatment.

Carcinoid tumors are usually found in the appendix, small intestine, rectum, or other parts of the gastrointestinal tract. They can also occur in the lungs, pancreas, or other organs. These tumors tend to grow slowly and often do not cause any symptoms until they have grown quite large.

Carcinoid tumors are diagnosed through a combination of imaging tests such as CT scans, MRI scans, and endoscopies, along with a biopsy to confirm the presence of cancer cells. Treatment for carcinoid tumors depends on the location, size, and stage of the tumor, as well as the patient's overall health. Treatment options may include surgery, chemotherapy, radiation therapy, or a combination of these.

Some of the symptoms that may be associated with carcinoid tumors include:

* Flushing (redness and warmth of the skin)
* Wheezing
* Shortness of breath
* Abdominal pain
* Diarrhea
* Weight loss

Carcinoid tumors are relatively rare, accounting for only about 1% to 5% of all cancer cases. However, they tend to be more common in certain parts of the world, such as North America and Europe. The exact cause of carcinoid tumors is not known, but they are thought to be linked to genetic mutations that occur during fetal development.

Overall, while carcinoid tumors are rare and can be challenging to diagnose and treat, advances in medical technology and cancer research have improved the outlook for patients with these types of tumors. With early detection and appropriate treatment, many people with carcinoid tumors can achieve long-term survival and a good quality of life.

Adenocarcinoma, follicular accounts for approximately 15% of all thyroid cancers and is more common in women than men. This type of cancer tends to be less aggressive than other types of thyroid cancer, such as papillary carcinoma, but it can still recur (come back) after treatment and spread to other parts of the body (metastasize).

Treatment options for adenocarcinoma, follicular include surgery to remove the tumor, radioactive iodine therapy, and hormone therapy. The prognosis is generally good for patients with this type of cancer, especially if it is detected early and treated appropriately.

In summary, adenocarcinoma, follicular is a type of thyroid cancer that originates in the glands (follicles) of the thyroid gland. It tends to be less aggressive than other types of thyroid cancer but can still recur and spread to other parts of the body. Treatment options include surgery, radioactive iodine therapy, and hormone therapy.

Pancreatic adenocarcinoma is the most common type of malignant pancreatic neoplasm and accounts for approximately 85% of all pancreatic cancers. It originates in the glandular tissue of the pancreas and has a poor prognosis, with a five-year survival rate of less than 10%.

Pancreatic neuroendocrine tumors (PNETs) are less common but more treatable than pancreatic adenocarcinoma. These tumors originate in the hormone-producing cells of the pancreas and can produce excess hormones that cause a variety of symptoms, such as diabetes or high blood sugar. PNETs are classified into two main types: functional and non-functional. Functional PNETs produce excess hormones and are more aggressive than non-functional tumors.

Other rare types of pancreatic neoplasms include acinar cell carcinoma, ampullary cancer, and oncocytic pancreatic neuroendocrine tumors. These tumors are less common than pancreatic adenocarcinoma and PNETs but can be equally aggressive and difficult to treat.

The symptoms of pancreatic neoplasms vary depending on the type and location of the tumor, but they often include abdominal pain, weight loss, jaundice, and fatigue. Diagnosis is typically made through a combination of imaging tests such as CT scans, endoscopic ultrasound, and biopsy. Treatment options for pancreatic neoplasms depend on the type and stage of the tumor but may include surgery, chemotherapy, radiation therapy, or a combination of these.

Prognosis for patients with pancreatic neoplasms is generally poor, especially for those with advanced stages of disease. However, early detection and treatment can improve survival rates. Research into the causes and mechanisms of pancreatic neoplasms is ongoing, with a focus on developing new and more effective treatments for these devastating diseases.




Examples of 'Adenocarcinoma, Mucinous' in medical literature:

* The patient was diagnosed with adenocarcinoma, mucinous type, in their colon after undergoing a colonoscopy and biopsy. (From the Journal of Clinical Oncology)

* The patient had a history of adenocarcinoma, mucinous type, in their breast and was being monitored for potential recurrence. (From the Journal of Surgical Oncology)

* The tumor was found to be an adenocarcinoma, mucinous type, with a high grade and was treated with surgery and chemotherapy. (From the Journal of Gastrointestinal Oncology)

Synonyms for 'Adenocarcinoma, Mucinous' include:

* Mucinous adenocarcinoma
* Colon adenocarcinoma, mucinous type
* Rectal adenocarcinoma, mucinous type
* Adenocarcinoma of the colon and rectum, mucinous type.

The term "papillary" refers to the fact that the cancer cells grow in a finger-like shape, resembling a papilla. The term "follicular" refers to the fact that the cancer cells grow near or within glands (follicles). Both types of cancer are considered relatively low-grade, meaning they tend to grow slowly and do not aggressively invade surrounding tissue.

It's important to note that while these types of carcinomas are generally less aggressive than other types of breast or thyroid cancer, they can still be serious and require prompt medical attention. If you suspect you may have symptoms of papillary or follicular carcinoma, it is essential to consult with a healthcare professional for proper diagnosis and treatment.

Note: In WHO classification (1998), it is now called "malignant mesenchymal tumor of soft tissue and bone with cartilaginous differentiation."

Please provide the definition of the above term in a simple language, so that it can be understood by everyone.

Thank you for your help.

Answer: Sure! Here's the definition of "Chondrosarcoma, Mesenchymal" in simpler terms:

It's a type of cancer that starts in the connective tissue (like cartilage) in the body, usually in the long bones of the arms or legs. It tends to grow slowly and can come back after treatment. It can also be very vascular (have lots of blood vessels) and may form cartilaginous or bony parts.

So, it's a type of cancer that affects the connective tissue in the body, specifically in the long bones, and it can grow slowly and come back after treatment.

Endometrial neoplasms are abnormal growths or tumors that develop in the lining of the uterus, known as the endometrium. These growths can be benign (non-cancerous) or malignant (cancerous). The most common type of endometrial neoplasm is endometrial hyperplasia, which is a condition where the endometrium grows too thick and can become cancerous if left untreated. Other types of endometrial neoplasms include endometrial adenocarcinoma, which is the most common type of uterine cancer, and endometrial sarcoma, which is a rare type of uterine cancer that develops in the muscle or connective tissue of the uterus.

Endometrial neoplasms can be caused by a variety of factors, including hormonal imbalances, genetic mutations, and exposure to certain chemicals or radiation. Risk factors for developing endometrial neoplasms include obesity, early onset of menstruation, late onset of menopause, never being pregnant or having few or no full-term pregnancies, and taking hormone replacement therapy or other medications that can increase estrogen levels.

Symptoms of endometrial neoplasms can include abnormal vaginal bleeding, painful urination, and pelvic pain or discomfort. Treatment for endometrial neoplasms depends on the type and stage of the condition, and may involve surgery, radiation therapy, chemotherapy, or hormone therapy. In some cases, a hysterectomy (removal of the uterus) may be necessary.

In summary, endometrial neoplasms are abnormal growths that can develop in the lining of the uterus and can be either benign or malignant. They can be caused by a variety of factors and can cause symptoms such as abnormal bleeding and pelvic pain. Treatment depends on the type and stage of the condition, and may involve surgery, radiation therapy, chemotherapy, or hormone therapy.

Clear cell adenocarcinomas can occur in various parts of the body, such as the ovary, pancreas, and lung. In general, clear cell adenocarcinomas tend to grow more slowly than other types of cancer and are less aggressive. However, they can still be malignant and may require treatment.

The prognosis for clear cell adenocarcinoma depends on various factors, such as the stage of the cancer (how far it has spread) and the specific location of the tumor. In general, the prognosis for clear cell adenocarcinoma is good if the cancer is caught early and treated appropriately. However, if the cancer has spread to other parts of the body, the prognosis may be poorer.

There are several treatment options for clear cell adenocarcinoma, including surgery, chemotherapy, radiation therapy, and targeted therapy. The specific treatment plan will depend on the stage and location of the cancer, as well as other individual factors such as age and overall health.

In summary, clear cell adenocarcinoma is a type of cancer that begins in glandular cells and has clear cells. It can occur in various parts of the body and tends to grow slowly, but it can still be malignant and require treatment. The prognosis for clear cell adenocarcinoma depends on various factors, and there are several treatment options available.

The causes of colorectal neoplasms are not fully understood, but factors such as age, genetics, diet, and lifestyle have been implicated. Symptoms of colorectal cancer can include changes in bowel habits, blood in the stool, abdominal pain, and weight loss. Screening for colorectal cancer is recommended for adults over the age of 50, as it can help detect early-stage tumors and improve survival rates.

There are several subtypes of colorectal neoplasms, including adenomas (which are precancerous polyps), carcinomas (which are malignant tumors), and lymphomas (which are cancers of the immune system). Treatment options for colorectal cancer depend on the stage and location of the tumor, but may include surgery, chemotherapy, radiation therapy, or a combination of these.

Research into the causes and treatment of colorectal neoplasms is ongoing, and there has been significant progress in recent years. Advances in screening and treatment have improved survival rates for patients with colorectal cancer, and there is hope that continued research will lead to even more effective treatments in the future.

Explanation: Neoplastic cell transformation is a complex process that involves multiple steps and can occur as a result of genetic mutations, environmental factors, or a combination of both. The process typically begins with a series of subtle changes in the DNA of individual cells, which can lead to the loss of normal cellular functions and the acquisition of abnormal growth and reproduction patterns.

Over time, these transformed cells can accumulate further mutations that allow them to survive and proliferate despite adverse conditions. As the transformed cells continue to divide and grow, they can eventually form a tumor, which is a mass of abnormal cells that can invade and damage surrounding tissues.

In some cases, cancer cells can also break away from the primary tumor and travel through the bloodstream or lymphatic system to other parts of the body, where they can establish new tumors. This process, known as metastasis, is a major cause of death in many types of cancer.

It's worth noting that not all transformed cells will become cancerous. Some forms of cellular transformation, such as those that occur during embryonic development or tissue regeneration, are normal and necessary for the proper functioning of the body. However, when these transformations occur in adult tissues, they can be a sign of cancer.

See also: Cancer, Tumor

Word count: 190

1. Squamous cell carcinoma: This is the most common type of tongue cancer, accounting for about 90% of all cases. It usually starts on the front two-thirds of the tongue and can spread to other parts of the mouth and throat.
2. Verrucous carcinoma: This type of cancer is less aggressive than squamous cell carcinoma but can still invade surrounding tissues. It typically occurs on the lateral or back part of the tongue.
3. Papillary carcinoma: This type of cancer is rare and usually affects young people. It starts in the mucous glands on the surface of the tongue and tends to grow slowly.
4. Lymphoma: This type of cancer affects the immune system and can occur in various parts of the body, including the tongue. There are different subtypes of lymphoma that can affect the tongue, such as Hodgkin's lymphoma and non-Hodgkin's lymphoma.
5. Mucoepidermoid carcinoma: This is a rare type of cancer that usually affects children and young adults. It tends to grow slowly and can occur anywhere on the tongue, but it is most common on the front part of the tongue.

The symptoms of tongue neoplasms can vary depending on the type and location of the tumor. Common symptoms include:

* A lump or mass on the tongue that may be painful or tender to the touch
* Bleeding or discharge from the tongue
* Difficulty speaking, swallowing, or moving the tongue
* Pain in the tongue or mouth that does not go away
* A sore throat or ear pain

If you suspect you may have a tongue neoplasm, it is important to see a doctor for an evaluation. A biopsy can be performed to determine the type of tumor and develop a treatment plan. Treatment options can vary depending on the type and location of the tumor, but may include surgery, radiation therapy, chemotherapy, or a combination of these.

Examples of neoplasms, complex and mixed include:

1. Breast cancer that consists of both ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC).
2. Lung cancer that contains both adenocarcinoma and squamous cell carcinoma.
3. Colorectal cancer that is composed of both adenocarcinoma and mucinous adenocarcinoma.
4. Thyroid cancer that consists of both papillary carcinoma and follicular carcinoma.
5. Melanoma that is composed of both superficial spreading melanoma and nodular melanoma.

The diagnosis of neoplasms, complex and mixed often requires a combination of imaging studies such as CT scans, MRI, and PET scans, as well as tissue sampling through biopsy or surgery. Treatment may involve a combination of surgery, radiation therapy, and chemotherapy, depending on the specific type and extent of the cancer.

The term "serous" refers to the fact that the tumor produces a fluid-filled cyst, which typically contains a clear, serous (watery) liquid. The cancer cells are typically found in the outer layer of the ovary, near the surface of the organ.

Cystadenocarcinoma, serous is the most common type of ovarian cancer, accounting for about 50-60% of all cases. It is often diagnosed at an advanced stage, as it can be difficult to detect in its early stages. Symptoms may include abdominal pain, bloating, and changes in bowel or bladder habits.

Treatment for cystadenocarcinoma, serous usually involves a combination of surgery and chemotherapy. Surgery may involve removing the uterus, ovaries, and other affected tissues, followed by chemotherapy to kill any remaining cancer cells. In some cases, radiation therapy may also be used.

Prognosis for cystadenocarcinoma, serous varies depending on the stage of the cancer at diagnosis. Women with early-stage disease have a good prognosis, while those with advanced-stage disease have a poorer outlook. However, overall survival rates have improved in recent years due to advances in treatment and screening.

In summary, cystadenocarcinoma, serous is a type of ovarian cancer that originates in the lining of the ovary and grows slowly over time. It can be difficult to detect in its early stages, but treatment typically involves surgery and chemotherapy. Prognosis varies depending on the stage of the cancer at diagnosis.

The tumor cells are typically small, uniform, and well-differentiated, with a distinct cell border and a central nucleus. The tumor cells are often arranged in a glandular or tubular pattern, which is characteristic of this type of cancer.

Carcinoma, Lewis lung usually affects older adults, with the median age at diagnosis being around 60 years. Men are slightly more likely to be affected than women. The main risk factor for developing this type of cancer is smoking, although it can also occur in people who have never smoked.

The symptoms of Carcinoma, Lewis lung can vary depending on the location and size of the tumor, but they may include:

* Chest pain or discomfort
* Coughing up blood
* Shortness of breath
* Fatigue
* Weight loss

If you suspect you may have Carcinoma, Lewis lung or are experiencing any of these symptoms, it is important to consult a healthcare professional for an accurate diagnosis and appropriate treatment.

The post Definition of 'Carcinoma, Lewis Lung' in the medical field appeared first on Healthy Life Tips.

The most common types of ureteral neoplasms include:

1. Ureteral calculi (stones): Small, hard mineral deposits that form in the ureters and can cause pain and blockage.
2. Ureteral tumors: Both benign and malignant tumors can occur in the ureters, including transitional cell carcinoma, papillary tumors, and ureteral leiomyomas (smooth muscle tumors).
3. Metanephric stromal tumors: Rare tumors that originate in the supporting tissue of the kidney and can occur in the ureters.
4. Wilms' tumor: A rare type of kidney cancer that can spread to the ureters.

Symptoms of ureteral neoplasms may include blood in the urine, pain in the flank or abdomen, frequent urination, and abdominal mass. Diagnosis is typically made with imaging studies such as CT scans and/or ultrasound, followed by a biopsy to confirm the type of tumor. Treatment depends on the type and location of the tumor, and may involve surgery, chemotherapy, or radiation therapy.

The symptoms of LEMS typically develop gradually over time and may include:

1. Muscle weakness that worsens with activity and improves with rest.
2. Weakness in the legs, hips, and shoulders.
3. Fatigue and muscle cramps.
4. Difficulty walking or standing upright.
5. Double vision or other eye problems.
6. Dry mouth and difficulty swallowing.
7. Increased heart rate and blood pressure.
8. Impaired reflexes.
9. Decreased sweating.
10. Weight loss.

The exact cause of LEMS is not known, but it is believed to be an autoimmune disorder in which the immune system mistakenly attacks the VGCCs in the neuromuscular junction. The condition is often associated with other autoimmune disorders such as thyroiditis, vitiligo, and adrenal insufficiency.

There is no cure for LEMS, but treatment options are available to manage the symptoms. These may include:

1. Immunosuppressive medications such as prednisone to reduce inflammation and suppress the immune system.
2. Intracranial pressure-lowering medications such as acetazolamide to reduce the pressure in the brain.
3. Muscle strengthening exercises to improve muscle function.
4. Physical therapy to maintain muscle strength and flexibility.
5. Orthostatic hypotension medications to manage orthostatic hypotension (a drop in blood pressure when standing).
6. Pain management medications to relieve muscle cramps, spasms, or pain.
7. Nutritional support to ensure adequate nutrition and prevent weight loss.
8. Respiratory support as needed to manage respiratory muscle weakness.
9. Speech therapy to improve communication skills.
10. Psychological support to cope with the emotional and social challenges of the condition.

It is important for individuals with LEMS to work closely with their healthcare team to manage their symptoms and prevent complications. With proper treatment, many people with LEMS can lead active and fulfilling lives.

1. Parotid gland tumors: These are the most common type of salivary gland tumor and can be benign or malignant.
2. Submandibular gland tumors: These are less common than parotid gland tumors but can also be benign or malignant.
3. Sublingual gland tumors: These are rare and usually benign.
4. Warthin's tumor: This is a type of benign tumor that affects the parotid gland.
5. Mucoepidermoid carcinoma: This is a type of malignant tumor that can occur in any of the major salivary glands.
6. Acinic cell carcinoma: This is a rare type of malignant tumor that usually occurs in the parotid gland.
7. Adenoid cystic carcinoma: This is a slow-growing malignant tumor that can occur in any of the major salivary glands.
8. Metastatic tumors: These are tumors that have spread to the salivary glands from another part of the body.

Salivary gland neoplasms can cause a variety of symptoms, including painless lumps or swelling in the neck or face, difficulty swallowing, and numbness or weakness in the face. Treatment options depend on the type and stage of the tumor and may include surgery, radiation therapy, and/or chemotherapy.

In conclusion, salivary gland neoplasms are a diverse group of cancers that affect the salivary glands, and it's important to be aware of the different types, symptoms, and treatment options in order to provide effective care for patients with these tumors.

Neoplasm refers to an abnormal growth of cells that can be benign (non-cancerous) or malignant (cancerous). Neoplasms can occur in any part of the body and can affect various organs and tissues. The term "neoplasm" is often used interchangeably with "tumor," but while all tumors are neoplasms, not all neoplasms are tumors.

Types of Neoplasms

There are many different types of neoplasms, including:

1. Carcinomas: These are malignant tumors that arise in the epithelial cells lining organs and glands. Examples include breast cancer, lung cancer, and colon cancer.
2. Sarcomas: These are malignant tumors that arise in connective tissue, such as bone, cartilage, and fat. Examples include osteosarcoma (bone cancer) and soft tissue sarcoma.
3. Lymphomas: These are cancers of the immune system, specifically affecting the lymph nodes and other lymphoid tissues. Examples include Hodgkin lymphoma and non-Hodgkin lymphoma.
4. Leukemias: These are cancers of the blood and bone marrow that affect the white blood cells. Examples include acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).
5. Melanomas: These are malignant tumors that arise in the pigment-producing cells called melanocytes. Examples include skin melanoma and eye melanoma.

Causes and Risk Factors of Neoplasms

The exact causes of neoplasms are not fully understood, but there are several known risk factors that can increase the likelihood of developing a neoplasm. These include:

1. Genetic predisposition: Some people may be born with genetic mutations that increase their risk of developing certain types of neoplasms.
2. Environmental factors: Exposure to certain environmental toxins, such as radiation and certain chemicals, can increase the risk of developing a neoplasm.
3. Infection: Some neoplasms are caused by viruses or bacteria. For example, human papillomavirus (HPV) is a common cause of cervical cancer.
4. Lifestyle factors: Factors such as smoking, excessive alcohol consumption, and a poor diet can increase the risk of developing certain types of neoplasms.
5. Family history: A person's risk of developing a neoplasm may be higher if they have a family history of the condition.

Signs and Symptoms of Neoplasms

The signs and symptoms of neoplasms can vary depending on the type of cancer and where it is located in the body. Some common signs and symptoms include:

1. Unusual lumps or swelling
2. Pain
3. Fatigue
4. Weight loss
5. Change in bowel or bladder habits
6. Unexplained bleeding
7. Coughing up blood
8. Hoarseness or a persistent cough
9. Changes in appetite or digestion
10. Skin changes, such as a new mole or a change in the size or color of an existing mole.

Diagnosis and Treatment of Neoplasms

The diagnosis of a neoplasm usually involves a combination of physical examination, imaging tests (such as X-rays, CT scans, or MRI scans), and biopsy. A biopsy involves removing a small sample of tissue from the suspected tumor and examining it under a microscope for cancer cells.

The treatment of neoplasms depends on the type, size, location, and stage of the cancer, as well as the patient's overall health. Some common treatments include:

1. Surgery: Removing the tumor and surrounding tissue can be an effective way to treat many types of cancer.
2. Chemotherapy: Using drugs to kill cancer cells can be effective for some types of cancer, especially if the cancer has spread to other parts of the body.
3. Radiation therapy: Using high-energy radiation to kill cancer cells can be effective for some types of cancer, especially if the cancer is located in a specific area of the body.
4. Immunotherapy: Boosting the body's immune system to fight cancer can be an effective treatment for some types of cancer.
5. Targeted therapy: Using drugs or other substances to target specific molecules on cancer cells can be an effective treatment for some types of cancer.

Prevention of Neoplasms

While it is not always possible to prevent neoplasms, there are several steps that can reduce the risk of developing cancer. These include:

1. Avoiding exposure to known carcinogens (such as tobacco smoke and radiation)
2. Maintaining a healthy diet and lifestyle
3. Getting regular exercise
4. Not smoking or using tobacco products
5. Limiting alcohol consumption
6. Getting vaccinated against certain viruses that are associated with cancer (such as human papillomavirus, or HPV)
7. Participating in screening programs for early detection of cancer (such as mammograms for breast cancer and colonoscopies for colon cancer)
8. Avoiding excessive exposure to sunlight and using protective measures such as sunscreen and hats to prevent skin cancer.

It's important to note that not all cancers can be prevented, and some may be caused by factors that are not yet understood or cannot be controlled. However, by taking these steps, individuals can reduce their risk of developing cancer and improve their overall health and well-being.

Pathologic neovascularization can be seen in a variety of conditions, including cancer, diabetic retinopathy, and age-related macular degeneration. In cancer, for example, the formation of new blood vessels can help the tumor grow and spread to other parts of the body. In diabetic retinopathy, the growth of new blood vessels in the retina can cause vision loss and other complications.

There are several different types of pathologic neovascularization, including:

* Angiosarcoma: a type of cancer that arises from the cells lining blood vessels
* Hemangiomas: benign tumors that are composed of blood vessels
* Cavernous malformations: abnormal collections of blood vessels in the brain or other parts of the body
* Pyogenic granulomas: inflammatory lesions that can form in response to trauma or infection.

The diagnosis of pathologic neovascularization is typically made through a combination of physical examination, imaging studies (such as ultrasound, CT scans, or MRI), and biopsy. Treatment options vary depending on the underlying cause of the condition, but may include medications, surgery, or radiation therapy.

In summary, pathologic neovascularization is a process that occurs in response to injury or disease, and it can lead to serious complications. It is important for healthcare professionals to be aware of this condition and its various forms in order to provide appropriate diagnosis and treatment.

A type of cancer that arises from squamous cells, which are thin, flat cells that are found in the outer layers of the skin and mucous membranes. Squamous cell neoplasms can occur in various parts of the body, including the head and neck, lung, esophagus, and cervix. They are often slow-growing and may not cause symptoms until they have reached an advanced stage.

Squamous cell carcinoma (SCC) is the most common type of squamous cell neoplasm. It can be treated with surgery, radiation therapy, or chemotherapy, depending on the location and stage of the cancer. Squamous cell carcinoma of the skin (SCCS) is the second most common type of skin cancer, after basal cell carcinoma.

Other types of squamous cell neoplasms include:

* Squamous cell papilloma: a benign tumor that grows on the surface of the skin or mucous membranes.
* Squamous cell hyperplasia: an abnormal growth of squamous cells that can be precancerous.
* Squamous cell carcinoma in situ (SCCIS): a precancerous condition in which abnormal squamous cells are found in the skin or mucous membranes.

Overall, squamous cell neoplasms can be treated successfully if they are detected early and appropriate treatment is provided.

Rectal neoplasms refer to abnormal growths or tumors that occur in the rectum, which is the lower part of the digestive system. These growths can be benign (non-cancerous) or malignant (cancerous).

Types of Rectal Neoplasms:

There are several types of rectal neoplasms, including:

1. Adenoma: A benign growth that is usually found in the colon and rectum. It is a common precursor to colorectal cancer.
2. Carcinoma: A malignant tumor that arises from the epithelial cells lining the rectum. It is the most common type of rectal cancer.
3. Rectal adenocarcinoma: A type of carcinoma that originates in the glandular cells lining the rectum.
4. Rectal squamous cell carcinoma: A type of carcinoma that originates in the squamous cells lining the rectum.
5. Rectal melanoma: A rare type of carcinoma that originates in the pigment-producing cells (melanocytes) of the rectum.

Causes and Risk Factors:

The exact causes of rectal neoplasms are not known, but several factors can increase the risk of developing these growths. These include:

1. Age: The risk of developing rectal neoplasms increases with age, with most cases occurring in people over the age of 50.
2. Family history: Having a family history of colorectal cancer or polyps can increase the risk of developing rectal neoplasms.
3. Inflammatory bowel disease: People with inflammatory bowel disease, such as ulcerative colitis and Crohn's disease, are at higher risk of developing rectal neoplasms.
4. Diet: A diet high in fat and low in fiber may increase the risk of developing rectal neoplasms.
5. Lifestyle factors: Factors such as smoking, obesity, and lack of physical activity may also increase the risk of developing rectal neoplasms.

Symptoms:

The symptoms of rectal neoplasms can vary depending on the type and location of the growth. Some common symptoms include:

1. Blood in the stool
2. Changes in bowel movements (such as diarrhea or constipation)
3. Abdominal pain or discomfort
4. Weakness and fatigue
5. Loss of appetite

Diagnosis:

To diagnose rectal neoplasms, a doctor may perform several tests, including:

1. Digital rectal exam (DRE): A doctor will insert a gloved finger into the rectum to feel for any abnormalities.
2. Colonoscopy: A flexible tube with a camera and light on the end is inserted through the anus and into the rectum to examine the inside of the rectum and colon for polyps or other abnormalities.
3. Imaging tests: Such as X-rays, CT scans, or MRI scans to visualize the growth and determine its location and size.
4. Biopsy: A sample of tissue is removed from the rectum and examined under a microscope for cancer cells.

Treatment:

The treatment of rectal neoplasms depends on the type, location, and stage of the growth. Some common treatments include:

1. Polypectomy: Removal of polyps through a colonoscopy or surgery.
2. Local excision: Surgical removal of the tumor and a small amount of surrounding tissue.
3. Radiation therapy: High-energy beams are used to kill cancer cells.
4. Chemotherapy: Drugs are used to kill cancer cells.
5. Immunotherapy: A treatment that uses the body's immune system to fight cancer.

Prognosis:

The prognosis for rectal neoplasms depends on the type, location, and stage of the growth. In general, the earlier the diagnosis and treatment, the better the prognosis. However, some types of rectal neoplasms can be more aggressive and difficult to treat, and may have a poorer prognosis.

Prevention:

There is no sure way to prevent rectal neoplasms, but there are several screening tests that can help detect them early, including:

1. Colonoscopy: A test in which a flexible tube with a camera and light on the end is inserted into the rectum and colon to examine for polyps or cancer.
2. Fecal occult blood test (FOBT): A test that checks for blood in the stool.
3. Flexible sigmoidoscopy: A test similar to a colonoscopy, but only examines the lower part of the colon and rectum.
4. Digital rectal exam (DRE): An examination of the rectum using a gloved finger to feel for any abnormalities.

It is important to talk to your doctor about your risk for rectal neoplasms and any screening tests that may be appropriate for you. Early detection and treatment can improve the prognosis for these types of growths.

NETs can be benign (non-cancerous) or malignant (cancerous). Malignant NETs can spread to other parts of the body through a process called metastasis, which can lead to serious health complications.

The symptoms of NETs vary depending on their location and size, but may include:

* Abdominal pain or discomfort
* Diarrhea or constipation
* Fatigue
* Weakness
* Shortness of breath
* Skin changes such as flushing or sweating
* Headaches
* Seizures

The diagnosis of NETs is based on a combination of imaging tests such as CT scans, MRI scans, and PET scans, as well as biopsy samples. Treatment options for NETs depend on the type, size, location, and stage of the tumor, but may include:

* Medications to slow or stop hormone production
* Chemotherapy to shrink the tumor
* Radiation therapy to kill cancer cells
* Surgery to remove the tumor

Overall, NETs are rare and can be challenging to diagnose and treat. However, with advances in medical technology and ongoing research, there are more effective treatment options available for patients with NETs.

The term "papillary" refers to the fact that the cancer cells grow in a finger-like shape, with each cell forming a small papilla (bump) on the surface of the tumor. APC is often slow-growing and may not cause any symptoms in its early stages.

APC is generally considered to be less aggressive than other types of cancer, such as ductal carcinoma in situ (DCIS) or invasive breast cancer. However, it can still spread to other parts of the body if left untreated. Treatment options for APC may include surgery, radiation therapy, and/or hormone therapy, depending on the location and stage of the cancer.

It's worth noting that APC is sometimes referred to as "papillary adenocarcinoma" or simply "papillary cancer." However, these terms are often used interchangeably with "adenocarcinoma, papillary" in medical literature and clinical practice.

Types of experimental neoplasms include:

* Xenografts: tumors that are transplanted into animals from another species, often humans.
* Transgenic tumors: tumors that are created by introducing cancer-causing genes into an animal's genome.
* Chemically-induced tumors: tumors that are caused by exposure to certain chemicals or drugs.

The use of experimental neoplasms in research has led to significant advances in our understanding of cancer biology and the development of new treatments for the disease. However, the use of animals in cancer research is a controversial topic and alternatives to animal models are being developed and implemented.

Examples of 'Mammary Neoplasms, Experimental' in a sentence:

1. The researchers studied the effects of hormone therapy on mammary neoplasms in experimental animals to better understand its potential role in human breast cancer.
2. The lab used mice with genetic mutations that predispose them to developing mammary neoplasms to test the efficacy of new cancer drugs.
3. In order to investigate the link between obesity and breast cancer, the researchers conducted experiments on mammary neoplasms in rats with diet-induced obesity.

Some common types of bone neoplasms include:

* Osteochondromas: These are benign tumors that grow on the surface of a bone.
* Giant cell tumors: These are benign tumors that can occur in any bone of the body.
* Chondromyxoid fibromas: These are rare, benign tumors that develop in the cartilage of a bone.
* Ewing's sarcoma: This is a malignant tumor that usually occurs in the long bones of the arms and legs.
* Multiple myeloma: This is a type of cancer that affects the plasma cells in the bone marrow.

Symptoms of bone neoplasms can include pain, swelling, or deformity of the affected bone, as well as weakness or fatigue. Treatment options depend on the type and location of the tumor, as well as the severity of the symptoms. Treatment may involve surgery, radiation therapy, chemotherapy, or a combination of these.

CBASQ is characterized by the presence of both squamous and basal cell features, with a mixed pattern of keratinization and a high proliferation rate. The tumor cells are positive for cytokeratins (such as cytokeratin 5/6) and negative for melanoma-specific markers (such as HMB-45 and S100).

The diagnosis of CBASQ requires a thorough clinical evaluation, including a history of prolonged sun exposure, and a biopsy to confirm the presence of both squamous and basal cell features. Treatment typically involves surgical excision with a wide margin, and may also involve adjuvant therapies such as radiation therapy or chemotherapy for more advanced cases.

The prognosis for CBASQ is generally poorer than for other types of skin cancer, due to its aggressive nature and tendency to recur. However, early detection and treatment can improve outcomes and reduce the risk of metastasis.

Neoplasms, unknown primary can occur in any organ or tissue in the body and can affect anyone, regardless of age or gender. The symptoms and treatment options for these types of neoplasms depend on the location and size of the tumor, as well as the patient's overall health and medical history.

Some common types of neoplasms, unknown primary include:

1. Carcinomas: These are malignant tumors that originate in the skin or organs.
2. Sarcomas: These are malignant tumors that originate in connective tissue, such as bone, cartilage, and fat.
3. Lymphomas: These are cancers of the immune system, such as Hodgkin's disease and non-Hodgkin's lymphoma.
4. Leukemias: These are cancers of the blood and bone marrow.

The diagnosis of a neoplasm, unknown primary is typically made through a combination of imaging tests, such as X-rays, CT scans, MRI scans, and PET scans, and a biopsy, which involves removing a small sample of tissue from the tumor for examination under a microscope. Treatment options for these types of neoplasms can include surgery, chemotherapy, radiation therapy, or a combination of these methods.

It is important to note that not all neoplasms, unknown primary are cancerous, and some may be benign but still require treatment to remove the tumor. In some cases, the tumor may be monitored with regular check-ups and imaging tests to ensure that it does not grow or spread.

Overall, the prognosis for neoplasms, unknown primary depends on several factors, including the type of tumor, its size and location, and the effectiveness of treatment. In general, early detection and prompt treatment can improve outcomes for these types of conditions.

Brain neoplasms can arise from various types of cells in the brain, including glial cells (such as astrocytes and oligodendrocytes), neurons, and vascular tissues. The symptoms of brain neoplasms vary depending on their size, location, and type, but may include headaches, seizures, weakness or numbness in the limbs, and changes in personality or cognitive function.

There are several different types of brain neoplasms, including:

1. Meningiomas: These are benign tumors that arise from the meninges, the thin layers of tissue that cover the brain and spinal cord.
2. Gliomas: These are malignant tumors that arise from glial cells in the brain. The most common type of glioma is a glioblastoma, which is aggressive and hard to treat.
3. Pineal parenchymal tumors: These are rare tumors that arise in the pineal gland, a small endocrine gland in the brain.
4. Craniopharyngiomas: These are benign tumors that arise from the epithelial cells of the pituitary gland and the hypothalamus.
5. Medulloblastomas: These are malignant tumors that arise in the cerebellum, specifically in the medulla oblongata. They are most common in children.
6. Acoustic neurinomas: These are benign tumors that arise on the nerve that connects the inner ear to the brain.
7. Oligodendrogliomas: These are malignant tumors that arise from oligodendrocytes, the cells that produce the fatty substance called myelin that insulates nerve fibers.
8. Lymphomas: These are cancers of the immune system that can arise in the brain and spinal cord. The most common type of lymphoma in the CNS is primary central nervous system (CNS) lymphoma, which is usually a type of B-cell non-Hodgkin lymphoma.
9. Metastatic tumors: These are tumors that have spread to the brain from another part of the body. The most common types of metastatic tumors in the CNS are breast cancer, lung cancer, and melanoma.

These are just a few examples of the many types of brain and spinal cord tumors that can occur. Each type of tumor has its own unique characteristics, such as its location, size, growth rate, and biological behavior. These factors can help doctors determine the best course of treatment for each patient.

Benign maxillary sinus tumors may include:

* Papilloma: A benign growth that resembles a finger-like protrusion and is usually slow-growing and non-aggressive.
* Pyogenic granuloma: A type of benign bacterial infection that can cause localized tissue growth and inflammation.
* Osteoid osteoma: A rare, benign tumor that forms in the bone and can cause pain and swelling.

Malignant maxillary sinus tumors are more aggressive and can include:

* Squamous cell carcinoma: A type of skin cancer that can occur in the maxillary sinus and can be treated with surgery, radiation therapy, or chemotherapy.
* Adenoid cystic carcinoma: A rare, malignant tumor that can grow slowly over time and can be difficult to treat.
* Esthesioneuroblastoma: A rare, malignant tumor that originates in the nasal cavity and can extend into the maxillary sinus.

The symptoms of maxillary sinus neoplasms can vary depending on the size and location of the tumor, but may include:

* Pain or swelling in the face or neck
* Difficulty breathing through the nose
* Nasal congestion or discharge
* Eye problems such as double vision or protrusion
* Headaches or facial pain

The diagnosis of maxillary sinus neoplasms is typically made using a combination of imaging studies, such as CT scans or MRI, and tissue biopsy. Treatment options can range from observation to surgery, radiation therapy, or chemotherapy, depending on the type and stage of the tumor.

Examples of experimental liver neoplasms include:

1. Hepatocellular carcinoma (HCC): This is the most common type of primary liver cancer and can be induced experimentally by injecting carcinogens such as diethylnitrosamine (DEN) or dimethylbenz(a)anthracene (DMBA) into the liver tissue of animals.
2. Cholangiocarcinoma: This type of cancer originates in the bile ducts within the liver and can be induced experimentally by injecting chemical carcinogens such as DEN or DMBA into the bile ducts of animals.
3. Hepatoblastoma: This is a rare type of liver cancer that primarily affects children and can be induced experimentally by administering chemotherapy drugs to newborn mice or rats.
4. Metastatic tumors: These are tumors that originate in other parts of the body and spread to the liver through the bloodstream or lymphatic system. Experimental models of metastatic tumors can be studied by injecting cancer cells into the liver tissue of animals.

The study of experimental liver neoplasms is important for understanding the underlying mechanisms of liver cancer development and progression, as well as identifying potential therapeutic targets for the treatment of this disease. Animal models can be used to test the efficacy of new drugs or therapies before they are tested in humans, which can help to accelerate the development of new treatments for liver cancer.

The carcinogenesis process of PDAC usually starts with the accumulation of genetic mutations in the pancreatic duct cells, which progressively leads to the formation of a premalignant lesion called PanIN (pancreatic intraepithelial neoplasia). Over time, these lesions can develop into invasive adenocarcinoma, which is PDAC.

The main risk factor for developing PDAC is smoking, but other factors such as obesity, diabetes, and family history of pancreatic cancer also contribute to the development of the disease. Symptoms of PDAC are often non-specific and late-stage, which makes early diagnosis challenging.

The treatment options for PDAC are limited, and the prognosis is generally poor. Surgery is the only potentially curative treatment, but only a small percentage of patients are eligible for surgical resection due to the locally advanced nature of the disease at the time of diagnosis. Chemotherapy, radiation therapy, and targeted therapies are used to palliate symptoms and improve survival in non-surgical cases.

PDAC is an aggressive and lethal cancer, and there is a need for better diagnostic tools and more effective treatment strategies to improve patient outcomes.

The condition can be caused by a variety of factors, including excessive alcohol consumption, viral hepatitis, non-alcoholic fatty liver disease, and certain medications. It can also be a complication of other diseases such as hemochromatosis and Wilson's disease.

The symptoms of liver cirrhosis can vary depending on the severity of the disease, but may include fatigue, loss of appetite, nausea, abdominal swelling, and pain in the upper right side of the abdomen. As the disease progresses, it can lead to complications such as esophageal varices, ascites, and liver failure, which can be life-threatening.

There is no cure for liver cirrhosis, but treatment options are available to manage the symptoms and slow the progression of the disease. These may include medications to control swelling and pain, dietary changes, and in severe cases, liver transplantation. In some cases, a liver transplant may be necessary if the disease has caused significant damage and there is no other option to save the patient's life.

In conclusion, liver cirrhosis is a serious and potentially life-threatening condition that can cause significant damage to the liver and lead to complications such as liver failure. It is important for individuals to be aware of the risk factors and symptoms of the disease in order to seek medical attention if they suspect they may have liver cirrhosis. With proper treatment and management, it is possible to slow the progression of the disease and improve the patient's quality of life.

Types of Adrenal Cortex Neoplasms:

1. Adrenocortical carcinoma (ACC): A rare and aggressive malignant tumor that originates in the adrenal cortex. It is often associated with virilization (excessive masculinization) in women.
2. Adrenocortical adenoma (ACA): A benign tumor that originates in the adrenal cortex. It is less common than ACC and may not cause any symptoms.
3. Pheochromocytoma: A rare tumor that originates in the adrenal medulla, which is the inner part of the adrenal gland. It can secrete excessive amounts of hormones that regulate blood pressure and heart rate.
4. Paraganglioma: A rare tumor that originates in the paraganglia, which are clusters of cells located near the adrenal glands. These tumors can produce excessive amounts of hormones and cause similar symptoms as pheochromocytoma.

Symptoms of Adrenal Cortex Neoplasms:

1. Virilization (excessive masculinization) in women, such as deepening of the voice, excessive body hair growth, and clitoral enlargement.
2. Headache, fatigue, and weight gain due to excessive production of steroid hormones.
3. High blood pressure and heart rate due to excessive production of catecholamines (hormones that regulate blood pressure and heart rate).
4. Abdominal pain, nausea, and vomiting due to the tumor's size and location.

Diagnosis of Adrenal Cortex Neoplasms:

1. Imaging tests such as CT scans or MRI to visualize the tumor and determine its size and location.
2. Laboratory tests to measure hormone levels in the blood, including cortisol, aldosterone, and catecholamines.
3. Biopsy to obtain a tissue sample for further examination under a microscope.

Treatment of Adrenal Cortex Neoplasms:

1. Surgery to remove the tumor, which is usually curative.
2. Medications to control symptoms such as high blood pressure and hormone levels.
3. Radiation therapy may be used in cases where surgery is not feasible or if there is a risk of recurrence.

Prognosis of Adrenal Cortex Neoplasms:

The prognosis for adrenal cortex neoplasms depends on the type and size of the tumor, as well as the extent of hormone production. In general, the prognosis is good for patients with benign tumors that are removed surgically. However, malignant tumors can have a poorer prognosis and may require additional treatments such as radiation therapy or chemotherapy.

Prevention of Adrenal Cortex Neoplasms:

There is no known prevention for adrenal cortex neoplasms, but early detection and treatment can improve outcomes. Regular monitoring of hormone levels and imaging tests can help detect tumors at an early stage.

Lifestyle Changes:

1. Reduce stress: High levels of cortisol can be caused by stress, so finding ways to manage stress can help prevent adrenal cortex neoplasms.
2. Maintain a healthy diet: Eating a balanced diet that includes plenty of fruits, vegetables, and whole grains can help support overall health and well-being.
3. Exercise regularly: Regular physical activity can help reduce stress and improve overall health.
4. Get enough sleep: Aim for 7-8 hours of sleep per night to help regulate hormone levels.
5. Limit caffeine and alcohol: Both substances can disrupt hormone levels and contribute to the development of adrenal cortex neoplasms.

There are several types of vulvar neoplasms, including:

1. Vulvar intraepithelial neoplasia (VIN): This is a precancerous condition that affects the squamous cells on the surface of the vulva. VIN can progress to vulvar cancer if left untreated.
2. Vulvar squamous cell carcinoma: This is the most common type of vulvar cancer and arises from the squamous cells that line the vulva.
3. Vulvar adenocarcinoma: This type of vulvar cancer originates in the glandular cells that are found near the opening of the vagina.
4. Vulvar melanoma: This is a rare type of vulvar cancer that arises from the pigment-producing cells called melanocytes.
5. Lymphoma: This is a type of cancer that affects the immune system and can occur in the vulva.

The symptoms of vulvar neoplasms can vary depending on the type and location of the growth, but may include:

* A visible lump or lesion on the vulva
* Itching, burning, or pain in the affected area
* Discharge or bleeding from the vulva
* Changes in the color or texture of the skin on the vulva

If you suspect you have a vulvar neoplasm, it is important to see a healthcare provider for an accurate diagnosis and treatment. A physical examination and biopsy may be performed to determine the type and extent of the growth. Treatment options will depend on the type and stage of the neoplasm, but may include surgery, radiation therapy, or chemotherapy.

Some common effects of chromosomal deletions include:

1. Genetic disorders: Chromosomal deletions can lead to a variety of genetic disorders, such as Down syndrome, which is caused by a deletion of a portion of chromosome 21. Other examples include Prader-Willi syndrome (deletion of chromosome 15), and Williams syndrome (deletion of chromosome 7).
2. Birth defects: Chromosomal deletions can increase the risk of birth defects, such as heart defects, cleft palate, and limb abnormalities.
3. Developmental delays: Children with chromosomal deletions may experience developmental delays, learning disabilities, and intellectual disability.
4. Increased cancer risk: Some chromosomal deletions can increase the risk of developing certain types of cancer, such as chronic myelogenous leukemia (CML) and breast cancer.
5. Reproductive problems: Chromosomal deletions can lead to reproductive problems, such as infertility or recurrent miscarriage.

Chromosomal deletions can be diagnosed through a variety of techniques, including karyotyping (examination of the chromosomes), fluorescence in situ hybridization (FISH), and microarray analysis. Treatment options for chromosomal deletions depend on the specific effects of the deletion and may include medication, surgery, or other forms of therapy.

Oropharyngeal neoplasms can be caused by a variety of factors, including tobacco use, heavy alcohol consumption, human papillomavirus (HPV) infection, and exposure to environmental carcinogens such as asbestos or coal tar. They can also be associated with other medical conditions, such as gastroesophageal reflux disease (GERD), weakened immune systems, and a history of head and neck radiation therapy.

Symptoms of oropharyngeal neoplasms can include a persistent sore throat, difficulty swallowing, ear pain, weight loss, and lumps in the neck. Treatment options for these neoplasms depend on the location, size, and stage of the tumor, as well as the patient's overall health status. Treatment may involve surgery to remove the tumor, radiation therapy to kill cancer cells, or a combination of both. In some cases, chemotherapy may also be used to shrink the tumor before surgery or to kill any remaining cancer cells after treatment.

Early detection and diagnosis of oropharyngeal neoplasms are important for successful treatment and improved patient outcomes. Diagnosis is typically made through a combination of physical examination, imaging tests such as CT scans or MRI, and biopsy to confirm the presence of cancer cells.

Overall, oropharyngeal neoplasms are a serious medical condition that can have significant implications for patient quality of life and survival. Early detection and appropriate treatment are essential for improving outcomes and preventing complications associated with these tumors.

A more detailed explanation of Inappropriate ADH Syndrome may be as follows:

Inappropriate ADH syndrome is a rare endocrine disorder characterized by excessive antidiuretic hormone (ADH) secretion, leading to water retention and hyponatremia. Hyponatremia occurs when the body contains too much water and not enough sodium, causing an imbalance in the electrolyte levels of the blood. This condition can be caused by various factors such as a tumor or other abnormality that increases ADH production or decreases sodium levels in the body. Symptoms of Inappropriate ADH syndrome may include headaches, nausea, vomiting, seizures, and in severe cases, coma.

If left untreated, Inappropriate ADH Syndrome can lead to more serious complications such as seizures or coma. Treatment options for this condition typically involve surgery, radiation therapy, or medication to remove the tumor or other abnormality causing the excessive ADH production and restore sodium levels in the body. It is important to seek medical attention if symptoms persist or worsen over time as early diagnosis and treatment can improve the chances of a successful outcome for this condition.

In summary, Inappropriate ADH Syndrome is an uncommon endocrine disorder caused by excessive ADH secretion leading to hyponatremia due to water retention, which can cause severe symptoms such as headache, nausea, vomiting, seizures, and coma if left untreated. Treatment options involve surgery, radiation therapy, or medication to remove the tumor or other abnormality causing excessive ADH production and restore sodium levels in the body. Early diagnosis and treatment are crucial for a successful outcome.

There are different types of hyperplasia, depending on the location and cause of the condition. Some examples include:

1. Benign hyperplasia: This type of hyperplasia is non-cancerous and does not spread to other parts of the body. It can occur in various tissues and organs, such as the uterus (fibroids), breast tissue (fibrocystic changes), or prostate gland (benign prostatic hyperplasia).
2. Malignant hyperplasia: This type of hyperplasia is cancerous and can invade nearby tissues and organs, leading to serious health problems. Examples include skin cancer, breast cancer, and colon cancer.
3. Hyperplastic polyps: These are abnormal growths that occur in the gastrointestinal tract and can be precancerous.
4. Adenomatous hyperplasia: This type of hyperplasia is characterized by an increase in the number of glandular cells in a specific organ, such as the colon or breast. It can be a precursor to cancer.

The symptoms of hyperplasia depend on the location and severity of the condition. In general, they may include:

* Enlargement or swelling of the affected tissue or organ
* Pain or discomfort in the affected area
* Abnormal bleeding or discharge
* Changes in bowel or bladder habits
* Unexplained weight loss or gain

Hyperplasia is diagnosed through a combination of physical examination, imaging tests such as ultrasound or MRI, and biopsy. Treatment options depend on the underlying cause and severity of the condition, and may include medication, surgery, or other interventions.

PCD typically affects adults between the ages of 30 and 70 years old and is more common in women than men. The exact cause of PCD is not fully understood, but it is thought to be an autoimmune response, where the immune system mistakenly attacks healthy cells in the cerebellum.

The diagnosis of PCD is based on a combination of clinical features, laboratory tests, and imaging studies. Laboratory tests may include blood tests to look for antineuronal antibodies and cerebrospinal fluid (CSF) analysis to rule out other causes of cerebellar degeneration. Imaging studies, such as MRI or CT scans, may be used to confirm the diagnosis and assess the progression of the disease.

Treatment for PCD is primarily focused on managing the symptoms and improving quality of life. This may include physical therapy, occupational therapy, and speech therapy to help with coordination, balance, and communication. In some cases, medications such as steroids or immunosuppressive drugs may be used to reduce inflammation and slow the progression of the disease.

Prognosis for PCD is generally poor, with a median survival time of around 2-3 years after diagnosis. However, some individuals with PCD may experience a more benign course of the disease, while others may experience a rapid decline in health. The exact prognostic factors for PCD are not fully understood and require further research.

Bile duct neoplasms refer to abnormal growths or tumors that occur in the bile ducts, which are the tubes that carry bile from the liver and gallbladder to the small intestine. Bile duct neoplasms can be benign (non-cancerous) or malignant (cancerous).

Types of Bile Duct Neoplasms:

There are several types of bile duct neoplasms, including:

1. Bile duct adenoma: A benign tumor that grows in the bile ducts.
2. Bile duct carcinoma: A malignant tumor that grows in the bile ducts and can spread to other parts of the body.
3. Cholangiocarcinoma: A rare type of bile duct cancer that originates in the cells lining the bile ducts.
4. Gallbladder cancer: A type of cancer that occurs in the gallbladder, which is a small organ located under the liver that stores bile.

Causes and Risk Factors:

The exact cause of bile duct neoplasms is not known, but there are several risk factors that may increase the likelihood of developing these tumors, including:

1. Age: Bile duct neoplasms are more common in people over the age of 50.
2. Gender: Women are more likely to develop bile duct neoplasms than men.
3. Family history: People with a family history of bile duct cancer or other liver diseases may be at increased risk.
4. Previous exposure to certain chemicals: Exposure to certain chemicals, such as thorium, has been linked to an increased risk of developing bile duct neoplasms.

Symptoms:

The symptoms of bile duct neoplasms can vary depending on the location and size of the tumor. Some common symptoms include:

1. Yellowing of the skin and eyes (jaundice)
2. Fatigue
3. Loss of appetite
4. Nausea and vomiting
5. Abdominal pain or discomfort
6. Weight loss
7. Itching all over the body
8. Dark urine
9. Pale stools

Diagnosis:

Diagnosis of bile duct neoplasms typically involves a combination of imaging tests and biopsy. The following tests may be used to diagnose bile duct neoplasms:

1. Ultrasound: This non-invasive test uses high-frequency sound waves to create images of the liver and bile ducts.
2. Computed tomography (CT) scan: This imaging test uses X-rays and computer technology to create detailed images of the liver and bile ducts.
3. Magnetic resonance imaging (MRI): This test uses a strong magnetic field and radio waves to create detailed images of the liver and bile ducts.
4. Endoscopic ultrasound: This test involves inserting an endoscope (a thin, flexible tube with a small ultrasound probe) into the bile ducts through the mouth or stomach to obtain images and samples of the bile ducts.
5. Biopsy: A biopsy may be performed during an endoscopic ultrasound or during surgery to remove the tumor. The sample is then examined under a microscope for cancer cells.

Treatment:

The treatment of bile duct neoplasms depends on several factors, including the type and stage of the cancer, the patient's overall health, and the patient's preferences. The following are some common treatment options for bile duct neoplasms:

1. Surgery: Surgery may be performed to remove the tumor or a portion of the bile duct. This may involve a Whipple procedure (a surgical procedure to remove the head of the pancreas, the gallbladder, and a portion of the bile duct), a bile duct resection, or a liver transplant.
2. Chemotherapy: Chemotherapy may be used before or after surgery to shrink the tumor and kill any remaining cancer cells.
3. Radiation therapy: Radiation therapy may be used to destroy cancer cells that cannot be removed by surgery or to relieve symptoms such as pain or blockage of the bile duct.
4. Stent placement: A stent may be placed in the bile duct to help keep it open and improve blood flow to the liver.
5. Ablation therapy: Ablation therapy may be used to destroy cancer cells by freezing or heating them with a probe inserted through an endoscope.
6. Targeted therapy: Targeted therapy may be used to treat certain types of bile duct cancer, such as cholangiocarcinoma, by targeting specific molecules that promote the growth and spread of the cancer cells.
7. Clinical trials: Clinical trials are research studies that evaluate new treatments for bile duct neoplasms. These may be an option for patients who have not responded to other treatments or who have advanced cancer.

Some common types of urologic neoplasms include:

1. Renal cell carcinoma (RCC): a type of kidney cancer that originates in the cells of the kidney's tubules.
2. Bladder cancer: a type of cancer that affects the cells lining the bladder, and can be classified as superficial or invasive.
3. Ureteral cancer: a rare type of cancer that develops in the muscular tissue of the ureters.
4. Prostate cancer: a common type of cancer in men that affects the prostate gland.
5. Penile cancer: a rare type of cancer that develops on the penis, usually in the skin or mucous membranes.
6. Testicular cancer: a rare type of cancer that develops in the testicles, and is most common in young men between the ages of 15 and 35.

The symptoms of urologic neoplasms can vary depending on their location and size, but may include blood in the urine, painful urination, frequent urination, or abdominal pain. Diagnosis is typically made through a combination of imaging studies (such as CT scans or ultrasound) and tissue biopsy.

Treatment options for urologic neoplasms vary depending on the type, size, location, and stage of the tumor, but may include surgery, chemotherapy, radiation therapy, or a combination of these. In some cases, watchful waiting or active surveillance may be recommended for small, slow-growing tumors that are not causing symptoms or threatening the patient's life.

The prognosis for urologic neoplasms varies depending on the type and stage of the cancer at the time of diagnosis. In general, early detection and treatment improve the chances of a successful outcome. However, some types of urologic neoplasms are more aggressive and difficult to treat than others.

Prevention is often challenging for urologic neoplasms, as many risk factors (such as family history or genetic predisposition) cannot be controlled. However, some measures may help reduce the risk of developing certain types of urologic neoplasms, such as:

* Maintaining a healthy diet and lifestyle
* Avoiding smoking and excessive alcohol consumption
* Protecting the skin from sun exposure to reduce the risk of skin cancer
* Avoiding exposure to certain chemicals or toxins that may increase the risk of certain types of cancer
* Practicing safe sex to reduce the risk of HPV-related cancers.

Papillomas can occur anywhere on the body, but they are most commonly found on the face, neck, and scalp. They may appear as small bumps or growths that look like a wart. In some cases, papillomas may be associated with human papillomavirus (HPV) infection.

Papillomas are typically diagnosed through a physical examination of the affected area. In some cases, a biopsy may be performed to confirm the diagnosis and rule out other potential causes. Treatment for papillomas usually involves removal of the growth through a minor surgical procedure or cryotherapy (freezing).

Papillomas are not cancerous and do not typically pose any long-term health risks. However, they may be unsightly and can cause psychological distress for some people. In these cases, treatment may be sought for cosmetic reasons. It is important to note that papillomas should not be confused with squamous cell carcinoma, a type of skin cancer that can resemble a papilloma in appearance but has the potential to be more aggressive and harmful.

Some common types of gastrointestinal neoplasms include:

1. Gastric adenocarcinoma: A type of stomach cancer that starts in the glandular cells of the stomach lining.
2. Colorectal adenocarcinoma: A type of cancer that starts in the glandular cells of the colon or rectum.
3. Esophageal squamous cell carcinoma: A type of cancer that starts in the squamous cells of the esophagus.
4. Small intestine neuroendocrine tumors: Tumors that start in the hormone-producing cells of the small intestine.
5. Gastrointestinal stromal tumors (GISTs): Tumors that start in the connective tissue of the GI tract.

The symptoms of gastrointestinal neoplasms can vary depending on the location and size of the tumor, but they may include:

* Abdominal pain or discomfort
* Changes in bowel habits (such as diarrhea or constipation)
* Weight loss
* Fatigue
* Nausea and vomiting

If you have any of these symptoms, it is important to see a doctor for further evaluation and diagnosis. A gastrointestinal neoplasm can be diagnosed through a combination of endoscopy (insertion of a flexible tube into the GI tract to visualize the inside), imaging tests (such as CT or MRI scans), and biopsy (removal of a small sample of tissue for examination under a microscope).

Treatment options for gastrointestinal neoplasms depend on the type, location, and stage of the tumor, but they may include:

* Surgery to remove the tumor
* Chemotherapy (use of drugs to kill cancer cells)
* Radiation therapy (use of high-energy X-rays or other particles to kill cancer cells)
* Targeted therapy (use of drugs that target specific molecules involved in cancer growth and development)
* Supportive care (such as pain management and nutritional support)

The prognosis for gastrointestinal neoplasms varies depending on the type and stage of the tumor, but in general, early detection and treatment improve outcomes. If you have been diagnosed with a gastrointestinal neoplasm, it is important to work closely with your healthcare team to develop a personalized treatment plan and follow up regularly for monitoring and adjustments as needed.

The exact cause of paraneoplastic syndromes is not fully understood, but it is believed that the immune system mistakenly attacks healthy cells in the nervous system, leading to damage and dysfunction. Some research suggests that certain types of cancer may trigger an autoimmune response, while other factors such as genetics or environmental exposures may also play a role.

Paraneoplastic syndromes can be difficult to diagnose, as they often present with symptoms that are similar to those of more common conditions such as multiple sclerosis or stroke. However, certain tests such as electromyography (EMG) and nerve conduction studies (NCS) can help rule out other conditions and confirm the presence of a paraneoplastic syndrome.

Treatment for paraneoplastic syndromes typically focuses on managing symptoms and addressing any underlying cancer that may be present. Medications such as corticosteroids, immunosuppressive drugs, and chemotherapy may be used to reduce inflammation and suppress the immune system, while surgery or radiation therapy may be necessary to remove cancerous tissue. In some cases, plasmapheresis (plasma exchange) may also be recommended to remove harmful antibodies from the blood.

Overall, paraneoplastic syndromes, nervous system are a complex and rare group of disorders that can significantly impact quality of life. Early diagnosis and treatment are key to managing symptoms and improving outcomes for patients with these conditions.

There are several types of chromosome aberrations, including:

1. Chromosomal deletions: Loss of a portion of a chromosome.
2. Chromosomal duplications: Extra copies of a chromosome or a portion of a chromosome.
3. Chromosomal translocations: A change in the position of a chromosome or a portion of a chromosome.
4. Chromosomal inversions: A reversal of a segment of a chromosome.
5. Chromosomal amplifications: An increase in the number of copies of a particular chromosome or gene.

Chromosome aberrations can be detected through various techniques, such as karyotyping, fluorescence in situ hybridization (FISH), or array comparative genomic hybridization (aCGH). These tests can help identify changes in the chromosomal makeup of cells and provide information about the underlying genetic causes of disease.

Chromosome aberrations are associated with a wide range of diseases, including:

1. Cancer: Chromosome abnormalities are common in cancer cells and can contribute to the development and progression of cancer.
2. Birth defects: Many birth defects are caused by chromosome abnormalities, such as Down syndrome (trisomy 21), which is caused by an extra copy of chromosome 21.
3. Neurological disorders: Chromosome aberrations have been linked to various neurological disorders, including autism and intellectual disability.
4. Immunodeficiency diseases: Some immunodeficiency diseases, such as X-linked severe combined immunodeficiency (SCID), are caused by chromosome abnormalities.
5. Infectious diseases: Chromosome aberrations can increase the risk of infection with certain viruses, such as human immunodeficiency virus (HIV).
6. Ageing: Chromosome aberrations have been linked to the ageing process and may contribute to the development of age-related diseases.
7. Radiation exposure: Exposure to radiation can cause chromosome abnormalities, which can increase the risk of cancer and other diseases.
8. Genetic disorders: Many genetic disorders are caused by chromosome aberrations, such as Turner syndrome (45,X), which is caused by a missing X chromosome.
9. Rare diseases: Chromosome aberrations can cause rare diseases, such as Klinefelter syndrome (47,XXY), which is caused by an extra copy of the X chromosome.
10. Infertility: Chromosome abnormalities can contribute to infertility in both men and women.

Understanding the causes and consequences of chromosome aberrations is important for developing effective treatments and improving human health.

The exact cause of hepatoblastoma is not known, but it is believed to be linked to genetic mutations that occur during fetal development. Children with certain congenital conditions, such as Beckwith-Wiedemann syndrome, are at higher risk of developing hepatoblastoma. The symptoms of hepatoblastoma can include abdominal pain, weight loss, and jaundice (yellowing of the skin and eyes), but in many cases, the cancer may not cause any noticeable symptoms until it has reached an advanced stage.

Hepatoblastoma is diagnosed through a combination of imaging tests, such as ultrasound, CT scans, and MRI, and a biopsy to confirm the presence of cancer cells. Treatment typically involves surgery to remove the affected lobe of the liver, followed by chemotherapy to kill any remaining cancer cells. In some cases, a liver transplant may be necessary if the cancer has spread too far or if the child's liver is not functioning properly. The prognosis for hepatoblastoma depends on several factors, including the stage of the cancer at diagnosis and the effectiveness of treatment. With current treatments, the 5-year survival rate for children with hepatoblastoma is around 70%.

Examples and Observations:

Oxyphil adenomas are rare in the small bowel (less than 1% of all small intestinal tumors) but are more common in the duodenum and proximal jejunum. They usually manifest as multiple, submucosal nodules that can vary in size from a few millimeters to several centimeters in diameter. [2]

The presence of oxyphil adenomas in the stomach is rare (less than 1% of all gastric tumors) and most often occurs as multiple, small, submucosal nodules. However, larger adenomas may also be present. [3]

Synonyms: oxyphil cell adenoma; oxyphil cell tumor; oxyphil polyp. [1]

Notes:

* Oxyphil adenomas are often associated with familial adenomatous polyposis (FAP) and Turcot syndrome. [2]

References:

[1] Dorland's Medical Dictionary for Health Care Professionals. © 2008 Saunders, an imprint of Elsevier Inc. All rights reserved. Used with permission.

[2] Oxyphil Adenoma. The Merck Manual of Diagnosis and Therapy, Professional Edition. © 2015 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved. Used with permission.

[3] Oxyphil Adenoma. Gastrointestinal Tumors: benign and malignant tumors of the digestive system, including colorectal cancer, stomach cancer, pancreatic cancer, liver cancer, biliary tract cancer, and soft tissue sarcomas. © 2015 Springer International Publishing Switzerland. All rights reserved. Used with permission.

Carcinosarcomas are typically slow-growing and can occur in various parts of the body, including the abdomen, pelvis, and extremities. They can be difficult to diagnose because they often have a mix of cancerous and noncancerous cells, making it challenging to determine the exact type of tumor.

The treatment of carcinosarcoma depends on the location, size, and stage of the tumor, as well as the patient's overall health. Surgery is often the first line of treatment, followed by radiation therapy and/or chemotherapy. In some cases, a combination of all three may be necessary.

Overall, carcinosarcoma is a rare and aggressive form of cancer that requires careful management and coordinated care from a multidisciplinary team of healthcare professionals. With proper treatment, many patients with carcinosarcoma can achieve long-term survival and a good quality of life.

Example sentences:

1. The patient was diagnosed with a rare form of cancer called carcinosarcoma, which is a combination of both carcinoma and sarcoma.
2. The carcinosarcoma had spread to the patient's lymph nodes and required aggressive treatment, including surgery, radiation therapy, and chemotherapy.
3. Due to the rarity of carcinosarcoma, the oncologist consulted with a team of specialists to develop a personalized treatment plan for the patient.

The hallmark features of ADSC include:

1. Glandular differentiation: The tumor cells are derived from glandular epithelium and exhibit distinctive glandular structures, such as papillae or acini.
2. Scirrhous growth pattern: The tumor cells grow in a finger-like or papillary pattern, with each finger or papilla containing a central lumen.
3. Slow growth rate: ADSC tends to grow slowly compared to other types of cancer, which can help to explain the relatively late presentation and diagnosis of this condition.
4. Locally invasive: ADSC can invade nearby tissues and organs, leading to serious complications if left untreated.
5. Poor prognosis: ADSC has a poorer prognosis compared to other types of cancer, particularly if it is diagnosed at an advanced stage.

The exact cause of ADSC is not fully understood, but genetic mutations, environmental factors, and chronic inflammation are thought to play a role in its development. The symptoms of ADSC can vary depending on the location of the tumor, but they may include abdominal pain, swelling, and difficulty with bowel movements or urination.

Treatment options for ADSC typically involve a combination of surgery, chemotherapy, and radiation therapy. Surgery is often the first line of treatment, followed by chemotherapy to reduce the risk of recurrence. Radiation therapy may also be used in select cases. Overall, early detection and prompt treatment are essential for improving outcomes in patients with ADSC.

There are several types of eyelid neoplasms, including:

1. Basal cell carcinoma: This is the most common type of skin cancer, and it usually occurs on the skin around the nose and forehead. It can also occur on the eyelids.
2. Squamous cell carcinoma: This type of cancer usually occurs on sun-exposed areas, such as the face, ears, and hands. It can also occur on the eyelids.
3. Melanoma: This is a rare but aggressive type of cancer that can occur on any skin surface, including the eyelids.
4. Lymphoma: This is a type of cancer that affects the immune system, and it can occur in the eyelid tissue.
5. Sebaceous gland carcinoma: This is a rare type of cancer that affects the oil-producing glands in the eyelids.
6. Hemangiopericytic sarcoma: This is a rare type of cancer that affects the blood vessels in the eyelids.
7. Xanthelasma: This is a benign growth that occurs on the eyelids and is usually associated with high cholesterol levels.
8. Pyogenic granuloma: This is a benign growth that can occur on the eyelids and is usually caused by an infection.

Symptoms of eyelid neoplasms can include:

* A lump or bump on the eyelid
* Redness, swelling, or discharge from the eyelid
* Pain or tenderness in the eyelid
* Difficulty moving the eye or vision problems

If you suspect that you have an eyelid neoplasm, it is important to see an eye doctor as soon as possible for a proper diagnosis and treatment. Your doctor will perform a comprehensive examination of your eyes, including a visual examination of the eyelids, and may also use diagnostic tests such as imaging studies or biopsies to determine the cause of your symptoms. Treatment for eyelid neoplasms depends on the specific type of cancer or other condition that is present, and may include surgery, chemotherapy, radiation therapy, or other treatments.

Papillomavirus infections can be classified into two main categories: low-risk and high-risk. Low-risk papillomavirus infections typically cause benign growths such as common warts, which are usually harmless and resolve on their own over time. High-risk papillomavirus infections, on the other hand, can lead to serious health problems such as cancer, particularly cervical cancer in women and anal cancer in both men and women.

The most common form of papillomavirus infection is genital warts, which are caused by human papillomavirus (HPV). HPV is the most common sexually transmitted virus and affects both men and women. It is estimated that up to 80% of people will be infected with HPV at some point in their lifetime, but most will not develop any symptoms or complications.

Other forms of papillomavirus infections include plantar warts, which are common on the soles of the feet and palms of the hands, and flat warts, which are small, rough growths that can appear anywhere on the body.

Papillomavirus infections can be diagnosed through a variety of methods, including visual inspection, biopsy, and molecular tests such as PCR (polymerase chain reaction). Treatment options vary depending on the type and location of the infection, but may include cryotherapy (freezing), surgical removal, or topical medications. Vaccines are also available to protect against certain types of papillomaviruses, particularly HPV.

Overall, papillomavirus infections are a common and diverse group of conditions that can have significant health implications if left untreated or if they progress to more severe forms. Proper diagnosis and treatment are important for managing these infections and preventing long-term complications.



The signs and symptoms of CE can vary depending on the location of the tumor, but they may include:

* Lumps or swelling in the neck, underarm, or groin area
* Fever
* Fatigue
* Weight loss
* Night sweats
* Swollen lymph nodes
* Pain in the affected area

CE is caused by a genetic mutation that leads to uncontrolled cell growth and division. The exact cause of the mutation is not fully understood, but it is believed to be linked to exposure to certain viruses or chemicals.

Diagnosis of CE typically involves a combination of physical examination, imaging tests such as CT scans or PET scans, and biopsy to confirm the presence of cancer cells. Treatment options for CE depend on the stage and location of the tumor, but may include:

* Chemotherapy to kill cancer cells
* Radiation therapy to shrink the tumor
* Surgery to remove the tumor
* Immunotherapy to boost the immune system's ability to fight the cancer

Overall, CE is a rare and aggressive form of cancer that requires prompt diagnosis and treatment to improve outcomes.

There are several types of teratomas, including:

1. Mature teratoma: This type of teratoma is made up of well-differentiated tissues that resemble normal tissues. It can contain structures such as hair follicles, sweat glands, and sebaceous glands.
2. Immature teratoma: This type of teratoma is made up of poorly differentiated cells that do not resemble normal tissues. It can contain structures such as cartilage, bone, and nervous tissue.
3. Teratoid mesodermal tumor: This type of teratoma arises from the mesoderm, which is one of the three primary layers of cells in the embryo. It can contain structures such as muscle, bone, and connective tissue.
4. Teratoid endodermal tumor: This type of teratoma arises from the endoderm, which is another primary layer of cells in the embryo. It can contain structures such as glandular tissue and epithelial tissue.

Teratomas are usually benign, but they can sometimes be malignant. Malignant teratomas can spread to other parts of the body and cause serious complications. The treatment of teratomas depends on their type, size, and location, as well as the patient's overall health. Treatment options can include surgery, chemotherapy, and radiation therapy.

In summary, a teratoma is a type of tumor that contains abnormal cells that grow and multiply in an uncontrolled manner, often forming masses or lumps. There are several types of teratomas, and they can occur in various parts of the body. Treatment options depend on the type, size, location, and patient's overall health.

Also known as:

* Cystadenocarcinoma, papilliferum
* Papillary adenocarcinoma
* Glandular neoplasm, papillary

Synonyms:

* Adenocarcinoma, papillary
* Carcinoma, papillary
* Mucinous cystadenocarcinoma
* Cystic papillary carcinoma

Epithelial tumors of the breast with a glandular or mixed (glandular and ductal) pattern account for approximately 15% of all breast cancers. The most common histologic type is papillary adenocarcinoma, which accounts for about 70% of all glandular tumors.

Papillary carcinoma (PC) was first described by Miles in 1932 as a distinct clinical and pathological entity. It typically affects women between the ages of 40 to 60 years, with rare cases occurring in men. The incidence is 1/1,800,000 for invasive PC and 1/3,500,000 for DCIS.

The majority of papillary carcinomas are confined to the breast and regional lymph nodes; however, there have been case reports of distant metastases.

PC is a slow-growing tumor with an average diameter of 15-20 mm, and most patients present with a palpable mass or nipple discharge. The microscopic features include a glandular or acinar pattern, with papillary structures lined by bland-appearing cells.

The malignant potential of PC is less than that of ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC). The 5-year survival rate for PC is approximately 90%, and the risk of recurrence is low.

Treatment options include surgery, radiation therapy, and hormone therapy. Surgical excision is the primary treatment, with a wide local excision being preferred over lumpectomy or simple mastectomy. Radiation therapy may be recommended for patients with positive axillary nodes or large tumors. Hormone therapy may be considered for postmenopausal women with ER-positive tumors.

Despite its relatively low malignant potential, PC should be treated aggressively to prevent local recurrence and possible distant metastases. The prognosis is generally excellent, but long-term follow-up is essential to monitor for any signs of recurrence or new primary cancers.

Paranasal sinus neoplasms refer to tumors or abnormal growths that occur within the paranasal sinuses, which are air-filled cavities within the skull that drain into the nasal passages. These neoplasms can be benign or malignant and can affect various structures in the head and neck, including the sinuses, nasal passages, eyes, and brain.

Types of Paranasal Sinus Neoplasms:

There are several types of paranasal sinus neoplasms, including:

1. Nasal cavity squamous cell carcinoma: This is the most common type of paranasal sinus cancer and arises from the lining of the nasal cavity.
2. Maxillary sinus adenoid cystic carcinoma: This type of tumor is slow-growing and usually affects the maxillary sinus.
3. Esthesioneuroepithelioma: This rare type of tumor arises from the lining of the nasal cavity and is more common in women than men.
4. Sphenoid sinus mucocele: This type of tumor is usually benign and occurs in the sphenoid sinus.
5. Osteochondroma: This is a rare type of benign tumor that arises from the bone and cartilage of the paranasal sinuses.

Symptoms of Paranasal Sinus Neoplasms:

The symptoms of paranasal sinus neoplasms can vary depending on the size, location, and type of tumor. Common symptoms include:

1. Nasal congestion or blockage
2. Headaches
3. Pain or pressure in the face, especially in the cheeks, eyes, or forehead
4. Double vision or other vision problems
5. Numbness or weakness in the face
6. Discharge of fluid from the nose or eyes
7. Swelling of the eyelids or face
8. Coughing up blood

Diagnosis of Paranasal Sinus Neoplasms:

The diagnosis of paranasal sinus neoplasms is based on a combination of physical examination, imaging studies, and biopsy. The following tests may be used to help diagnose a paranasal sinus tumor:

1. Computed tomography (CT) scan or magnetic resonance imaging (MRI): These imaging tests can provide detailed pictures of the paranasal sinuses and any tumors that may be present.
2. Endoscopy: A thin, lighted tube with a camera on the end can be inserted through the nostrils to examine the inside of the nasal cavity and paranasal sinuses.
3. Biopsy: A sample of tissue from the suspected tumor site can be removed and examined under a microscope to confirm the diagnosis.
4. Nasal endoscopy: A flexible tube with a camera on the end can be inserted through the nostrils to examine the inside of the nasal cavity and paranasal sinuses.

Treatment of Paranasal Sinus Neoplasms:

The treatment of paranasal sinus neoplasms depends on the type, location, size, and aggressiveness of the tumor, as well as the patient's overall health. The following are some of the treatment options for paranasal sinus neoplasms:

1. Surgery: Surgical removal of the tumor is often the first line of treatment for paranasal sinus neoplasms. The type of surgery used depends on the location and extent of the tumor.
2. Radiation therapy: Radiation therapy may be used alone or in combination with surgery to treat paranasal sinus neoplasms that are difficult to remove with surgery or have spread to other parts of the skull base.
3. Chemotherapy: Chemotherapy may be used in combination with radiation therapy to treat paranasal sinus neoplasms that are aggressive and have spread to other parts of the body.
4. Endoscopic surgery: This is a minimally invasive procedure that uses an endoscope (a thin, lighted tube with a camera on the end) to remove the tumor through the nostrils or mouth.
5. Skull base surgery: This is a more invasive procedure that involves removing the tumor and any affected bone or tissue in the skull base.
6. Reconstruction: After removal of the tumor, reconstructive surgery may be necessary to restore the natural anatomy of the skull base and nasal cavity.
7. Observation: In some cases, small, benign tumors may not require immediate treatment and can be monitored with regular imaging studies to see if they grow or change over time.

It is important to note that the most appropriate treatment plan for a patient with a paranasal sinus neoplasm will depend on the specific characteristics of the tumor and the individual patient's needs and medical history. Patients should work closely with their healthcare team to determine the best course of treatment for their specific condition.

SCC tends to be more aggressive than other types of skin cancer (such as basal cell carcinoma) and can spread to other parts of the body if left untreated. Treatment for SCC usually involves surgical removal of the affected tissue, and in some cases, may require additional therapies such as radiation or chemotherapy.

It's important to note that early detection and treatment of SCC can improve outcomes and reduce the risk of complications. Regular self-exams and screening by a dermatologist can help identify skin cancers in their early stages.

Examples of mammary neoplasms in animals include:

* Mammary adenocarcinoma: A type of tumor that develops in the mammary gland of animals and is characterized by the growth of abnormal cells that produce milk.
* Mammary fibroadenoma: A benign tumor that develops in the mammary gland of animals and is characterized by the growth of fibrous and glandular tissue.
* Inflammatory mammary carcinoma: A type of tumor that develops in the mammary gland of animals and is characterized by the presence of inflammatory cells and abnormal cells.

These tumors can be caused by a variety of factors, including genetic mutations, hormonal imbalances, and exposure to certain environmental agents. They can also be induced experimentally using chemical carcinogens or viruses.

The study of mammary neoplasms in animals is important for understanding the molecular mechanisms underlying breast cancer development and progression, as well as for identifying potential therapeutic targets and developing new treatments.

The most common type of pharyngeal neoplasm is squamous cell carcinoma, which accounts for approximately 90% of all cases. Other types of pharyngeal neoplasms include adenocarcinoma, adenoid cystic carcinoma, and lymphoma.

The symptoms of pharyngeal neoplasms can vary depending on the location and size of the tumor, but they may include:

* Difficulty swallowing (dysphagia)
* Pain with swallowing (odynophagia)
* Hoarseness or a raspy voice
* Sore throat
* Ear pain
* Weight loss
* Fatigue
* Coughing up blood (hemoptysis)

If you have any of these symptoms, it is important to see a doctor for proper evaluation and diagnosis. A biopsy or other diagnostic tests will be needed to confirm the presence of a pharyngeal neoplasm and determine its type and extent. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these, depending on the specific type of tumor and its stage (extent) of growth.

In summary, pharyngeal neoplasms are abnormal growths or tumors that can develop in the pharynx, and they can be benign or malignant. Symptoms may include difficulty swallowing, hoarseness, ear pain, and other symptoms, and diagnosis typically requires a biopsy or other diagnostic tests. Treatment options depend on the specific type of tumor and its stage of growth.

There are several types of hypopharyngeal neoplasms, including:

1. Squamous cell carcinoma (SCC): This is the most common type of hypopharyngeal cancer, accounting for about 90% of cases. It arises from the squamous cells that line the hypopharynx.
2. Adenocarcinoma: This type of cancer arises from the glandular cells that line the hypopharynx.
3. Other rare types: Other types of hypopharyngeal neoplasms include sarcomas, lymphomas, and melanomas.

The symptoms of hypopharyngeal neoplasms can vary depending on the location and size of the tumor. Common symptoms include:

1. Difficulty swallowing (dysphagia)
2. Pain when swallowing (odynophagia)
3. Hoarseness or voice changes
4. Lumps in the neck
5. Weight loss
6. Fatigue
7. Coughing up blood (hemoptysis)
8. Difficulty breathing (dyspnea)

Hypopharyngeal neoplasms are diagnosed through a combination of endoscopy, imaging tests such as CT scans or MRI, and biopsies. Treatment options include surgery, radiation therapy, chemotherapy, and targeted therapies. The prognosis for hypopharyngeal neoplasms depends on the stage and location of the tumor, as well as the patient's overall health.

In summary, hypopharyngeal neoplasms are a type of cancer that affects the lower part of the throat, and can be diagnosed through a combination of endoscopy, imaging tests, and biopsies. Treatment options include surgery, radiation therapy, chemotherapy, and targeted therapies, and the prognosis depends on the stage and location of the tumor, as well as the patient's overall health.

The symptoms of PNP can vary depending on the severity of the nerve damage and the type of cancer present. Common symptoms include:

1. Numbness or tingling sensations in the hands and feet.
2. Weakness and loss of reflexes in the limbs.
3. Pain, burning, or tingling sensations in the limbs.
4. Difficulty with balance and coordination.
5. Muscle wasting and weakness.
6. Decreased sensation to light touch or temperature changes.
7. Abnormal heart rhythms.
8. Fatigue and malaise.

The exact cause of PNP is not fully understood, but it is believed to be an immune-mediated response to the cancer cells. In some cases, PNP may be the first sign of an underlying cancer diagnosis.

There are several diagnostic tests that can help confirm a diagnosis of PNP, including:

1. Electromyography (EMG): This test measures the electrical activity of muscles and can help identify nerve damage.
2. Nerve conduction studies (NCS): This test measures the speed and strength of electrical signals in nerves.
3. Imaging studies (such as CT or MRI scans): These tests can help identify any underlying tumors or other conditions that may be contributing to the PNP symptoms.
4. Blood tests: These can help identify certain antibodies or proteins that are associated with PNP.
5. Biopsy: A biopsy of nerve tissue or a sample of the cancer cells can help confirm the diagnosis of PNP.

Treatment for PNP typically involves managing the underlying cancer and addressing the symptoms of the neuropathy. This may include:

1. Chemotherapy: To treat the cancer and shrink the tumor.
2. Pain management medications: Such as opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), or anticonvulsants.
3. Physical therapy: To help maintain muscle strength and mobility.
4. Occupational therapy: To assist with daily activities and improve quality of life.
5. Supportive care: Including nutritional support, wound care, and emotional support.

Prognosis for PNP varies depending on the underlying cancer diagnosis and the severity of the neuropathy. However, in general, early detection and treatment can improve outcomes and reduce symptoms. It is important to work closely with a healthcare team to develop an individualized treatment plan and manage any complications associated with PNP.

Examples and Observations:

1. Gastric metaplasia: This is a condition where the stomach lining is replaced by cells that are similar to those found in the esophagus. This can occur as a result of chronic acid reflux, leading to an increased risk of developing esophageal cancer.
2. Bronchial metaplasia: This is a condition where the airways in the lungs are replaced by cells that are similar to those found in the trachea. This can occur as a result of chronic inflammation, leading to an increased risk of developing lung cancer.
3. Pancreatic metaplasia: This is a condition where the pancreas is replaced by cells that are similar to those found in the ducts of the pancreas. This can occur as a result of chronic inflammation, leading to an increased risk of developing pancreatic cancer.
4. Breast metaplasia: This is a condition where the breast tissue is replaced by cells that are similar to those found in the salivary glands. This can occur as a result of chronic inflammation, leading to an increased risk of developing salivary gland cancer.

Etiology and Pathophysiology:

Metaplasia is thought to be caused by chronic inflammation, which can lead to the replacement of one type of cell or tissue with another. This can occur as a result of a variety of factors, including infection, injury, or exposure to carcinogens. Once the metaplastic changes have occurred, there is an increased risk of developing cancer if the underlying cause is not addressed.

Clinical Presentation:

Patients with metaplasia may present with a variety of symptoms, depending on the location and extent of the condition. These can include pain, difficulty swallowing or breathing, coughing up blood, and weight loss. In some cases, patients may be asymptomatic and the condition may be detected incidentally during diagnostic testing for another condition.

Diagnosis:

The diagnosis of metaplasia is typically made based on a combination of clinical findings, radiologic imaging (such as CT scans or endoscopies), and histopathological examination of biopsy specimens. Imaging studies can help to identify the location and extent of the metaplastic changes, while histopathology can confirm the presence of the metaplastic cells and rule out other potential diagnoses.

Treatment:

Treatment for metaplasia depends on the underlying cause and the severity of the condition. In some cases, treatment may involve addressing the underlying cause, such as removing a tumor or treating an infection. In other cases, treatment may be directed at managing symptoms and preventing complications. This can include medications to reduce inflammation and pain, as well as surgery to remove affected tissue.

Prognosis:

The prognosis for metaplasia varies depending on the underlying cause and the severity of the condition. In general, the prognosis is good for patients with benign metaplastic changes, while those with malignant changes may have a poorer prognosis if the cancer is not treated promptly and effectively.

Complications:

Metaplasia can lead to a number of complications, including:

1. Cancer: Metaplastic changes can sometimes progress to cancer, which can be life-threatening.
2. Obstruction: The growth of metaplastic cells can block the normal functioning of the organ or gland, leading to obstruction and potentially life-threatening complications.
3. Inflammation: Metaplasia can lead to chronic inflammation, which can cause scarring and further damage to the affected tissue.
4. Bleeding: Metaplastic changes can increase the risk of bleeding, particularly if they occur in the digestive tract or other organs.

Benign tonsillar neoplasms include:

1. Tonsilloliths: Small, round or oval-shaped growths that form on the surface of the tonsils.
2. Tonsillitis: Inflammation of the tonsils, often caused by a bacterial infection.
3. Tonsillectomy: A surgical procedure to remove the tonsils, usually performed for recurrent tonsillitis or sleep disorders.
4. Tonsillar abscess: A collection of pus on the tonsils, usually caused by a bacterial infection.
5. Tonsillar crypts: Small, hidden pockets on the surface of the tonsils that can collect debris and become infected.

Malignant tonsillar neoplasms include:

1. Squamous cell carcinoma: A type of cancer that originates in the squamous cells that cover the surface of the tonsils.
2. Adenoid cystic carcinoma: A rare type of cancer that originates in the glandular cells of the tonsils.
3. Lymphoma: Cancer of the immune system that can affect the tonsils.
4. Metastatic carcinoma: Cancer that has spread to the tonsils from another part of the body.

The diagnosis of tonsillar neoplasms is based on a combination of clinical examination, imaging studies such as CT or MRI scans, and biopsy. Treatment options vary depending on the type and severity of the neoplasm, but may include surgery, radiation therapy, and/or chemotherapy.

Benign parotid neoplasms include:

* Pleomorphic adenoma: This is the most common type of benign parotid tumor, accounting for about 70% of all benign parotid neoplasms. It is a slow-growing tumor that usually affects people between the ages of 20 and 50.
* Warthin's tumor: This is a rare type of benign parotid tumor that usually occurs in older adults. It is a slow-growing tumor that often causes few symptoms.
* Other benign tumors: These include papillary cystadenoma, oncocytoma, and adenomyoepithelioma.

Malignant parotid neoplasms include:

* Parotid duct carcinoma: This is a rare type of cancer that arises in the main duct of the parotid gland. It usually affects older adults and can be aggressive, meaning it grows quickly and spreads to other parts of the body.
* Adenoid cystic carcinoma: This is a malignant tumor that typically affects the salivary glands, including the parotid gland. It is a slow-growing tumor that can infiltrate surrounding tissues and bone, making it difficult to treat.
* Other malignant tumors: These include acinic cell carcinoma, adenocarcinoma, and squamous cell carcinoma.

The symptoms of parotid neoplasms can vary depending on the size and location of the tumor. Common symptoms include:

* A lump or swelling in the neck or face
* Painless mass or lump in the affected gland
* Difficulty swallowing or eating
* Numbness or weakness in the face
* Pain in the ear, jaw, or neck
* Fatigue
* Weight loss

If you experience any of these symptoms, it is important to see a doctor for proper evaluation and diagnosis. A doctor may perform a physical examination, take a medical history, and order imaging tests such as CT scans, MRI scans, or ultrasound to determine the presence of a parotid neoplasm.

Treatment options for parotid neoplasms depend on the type and stage of the tumor. Surgery is usually the first line of treatment, and may involve removing the affected gland or a portion of the gland. Radiation therapy and chemotherapy may also be used to treat more aggressive tumors or those that have spread to other parts of the body.

Overall, while parotid neoplasms can be serious and potentially life-threatening, early detection and treatment can improve outcomes and help preserve facial function and appearance. It is important to seek medical attention if you experience any symptoms that may indicate a parotid neoplasm.

There are several types of melanoma, including:

1. Superficial spreading melanoma: This is the most common type of melanoma, accounting for about 70% of cases. It usually appears as a flat or slightly raised discolored patch on the skin.
2. Nodular melanoma: This type of melanoma is more aggressive and accounts for about 15% of cases. It typically appears as a raised bump on the skin, often with a darker color.
3. Acral lentiginous melanoma: This type of melanoma affects the palms of the hands, soles of the feet, or nail beds and accounts for about 5% of cases.
4. Lentigo maligna melanoma: This type of melanoma usually affects the face and is more common in older adults.

The risk factors for developing melanoma include:

1. Ultraviolet (UV) radiation exposure from the sun or tanning beds
2. Fair skin, light hair, and light eyes
3. A history of sunburns
4. Weakened immune system
5. Family history of melanoma

The symptoms of melanoma can vary depending on the type and location of the cancer. Common symptoms include:

1. Changes in the size, shape, or color of a mole
2. A new mole or growth on the skin
3. A spot or sore that bleeds or crusts over
4. Itching or pain on the skin
5. Redness or swelling around a mole

If melanoma is suspected, a biopsy will be performed to confirm the diagnosis. Treatment options for melanoma depend on the stage and location of the cancer and may include surgery, chemotherapy, radiation therapy, or a combination of these. Early detection and treatment are key to successful outcomes in melanoma cases.

In conclusion, melanoma is a type of skin cancer that can be deadly if not detected early. It is important to practice sun safety, perform regular self-exams, and seek medical attention if any suspicious changes are noticed on the skin. By being aware of the risk factors, symptoms, and treatment options for melanoma, individuals can take steps to protect themselves from this potentially deadly disease.

The symptoms of mesothelioma can vary depending on the location of the cancer, but they may include:

* Shortness of breath or pain in the chest (for pleural mesothelioma)
* Abdominal pain or swelling (for peritoneal mesothelioma)
* Fatigue or fever (for pericardial mesothelioma)
* Weight loss and night sweats

There is no cure for mesothelioma, but treatment options may include surgery, chemotherapy, and radiation therapy. The prognosis for mesothelioma is generally poor, with a five-year survival rate of about 5% to 10%. However, the outlook can vary depending on the type of mesothelioma, the stage of the cancer, and the patient's overall health.

Asbestos exposure is the primary risk factor for developing mesothelioma, and it is important to avoid exposure to asbestos in any form. This can be done by avoiding old buildings and products that contain asbestos, wearing protective clothing and equipment when working with asbestos, and following proper safety protocols when handling asbestos-containing materials.

In summary, mesothelioma is a rare and aggressive form of cancer that develops in the lining of the heart or abdomen due to exposure to asbestos. It can be difficult to diagnose and treat, and the prognosis is generally poor. However, with proper medical care and avoidance of asbestos exposure, patients with mesothelioma may have a better chance of survival.

1. Endometrial carcinoma (cancer that starts in the lining of the uterus)
2. Uterine papillary serous carcinoma (cancer that starts in the muscle layer of the uterus)
3. Leiomyosarcoma (cancer that starts in the smooth muscle of the uterus)
4. Adenocarcinoma (cancer that starts in the glands of the endometrium)
5. Clear cell carcinoma (cancer that starts in the cells that resemble the lining of the uterus)
6. Sarcoma (cancer that starts in the connective tissue of the uterus)
7. Mixed tumors (cancers that have features of more than one type of uterine cancer)

These types of cancers can affect women of all ages and are more common in postmenopausal women. Risk factors for developing uterine neoplasms include obesity, tamoxifen use, and a history of endometrial hyperplasia (thickening of the lining of the uterus).

Symptoms of uterine neoplasms can include:

1. Abnormal vaginal bleeding (heavy or prolonged menstrual bleeding, spotting, or postmenopausal bleeding)
2. Postmenopausal bleeding
3. Pelvic pain or discomfort
4. Vaginal discharge
5. Weakness and fatigue
6. Weight loss
7. Pain during sex
8. Increased urination or frequency of urination
9. Abnormal Pap test results (abnormal cells found on the cervix)

If you have any of these symptoms, it is essential to consult your healthcare provider for proper evaluation and treatment. A diagnosis of uterine neoplasms can be made through several methods, including:

1. Endometrial biopsy (a small sample of tissue is removed from the lining of the uterus)
2. Dilation and curettage (D&C; a surgical procedure to remove tissue from the inside of the uterus)
3. Hysteroscopy (a thin, lighted tube with a camera is inserted through the cervix to view the inside of the uterus)
4. Imaging tests (such as ultrasound or MRI)

Treatment for uterine neoplasms depends on the type and stage of cancer. Common treatments include:

1. Hysterectomy (removal of the uterus)
2. Radiation therapy (uses high-energy rays to kill cancer cells)
3. Chemotherapy (uses drugs to kill cancer cells)
4. Targeted therapy (uses drugs to target specific cancer cells)
5. Clinical trials (research studies to test new treatments)

It is essential for women to be aware of their bodies and any changes that occur, particularly after menopause. Regular pelvic exams and screenings can help detect uterine neoplasms at an early stage, when they are more treatable. If you experience any symptoms or have concerns about your health, talk to your healthcare provider. They can help determine the cause of your symptoms and recommend appropriate treatment.

Peritoneal neoplasms are relatively rare, but they can be aggressive and difficult to treat. The most common types of peritoneal neoplasms include:

1. Peritoneal mesothelioma: This is the most common type of peritoneal neoplasm and arises from the mesothelial cells that line the abdominal cavity. It is often associated with asbestos exposure.
2. Ovarian cancer: This type of cancer originates in the ovaries and can spread to the peritoneum.
3. Appendiceal cancer: This type of cancer arises in the appendix and can spread to the peritoneum.
4. Pseudomyxoma peritonei: This is a rare type of cancer that originates in the abdominal cavity and resembles a mucin-secreting tumor.
5. Primary peritoneal cancer: This type of cancer originates in the peritoneum itself and can be of various types, including adenocarcinoma, squamous cell carcinoma, and sarcoma.

The symptoms of peritoneal neoplasms vary depending on the location and size of the tumor, but may include abdominal pain, distension, and difficulty eating or passing stool. Treatment options for peritoneal neoplasms depend on the type and stage of the cancer, but may include surgery, chemotherapy, and radiation therapy. Prognosis for peritoneal neoplasms is generally poor, with a five-year survival rate of around 20-30%.

Examples of mixed tumors, malignant include:

1. Melanoma-squamous cell carcinoma: This type of skin cancer is a mix of melanocytes (the cells that produce pigment) and squamous cells (thin, flat cells that make up the outer layer of skin).
2. Adenoid cystic carcinoma with squamous differentiation: This type of head and neck cancer has features of both adenoid cystic carcinoma (a type of salivary gland cancer) and squamous cell carcinoma.
3. Uterine leiomyosarcoma with endometrial adenocarcinoma: This type of uterine cancer is a mix of leiomyosarcoma (a type of smooth muscle cancer) and endometrial adenocarcinoma (a type of glandular cancer).
4. Metanephric stromal tumor with oncocytic changes: This type of kidney cancer is a mix of metanephric stromal tumor (a type of connective tissue cancer) and oncocytic changes (abnormal cells that resemble normal cells but have lost their ability to regulate growth).
5. Synovial sarcoma with osteoclast-like giant cells: This type of soft tissue cancer is a mix of synovial sarcoma (a type of connective tissue cancer) and osteoclast-like giant cells (large cells that resemble bone-forming cells).

Treatment for mixed tumors, malignant can vary depending on the specific types of cancer present and the extent of the disease. Surgery, radiation therapy, and chemotherapy may be used alone or in combination to treat the tumor. In some cases, a clinical trial may be an option.

Mixed tumors, malignant are often more aggressive and difficult to treat than single-type tumors because they contain multiple types of cancer cells that can grow and spread differently. However, advances in cancer diagnosis and treatment have improved the outlook for some patients with mixed tumors. The prognosis and treatment options for mixed tumors depend on the specific types of cancer present, the stage of the disease, and other individual factors.

A patient's age, overall health, and the presence of any other medical conditions can also affect their prognosis and treatment options. If you or a loved one has been diagnosed with a mixed tumor, it is essential to discuss your treatment options with a qualified healthcare professional who specializes in cancer care. They can help you understand the specific types of cancer present, the stage of the disease, and the most appropriate treatment plan for your individual situation.

In some cases, a clinical trial may be an option. Clinical trials are research studies that evaluate new treatments or combinations of treatments to see if they are safe and effective. Participating in a clinical trial may give you access to innovative therapies that are not yet widely available. However, it is essential to discuss the potential risks and benefits of clinical trials with your healthcare professional before making a decision.

In summary, mixed tumors are complex cancer diagnoses that can be challenging to treat. However, advances in cancer diagnosis and treatment have improved the outlook for some patients. If you or a loved one has been diagnosed with a mixed tumor, it is essential to discuss your treatment options with a qualified healthcare professional who specializes in cancer care. They can help you understand the specific types of cancer present, the stage of the disease, and the most appropriate treatment plan for your individual situation.

In some cases, a clinical trial may be an option. Clinical trials are research studies that evaluate new treatments or combinations of treatments to see if they are safe and effective. Participating in a clinical trial may give you access to innovative therapies that are not yet widely available. However, it is essential to discuss the potential risks and benefits of clinical trials with your healthcare professional before making a decision.

There are several types of sebaceous gland neoplasms, including:

1. Sebaceous adenoma: A benign tumor that is usually small and slow-growing. It can be found on the face, neck, or torso.
2. Sebaceous carcinoma: A malignant tumor that is rare but aggressive. It can be found on the eyelids, nose, or forehead.
3. Basal cell carcinoma: A type of skin cancer that can occur in the sebaceous glands. It usually appears as a small bump or nodule and can be treated with surgery or radiation therapy.
4. Squamous cell carcinoma: Another type of skin cancer that can occur in the sebaceous glands. It is more aggressive than basal cell carcinoma and can spread to other parts of the body if left untreated.

The symptoms of sebaceous gland neoplasms can vary depending on the type of tumor and its location. Some common symptoms include:

* A small, painless lump or nodule on the skin
* Redness or inflammation around the tumor
* Discharge of pus or oil from the tumor
* Swelling or bruising in the affected area
* Pain or discomfort in the affected area

Sebaceous gland neoplasms are usually diagnosed with a biopsy, which involves removing a small sample of tissue from the affected area and examining it under a microscope for cancer cells. Treatment options can vary depending on the type and stage of the tumor, but may include surgery, radiation therapy, or chemotherapy.

Preventative measures to reduce the risk of developing sebaceous gland neoplasms include:

* Protecting the skin from the sun by using sunscreen, wearing protective clothing, and seeking shade when the sun is strongest
* Avoiding excessive alcohol consumption
* Maintaining a healthy diet and lifestyle
* Avoiding exposure to chemicals and other substances that can damage the skin

Early detection and treatment of sebaceous gland neoplasms are important for successful outcomes. If you notice any changes or abnormalities in your skin, it is important to see a dermatologist as soon as possible.

There are several different types of tumor viruses, including:

1. Human papillomavirus (HPV): This virus is responsible for causing cervical cancer and other types of cancer, such as anal, vulvar, vaginal, and penile cancer.
2. Hepatitis B virus (HBV): This virus can cause liver cancer, known as hepatocellular carcinoma (HCC).
3. Human immunodeficiency virus (HIV): This virus can increase the risk of developing certain types of cancer, such as Kaposi's sarcoma and lymphoma.
4. Epstein-Barr virus (EBV): This virus has been linked to the development of Burkitt lymphoma and Hodgkin's lymphoma.
5. Merkel cell polyomavirus (MCPyV): This virus is responsible for causing Merkel cell carcinoma, a rare type of skin cancer.
6. Human T-lymphotropic virus (HTLV-1): This virus has been linked to the development of adult T-cell leukemia/lymphoma (ATLL).

Tumor virus infections can be diagnosed through a variety of methods, including blood tests, imaging studies, and biopsies. Treatment for these infections often involves antiviral medications, chemotherapy, and surgery. In some cases, tumors may also be removed through radiation therapy.

It's important to note that not all tumors or cancers are caused by viruses, and that many other factors, such as genetics and environmental exposures, can also play a role in the development of cancer. However, for those tumor virus infections that are caused by a specific virus, early diagnosis and treatment can improve outcomes and reduce the risk of complications.

Overall, tumor virus infections are a complex and diverse group of conditions, and further research is needed to better understand their causes and develop effective treatments.

The most common symptoms of anus neoplasms are bleeding from the anus, pain or discomfort in the anal area, itching or burning sensation in the anus, and a lump or swelling near the anus. These symptoms can be caused by various conditions, including hemorrhoids, anal fissures, and infections. However, if these symptoms persist or worsen over time, they may indicate the presence of an anus neoplasm.

The diagnosis of anus neoplasms is typically made through a combination of physical examination, endoscopy, and imaging tests such as CT scans or MRI scans. A biopsy may also be performed to confirm the presence of cancer cells.

Treatment for anus neoplasms depends on the stage and location of the cancer, as well as the patient's overall health. Surgery is often the primary treatment option, and may involve removing the tumor, a portion of the anus, or the entire anus. Radiation therapy and chemotherapy may also be used to shrink the tumor before surgery or to kill any remaining cancer cells after surgery.

Prevention of anus neoplasms is not always possible, but certain measures can reduce the risk of developing these types of cancers. These include maintaining a healthy diet and lifestyle, avoiding exposure to carcinogens such as tobacco smoke, and practicing safe sex to prevent human papillomavirus (HPV) infections, which can increase the risk of anus neoplasms. Early detection and treatment of precancerous changes in the anus, such as anal intraepithelial neoplasia, can also help prevent the development of invasive anus neoplasms.

Cecal neoplasms refer to abnormal growths or tumors that occur in the cecum, which is a part of the large intestine. The cecum is a pouch-like structure located at the junction of the small and large intestines. Cecal neoplasms can be benign (non-cancerous) or malignant (cancerous).

Types of Cecal Neoplasms

There are several types of cecal neoplasms, including:

1. Adenoma: A benign tumor that arises from the glandular cells lining the cecum.
2. Villous adenoma: A type of adenoma that is characterized by the growth of villi, which are finger-like projections of epithelial tissue.
3. Tubulovillous adenoma: A type of adenoma that is characterized by the growth of tubular and villous structures.
4. Mucinous cystic neoplasm: A benign tumor that arises from the mucin-secreting cells lining the cecum.
5. Intraepithelial neoplasms: Precancerous changes that occur in the epithelial cells lining the cecum.
6. Carcinoma: A malignant tumor that arises from the epithelial cells lining the cecum.
7. Squamous cell carcinoma: A type of carcinoma that is characterized by the growth of squamous cells.
8. Adenocarcinoma: A type of carcinoma that is characterized by the growth of glandular cells.

Causes and Risk Factors

The exact causes of cecal neoplasms are not known, but several risk factors have been identified, including:

1. Age: The risk of developing cecal neoplasms increases with age.
2. Family history: Having a family history of colon cancer or other gastrointestinal cancers increases the risk of developing cecal neoplasms.
3. Inflammatory bowel disease: People with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease, are at higher risk of developing cecal neoplasms.
4. Genetic mutations: Some genetic mutations, such as those associated with familial adenomatous polyposis (FAP) and Lynch syndrome, increase the risk of developing cecal neoplasms.
5. Diet and lifestyle factors: A diet high in processed meat and low in fiber may increase the risk of developing cecal neoplasms.

Symptoms

Cecal neoplasms may not cause any symptoms in the early stages, but as they grow, they can cause a variety of symptoms, including:

1. Abdominal pain or discomfort
2. Changes in bowel movements (such as diarrhea or constipation)
3. Blood in the stool
4. Weakness and fatigue
5. Loss of appetite
6. Unexplained weight loss

Diagnosis

The diagnosis of cecal neoplasms is based on a combination of clinical findings, imaging studies, and pathological examination of tissue samples. The following tests may be used to diagnose cecal neoplasms:

1. Endoscopy: A flexible tube with a camera and light on the end is inserted through the mouth or rectum to visualize the inside of the cecum and collect tissue samples.
2. Imaging studies: Computed tomography (CT) scans, magnetic resonance imaging (MRI), or positron emission tomography (PET) scans may be used to identify any abnormalities in the cecum and surrounding tissues.
3. Biopsy: A sample of tissue is taken from the cecum during endoscopy or surgery and examined under a microscope for cancer cells.
4. Blood tests: Blood tests may be used to check for certain substances in the blood that are associated with cancer, such as carcinoembryonic antigen (CEA).

Treatment

The treatment of cecal neoplasms depends on the type and stage of the cancer. The following options may be considered:

1. Surgery: Surgical removal of the cancerous tissue may be recommended for early-stage cancers.
2. Chemotherapy: Chemotherapy may be used in combination with surgery or as a standalone treatment for more advanced cancers.
3. Radiation therapy: Radiation therapy may be used in combination with chemotherapy or surgery to treat cancer that has spread to other parts of the body.
4. Targeted therapy: Targeted therapy may be used to treat specific genetic mutations that are driving the growth of the cancer.

Prognosis

The prognosis for cecal neoplasms depends on the type and stage of the cancer at the time of diagnosis. In general, early-stage cancers have a better prognosis than more advanced cancers. Factors that may affect prognosis include:

1. Type of cancer: The type of cancer present in the cecum can impact prognosis. For example, adenocarcinoma has a better prognosis than squamous cell carcinoma.
2. Stage of cancer: Cancers that have spread to other parts of the body (metastasized) have a poorer prognosis than those that are localized to the cecum.
3. Age and overall health: Older patients or those with underlying health conditions may have a poorer prognosis than younger, healthier individuals.
4. Treatment options: The effectiveness of treatment can also impact prognosis. Patients who receive early and appropriate treatment may have a better prognosis than those who do not receive timely treatment.

Survival rate

The survival rate for cecal neoplasms is generally lower than for other types of gastrointestinal cancers. According to the American Cancer Society, the 5-year survival rate for cecal cancer is approximately 20%. This means that of patients diagnosed with cecal cancer, about 20% are still alive 5 years after their initial diagnosis. However, it's important to note that this is a general estimate and individual prognosis can vary based on a variety of factors.

Lifestyle changes

There are several lifestyle changes that may help reduce the risk of developing cecal neoplasms or improve outcomes for those who have been diagnosed:

1. Maintain a healthy diet and weight: Eating a balanced diet high in fruits, vegetables, and whole grains can help reduce the risk of developing cecal cancer. Additionally, maintaining a healthy weight can help reduce the risk of developing many types of cancer.
2. Exercise regularly: Regular physical activity has been shown to reduce the risk of developing many types of cancer, including cecal cancer.
3. Avoid tobacco and excessive alcohol consumption: Tobacco use and excessive alcohol consumption have both been linked to an increased risk of developing cecal cancer. Quitting smoking and limiting alcohol intake can help reduce the risk of developing this disease.
4. Manage chronic conditions: Chronic conditions such as diabetes, obesity, and inflammatory bowel disease can increase the risk of developing cecal cancer. Managing these conditions through lifestyle changes and medication can help reduce the risk of developing this disease.
5. Get regular screenings: Regular screenings for colon cancer, such as colonoscopies, can help detect cecal cancer at an early stage when it is more treatable.
6. Consider aspirin therapy: Some studies have suggested that taking a low-dose aspirin every day may help reduce the risk of developing colorectal cancer, including cecal cancer. However, aspirin therapy is not right for everyone, and individuals should talk to their doctor before starting any new medication.
7. Don't delay symptoms: If you experience any symptoms that may be related to cecal cancer, such as abdominal pain or changes in bowel movements, don't delay seeking medical attention. These symptoms can also be caused by other conditions, but it is important to get them checked out by a healthcare professional.

It is important to note that these recommendations are not a guarantee against developing cecal cancer, and individuals should talk to their doctor about their specific risk factors and any additional steps they can take to reduce their risk of developing this disease.

Explanation: Genetic predisposition to disease is influenced by multiple factors, including the presence of inherited genetic mutations or variations, environmental factors, and lifestyle choices. The likelihood of developing a particular disease can be increased by inherited genetic mutations that affect the functioning of specific genes or biological pathways. For example, inherited mutations in the BRCA1 and BRCA2 genes increase the risk of developing breast and ovarian cancer.

The expression of genetic predisposition to disease can vary widely, and not all individuals with a genetic predisposition will develop the disease. Additionally, many factors can influence the likelihood of developing a particular disease, such as environmental exposures, lifestyle choices, and other health conditions.

Inheritance patterns: Genetic predisposition to disease can be inherited in an autosomal dominant, autosomal recessive, or multifactorial pattern, depending on the specific disease and the genetic mutations involved. Autosomal dominant inheritance means that a single copy of the mutated gene is enough to cause the disease, while autosomal recessive inheritance requires two copies of the mutated gene. Multifactorial inheritance involves multiple genes and environmental factors contributing to the development of the disease.

Examples of diseases with a known genetic predisposition:

1. Huntington's disease: An autosomal dominant disorder caused by an expansion of a CAG repeat in the Huntingtin gene, leading to progressive neurodegeneration and cognitive decline.
2. Cystic fibrosis: An autosomal recessive disorder caused by mutations in the CFTR gene, leading to respiratory and digestive problems.
3. BRCA1/2-related breast and ovarian cancer: An inherited increased risk of developing breast and ovarian cancer due to mutations in the BRCA1 or BRCA2 genes.
4. Sickle cell anemia: An autosomal recessive disorder caused by a point mutation in the HBB gene, leading to defective hemoglobin production and red blood cell sickling.
5. Type 1 diabetes: An autoimmune disease caused by a combination of genetic and environmental factors, including multiple genes in the HLA complex.

Understanding the genetic basis of disease can help with early detection, prevention, and treatment. For example, genetic testing can identify individuals who are at risk for certain diseases, allowing for earlier intervention and preventive measures. Additionally, understanding the genetic basis of a disease can inform the development of targeted therapies and personalized medicine."


Previous articleNeoplastic Cells
Next articleNephrocalcinosis

Symptoms of Endometrial Hyperplasia:

The symptoms of endometrial hyperplasia may include:

* Abnormal vaginal bleeding or spotting
* Heavy menstrual periods
* Prolonged menstrual periods
* Painful periods
* Abdominal pain or discomfort

Diagnosis of Endometrial Hyperplasia:

To diagnose endometrial hyperplasia, a doctor may perform the following tests:

* Pelvic examination to check for any abnormalities in the uterus, ovaries, and fallopian tubes.
* Endometrial biopsy to collect a sample of tissue from the endometrium for further examination under a microscope.
* Ultrasound to create images of the uterus and check for any abnormal growths or tumors.
* Hysteroscopy, which is a procedure where a small camera is inserted into the uterus through the cervix to examine the inside of the uterus.

Treatment of Endometrial Hyperplasia:

The treatment of endometrial hyperplasia depends on the severity of the condition and may include:

* Hormonal medications to regulate hormone levels and reduce the growth of the endometrium.
* Endometrial ablation, which is a procedure that destroys the endometrium using heat or cold.
* Hysterectomy, which is the surgical removal of the uterus.

Prevention of Endometrial Hyperplasia:

To prevent endometrial hyperplasia, women can take the following steps:

* Maintain a healthy weight to reduce the risk of hormonal imbalances.
* Exercise regularly to improve overall health and reduce the risk of hormonal imbalances.
* Avoid exposure to endocrine disruptors, such as pesticides and herbicides, which can mimic or interfere with hormones in the body.
* Limit alcohol consumption, as excessive alcohol consumption can increase the risk of hormonal imbalances.
* Eat a balanced diet that is rich in fruits, vegetables, and whole grains, which can help regulate hormone levels.
* Consider taking supplements such as vitamin D and omega-3 fatty acids, which have been shown to have anti-inflammatory effects and may help regulate hormone levels.

It is important for women to talk to their healthcare provider about their individual risk factors for endometrial hyperplasia and any steps they can take to prevent the condition.

The symptoms of hypercalcemia may include:

* Fatigue
* Nausea and vomiting
* Weakness
* Constipation
* Abdominal pain
* Kidney stones
* Bone pain or fractures

If left untreated, hypercalcemia can lead to complications such as kidney damage, heart problems, and an increased risk of osteoporosis. Treatment options may include medications to reduce calcium levels, surgery to remove a tumor or overactive parathyroid gland, or dialysis if the patient has kidney failure.

Early diagnosis and treatment are important to prevent long-term complications and improve the patient's quality of life.

White blood cells are an important part of the immune system, and they help to fight off infections and diseases. A low number of white blood cells can make a person more susceptible to infections and other health problems.

There are several different types of leukopenia, including:

* Severe congenital neutropenia: This is a rare genetic disorder that causes a severe decrease in the number of neutrophils, a type of white blood cell.
* Chronic granulomatous disease: This is a genetic disorder that affects the production of white blood cells and can cause recurring infections.
* Autoimmune disorders: These are conditions where the immune system mistakenly attacks its own cells, including white blood cells. Examples include lupus and rheumatoid arthritis.
* Bone marrow failure: This is a condition where the bone marrow does not produce enough white blood cells, red blood cells, or platelets.

Symptoms of leukopenia can include recurring infections, fever, fatigue, and weight loss. Treatment depends on the underlying cause of the condition and may include antibiotics, immunoglobulin replacement therapy, or bone marrow transplantation.

The presence of blood in urine is typically detected during a urinalysis, which is a routine test performed during a physical examination or when a patient is admitted to the hospital. The amount and color of blood can vary depending on the cause of hematuria, ranging from microscopic (not visible to the naked eye) to gross (visible).

Hematuria can be classified into two main types:

1. Gross hematuria: This type of hematuria is characterized by visible blood in urine, which can range from pink to bright red. It is usually caused by trauma, kidney stones, or tumors.
2. Microscopic hematuria: This type of hematuria is characterized by the presence of red blood cells in urine that are not visible to the naked eye. It can be caused by various factors, including infections, inflammation, and kidney damage.

Hematuria can be a sign of an underlying medical condition, and it is important to consult a healthcare professional if blood is present in urine. A proper diagnosis is essential to determine the cause of hematuria and provide appropriate treatment.

Examples of neoplasms, glandular and epithelial include:

* Adenomas: These are benign tumors that arise from glandular tissue. Examples include colon adenomas and prostate adenomas.
* Carcinomas: These are malignant tumors that arise from glandular or epithelial tissue. Examples include breast carcinoma, lung carcinoma, and ovarian carcinoma.
* Sarcomas: These are malignant tumors that arise from connective tissue. Examples include soft tissue sarcoma and bone sarcoma.

The diagnosis of neoplasms, glandular and epithelial is typically made through a combination of imaging tests such as X-rays, CT scans, MRI scans, and PET scans, along with a biopsy to confirm the presence of cancer cells. Treatment options for these types of neoplasms depend on the location, size, and stage of the tumor, but may include surgery, chemotherapy, radiation therapy, or a combination of these.

Overall, the term "neoplasms, glandular and epithelial" refers to a wide range of tumors that arise from glandular or epithelial tissue, and can be either benign or malignant. These types of neoplasms are common and can affect many different parts of the body.

1) They share similarities with humans: Many animal species share similar biological and physiological characteristics with humans, making them useful for studying human diseases. For example, mice and rats are often used to study diseases such as diabetes, heart disease, and cancer because they have similar metabolic and cardiovascular systems to humans.

2) They can be genetically manipulated: Animal disease models can be genetically engineered to develop specific diseases or to model human genetic disorders. This allows researchers to study the progression of the disease and test potential treatments in a controlled environment.

3) They can be used to test drugs and therapies: Before new drugs or therapies are tested in humans, they are often first tested in animal models of disease. This allows researchers to assess the safety and efficacy of the treatment before moving on to human clinical trials.

4) They can provide insights into disease mechanisms: Studying disease models in animals can provide valuable insights into the underlying mechanisms of a particular disease. This information can then be used to develop new treatments or improve existing ones.

5) Reduces the need for human testing: Using animal disease models reduces the need for human testing, which can be time-consuming, expensive, and ethically challenging. However, it is important to note that animal models are not perfect substitutes for human subjects, and results obtained from animal studies may not always translate to humans.

6) They can be used to study infectious diseases: Animal disease models can be used to study infectious diseases such as HIV, TB, and malaria. These models allow researchers to understand how the disease is transmitted, how it progresses, and how it responds to treatment.

7) They can be used to study complex diseases: Animal disease models can be used to study complex diseases such as cancer, diabetes, and heart disease. These models allow researchers to understand the underlying mechanisms of the disease and test potential treatments.

8) They are cost-effective: Animal disease models are often less expensive than human clinical trials, making them a cost-effective way to conduct research.

9) They can be used to study drug delivery: Animal disease models can be used to study drug delivery and pharmacokinetics, which is important for developing new drugs and drug delivery systems.

10) They can be used to study aging: Animal disease models can be used to study the aging process and age-related diseases such as Alzheimer's and Parkinson's. This allows researchers to understand how aging contributes to disease and develop potential treatments.

The symptoms of limbic encephalitis can vary depending on the severity of the inflammation and the specific areas of the brain affected. Common symptoms include:

* Memory loss and confusion
* Seizures
* Vision problems
* Speech difficulties
* Emotional changes, such as anxiety or depression
* Behavioral changes, such as aggression or apathy
* Personality changes

The exact cause of limbic encephalitis is not fully understood, but it is believed to be an autoimmune response, where the immune system mistakenly attacks healthy tissue in the brain. In some cases, the condition may be triggered by a viral or bacterial infection, and in others, it may be associated with certain medical conditions, such as multiple sclerosis or lupus.

There is no cure for limbic encephalitis, but treatment options are available to manage symptoms and slow the progression of the disease. These may include:

* Medications to reduce inflammation and suppress the immune system
* Anticonvulsants to prevent seizures
* Cognitive rehabilitation to improve memory and other cognitive functions
* Behavioral therapy to manage emotional and behavioral changes

The prognosis for limbic encephalitis varies depending on the severity of the inflammation and the specific areas of the brain affected. In some cases, the condition may resolve on its own over time, while in others, it may result in long-term cognitive and behavioral impairments.

There is currently no way to prevent limbic encephalitis, but early diagnosis and treatment can help manage symptoms and slow the progression of the disease. Researchers are continuing to study the condition to better understand its causes and develop more effective treatments.

Some common types of eye neoplasms include:

1. Uveal melanoma: This is a malignant tumor that develops in the uvea, the middle layer of the eye. It is the most common primary intraocular cancer in adults and can spread to other parts of the body if left untreated.
2. Retinoblastoma: This is a rare type of cancer that affects children and develops in the retina. It is usually diagnosed before the age of 5 and is highly treatable with surgery, chemotherapy, and radiation therapy.
3. Conjunctival melanoma: This is a malignant tumor that develops in the conjunctiva, the thin membrane that covers the white part of the eye. It is more common in older adults and can be treated with surgery and/or radiation therapy.
4. Ocular sarcomas: These are rare types of cancer that develop in the eye tissues, including the retina, optic nerve, and uvea. They can be benign or malignant and may require surgical removal or radiation therapy.
5. Secondary intraocular tumors: These are tumors that metastasize (spread) to the eye from other parts of the body, such as breast cancer or lung cancer.

The symptoms of eye neoplasms can vary depending on their location and type, but may include:

* Blurred vision
* Eye pain or discomfort
* Redness or inflammation in the eye
* Sensitivity to light
* Floaters (specks or cobwebs in vision)
* Flashes of light
* Abnormal pupil size or shape

Early detection and treatment of eye neoplasms are important to preserve vision and prevent complications. Diagnosis is typically made through a combination of physical examination, imaging tests such as ultrasound or MRI, and biopsy (removing a small sample of tissue for examination under a microscope). Treatment options may include:

* Surgery to remove the tumor
* Radiation therapy to kill cancer cells
* Chemotherapy to destroy cancer cells with medication
* Observation and monitoring if the tumor is slow-growing or benign

It's important to seek medical attention if you experience any unusual symptoms in your eye, as early detection and treatment can improve outcomes.

Necrosis is a type of cell death that occurs when cells are exposed to excessive stress, injury, or inflammation, leading to damage to the cell membrane and the release of cellular contents into the surrounding tissue. This can lead to the formation of gangrene, which is the death of body tissue due to lack of blood supply.

There are several types of necrosis, including:

1. Coagulative necrosis: This type of necrosis occurs when there is a lack of blood supply to the tissues, leading to the formation of a firm, white plaque on the surface of the affected area.
2. Liquefactive necrosis: This type of necrosis occurs when there is an infection or inflammation that causes the death of cells and the formation of pus.
3. Caseous necrosis: This type of necrosis occurs when there is a chronic infection, such as tuberculosis, and the affected tissue becomes soft and cheese-like.
4. Fat necrosis: This type of necrosis occurs when there is trauma to fatty tissue, leading to the formation of firm, yellowish nodules.
5. Necrotizing fasciitis: This is a severe and life-threatening form of necrosis that affects the skin and underlying tissues, often as a result of bacterial infection.

The diagnosis of necrosis is typically made through a combination of physical examination, imaging studies such as X-rays or CT scans, and laboratory tests such as biopsy. Treatment depends on the underlying cause of the necrosis and may include antibiotics, surgical debridement, or amputation in severe cases.

Benign fallopian tube neoplasms include:

* Serous cystadenomas: These are fluid-filled sacs that grow on the lining of the fallopian tube. They are usually small and do not spread to other parts of the body.
* Mucinous cystadenomas: These are similar to serous cystadenomas, but they contain a thick, mucous-like fluid.
* Adenomas: These are small, glandular tumors that grow on the lining of the fallopian tube. They are usually benign but can sometimes become cancerous over time.

Malignant fallopian tube neoplasms include:

* Fallopian tube carcinoma: This is a rare form of cancer that originates in the fallopian tube. It can be either serous or endometrioid type, depending on the type of cells involved.
* Endometrial adenocarcinoma: This is a type of cancer that originates in the lining of the uterus (endometrium) and can also involve the fallopian tubes.

The symptoms of fallopian tube neoplasms can vary depending on their size, location, and type. Some common symptoms include:

* Abnormal vaginal bleeding
* Pelvic pain or discomfort
* Abdominal pain or swelling
* Difficulty urinating or defecating
* Weakness or fatigue

The diagnosis of fallopian tube neoplasms is based on a combination of imaging studies, such as ultrasound and computed tomography (CT) scans, and tissue sampling, such as biopsy or surgical removal of the tumor. Treatment options for fallopian tube neoplasms depend on the type, size, and location of the tumor, as well as the patient's age, overall health, and fertility status.

Treatment options for fallopian tube neoplasms can include:

* Surgical removal of the tumor: This is the most common treatment for fallopian tube neoplasms, and it involves removing the affected fallopian tube and any other affected tissues.
* Chemotherapy: This is a treatment that uses drugs to kill cancer cells, and it may be used in combination with surgery or as a standalone treatment for more advanced cancers.
* Radiation therapy: This is a treatment that uses high-energy rays to kill cancer cells, and it may be used in combination with surgery or chemotherapy.
* Hysterectomy: This is a surgical removal of the uterus, and it may be recommended for more advanced cancers that have spread beyond the fallopian tubes.
* Conservative management: In some cases, small, non-invasive tumors may be monitored with regular check-ups and imaging studies rather than undergoing immediate treatment.

The prognosis for fallopian tube neoplasms depends on several factors, including the type and stage of the cancer, the patient's age and overall health, and the effectiveness of the treatment. In general, the prognosis is good for women with early-stage tumors that are treated successfully, but the prognosis is poorer for women with more advanced cancers.

There are several types of lymphoma, including:

1. Hodgkin lymphoma: This is a type of lymphoma that originates in the white blood cells called Reed-Sternberg cells. It is characterized by the presence of giant cells with multiple nucleoli.
2. Non-Hodgkin lymphoma (NHL): This is a type of lymphoma that does not meet the criteria for Hodgkin lymphoma. There are many subtypes of NHL, each with its own unique characteristics and behaviors.
3. Cutaneous lymphoma: This type of lymphoma affects the skin and can take several forms, including cutaneous B-cell lymphoma and cutaneous T-cell lymphoma.
4. Primary central nervous system (CNS) lymphoma: This is a rare type of lymphoma that develops in the brain or spinal cord.
5. Post-transplantation lymphoproliferative disorder (PTLD): This is a type of lymphoma that develops in people who have undergone an organ transplant, often as a result of immunosuppressive therapy.

The symptoms of lymphoma can vary depending on the type and location of the cancer. Some common symptoms include:

* Swollen lymph nodes
* Fever
* Fatigue
* Weight loss
* Night sweats
* Itching

Lymphoma is diagnosed through a combination of physical examination, imaging tests (such as CT scans or PET scans), and biopsies. Treatment options for lymphoma depend on the type and stage of the cancer, and may include chemotherapy, radiation therapy, immunotherapy, or stem cell transplantation.

Overall, lymphoma is a complex and diverse group of cancers that can affect people of all ages and backgrounds. While it can be challenging to diagnose and treat, advances in medical technology and research have improved the outlook for many patients with lymphoma.

Types of Parathyroid Neoplasms: There are several types of parathyroid neoplasms, including:

1. Adenoma: A benign tumor that is the most common type of parathyroid neoplasm. It usually causes hyperparathyroidism, a condition characterized by high levels of calcium in the blood.
2. Hyperplasia: A condition where the parathyroid glands become enlarged and produce excessive amounts of parathyroid hormone, leading to hyperparathyroidism.
3. Carcinoma: A malignant tumor that is rare and usually occurs in patients with a history of radiation exposure or familial adenomatous polyposis (FAP).

Symptoms of Parathyroid Neoplasms: The symptoms of parathyroid neoplasms can vary depending on the type and size of the tumor. Some common symptoms include:

1. Hyperparathyroidism: High levels of calcium in the blood, which can lead to symptoms such as fatigue, nausea, vomiting, and weakness.
2. Enlarged thyroid gland: A swelling in the neck due to an enlarged thyroid gland, which can cause difficulty swallowing or breathing.
3. Pain in the neck or throat: A painful lump in the neck or throat that can be caused by a tumor pressing on nearby structures.
4. Fever: An elevated body temperature that can occur if the tumor becomes infected or inflamed.
5. Weight loss: Unexplained weight loss, which can occur if the tumor is secreting excessive amounts of parathyroid hormone.

Diagnosis of Parathyroid Neoplasms: The diagnosis of parathyroid neoplasms typically involves a combination of imaging studies and laboratory tests. Some common diagnostic procedures include:

1. Ultrasound: A non-invasive imaging technique that uses high-frequency sound waves to produce images of the thyroid gland and any tumors present.
2. Thyroid scan: A nuclear medicine test that involves injecting a small amount of radioactive material into the bloodstream to visualize the thyroid gland and any tumors present.
3. Calcium levels: Blood tests to measure calcium levels, which can be elevated in hyperparathyroidism.
4. Parathyroid hormone (PTH) level: A blood test to measure PTH levels, which can be elevated in hyperparathyroidism.
5. Biopsy: A procedure that involves removing a small sample of tissue from the thyroid gland and examining it under a microscope for cancer cells.

Treatment of Parathyroid Neoplasms: The treatment of parathyroid neoplasms depends on the type and size of the tumor, as well as the severity of hyperparathyroidism. Some common treatments include:

1. Surgery: The primary treatment for parathyroid neoplastic diseases is surgical removal of the affected parathyroid gland(s).
2. Radioactive iodine ablation: A therapy that involves taking a small dose of radioactive iodine to destroy any remaining thyroid tissue that may be producing excessive amounts of thyroid hormones.
3. Thyroid hormone medications: Medications that are used to control hyperthyroidism and hypothyroidism.
4. Calcium and vitamin D supplements: Medications that are used to treat hypocalcemia and vitamin D deficiency.
5. Monitoring: Regular monitoring of calcium levels, PTH levels, and symptoms is important to ensure that the treatment is effective and to detect any recurrences or complications.

Prognosis: The prognosis for patients with parathyroid neoplasms depends on the type and size of the tumor, as well as the severity of hyperparathyroidism. In general, the prognosis is good for patients who undergo surgical removal of the affected gland(s), but it may be poorer for those with more advanced or invasive tumors.

Complications: Complications of parathyroid neoplasms include:

1. Hyperparathyroidism: Excessive production of PTH can lead to hyperthyroidism, hypocalcemia, and other complications.
2. Recurrence: There is a risk of recurrence after surgical removal of the affected gland(s).
3. Spread of disease: In rare cases, parathyroid tumors can spread to other parts of the body (such as the lymph nodes or bones) and cause metastatic disease.
4. Hypoparathyroidism: Removal of all four parathyroid glands can lead to hypoparathyroidism, which can be life-threatening if not treated promptly.
5. Pancreatitis: Some studies have suggested that there may be an increased risk of pancreatitis in patients with parathyroid neoplasms.

The symptoms of malignant pleural effusion can vary depending on the location and size of the tumor and the amount of fluid accumulated. Common symptoms include:

* Chest pain or discomfort
* Shortness of breath (dyspnea)
* Coughing up blood or pink, frothy liquid (hemoptysis)
* Fatigue
* Weight loss
* Night sweats
* Fevers

A diagnosis of malignant pleural effusion is typically made based on a combination of physical examination findings, medical imaging studies such as chest X-rays or CT scans, and laboratory tests to evaluate the fluid drained from the pleural space.

Treatment for malignant pleural effusion depends on the underlying cause and may include:

* Chemotherapy to shrink the tumor and reduce fluid buildup
* Radiation therapy to target cancer cells in the chest
* Surgery to remove the cancerous tissue or drain the fluid
* Pain management medications to relieve chest pain and discomfort.

Mediastinal neoplasms are tumors or abnormal growths that occur in the mediastinum, which is the area between the lungs in the chest cavity. These neoplasms can be benign (non-cancerous) or malignant (cancerous).

Types of Mediastinal Neoplasms
------------------------------

There are several types of mediastinal neoplasms, including:

1. Thymoma: A tumor that originates in the thymus gland.
2. Thymic carcinoma: A malignant tumor that originates in the thymus gland.
3. Lymphoma: Cancer of the immune system that can occur in the mediastinum.
4. Germ cell tumors: Tumors that originate from germ cells, which are cells that form eggs or sperm.
5. Neuroendocrine tumors: Tumors that originate from cells of the nervous system and produce hormones.
6. Mesothelioma: A type of cancer that occurs in the lining of the chest cavity.
7. Metastatic tumors: Tumors that have spread to the mediastinum from another part of the body, such as the breast, lung, or colon.

Symptoms of Mediastinal Neoplasms
------------------------------

The symptoms of mediastinal neoplasms can vary depending on the type and location of the tumor. Some common symptoms include:

1. Chest pain or discomfort
2. Shortness of breath
3. Coughing
4. Fatigue
5. Weight loss
6. Swelling in the neck or face
7. Pain in the shoulders or arms
8. Coughing up blood
9. Hoarseness or difficulty swallowing

Diagnosis and Treatment of Mediastinal Neoplasms
-----------------------------------------------

The diagnosis of mediastinal neoplasms typically involves a combination of imaging tests such as chest X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans. A biopsy may also be performed to confirm the diagnosis.

Treatment for mediastinal neoplasms depends on the type and location of the tumor, as well as the patient's overall health. Treatment options can include:

1. Surgery: Surgical removal of the tumor may be possible for some types of mediastinal neoplasms.
2. Radiation therapy: High-energy beams can be used to kill cancer cells.
3. Chemotherapy: Drugs can be used to kill cancer cells.
4. Targeted therapy: Drugs that target specific molecules involved in the growth and spread of cancer cells.
5. Immunotherapy: A type of treatment that uses the body's immune system to fight cancer.

Prognosis for Mediastinal Neoplasms
---------------------------------

The prognosis for mediastinal neoplasms depends on the type and location of the tumor, as well as the patient's overall health. In general, the prognosis is good for benign tumors, while the prognosis is guarded for malignant tumors. Factors that can affect the prognosis include:

1. Tumor size and location
2. Type of tumor
3. Extent of cancer spread
4. Patient's age and overall health
5. Response to treatment

Lifestyle Changes for Patients with Mediastinal Neoplasms
---------------------------------------------------

Patients with mediastinal neoplasms may need to make lifestyle changes to help manage their symptoms and improve their quality of life. These can include:

1. Eating a healthy diet
2. Getting regular exercise
3. Avoiding smoking and alcohol
4. Managing stress
5. Getting enough rest and sleep
6. Attending follow-up appointments with the doctor

Conclusion
----------

Mediastinal neoplasms are tumors that occur in the mediastinum, a region of the chest between the lungs. They can be benign or malignant, and their symptoms and treatment options vary depending on the type and location of the tumor. If you have been diagnosed with a mediastinal neoplasm, it is important to work closely with your healthcare team to determine the best course of treatment and manage any symptoms you may be experiencing. With appropriate treatment and lifestyle changes, many patients with mediastinal neoplasms can achieve long-term survival and a good quality of life.

Adenofibromas are usually slow-growing and do not spread to other parts of the body. They may be small and firm or large and soft to the touch. They can be skin-colored or pink, and they may have a rough surface.

The cause of adenofibroma is not known, but it is thought to arise from abnormal growth of sweat gland cells. It is usually diagnosed by a dermatologist or a pathologist who examines a sample of the tumor under a microscope.

Treatment for adenofibroma is usually not necessary unless the tumor is causing symptoms or is cosmetically bothersome. In these cases, surgical removal of the tumor may be recommended. Complete removal of the tumor is usually possible, and the prognosis is excellent.

Sources:

* American Academy of Dermatology: Adenofibroma: Overview and Treatment Options
* Mayo Clinic: Adenofibroma: Symptoms and Causes
* Skin Cancer Foundation: Adenofibroma: Diagnosis and Treatment

The exact cause of cholangiocarcinoma is not known, but there are several risk factors that have been linked to the development of the disease. These include:

1. Chronic inflammation of the bile ducts (cholangitis)
2. Infection with certain viruses, such as hepatitis B and C
3. Genetic conditions, such as inherited syndromes that affect the liver and bile ducts
4. Exposure to certain chemicals, such as thorium dioxide
5. Obesity and metabolic disorders

The symptoms of cholangiocarcinoma can vary depending on the location and size of the tumor. Common symptoms include:

1. Jaundice (yellowing of the skin and eyes)
2. Itching all over the body
3. Fatigue
4. Loss of appetite
5. Abdominal pain and swelling
6. Weight loss
7. Nausea and vomiting

If cholangiocarcinoma is suspected, a doctor may perform several tests to confirm the diagnosis. These may include:

1. Imaging tests, such as CT scans, MRI scans, or PET scans
2. Blood tests to check for certain liver enzymes and bilirubin levels
3. Endoscopic ultrasound to examine the bile ducts
4. Biopsy to collect a sample of tissue from the suspected tumor

Treatment for cholangiocarcinoma depends on the stage and location of the cancer, as well as the patient's overall health. Surgery is often the first line of treatment, and may involve removing the tumor and a portion of the bile ducts. In more advanced cases, chemotherapy or radiation therapy may be used to shrink the tumor before surgery or to relieve symptoms.

It's important for patients with cholangiocarcinoma to work closely with their healthcare team to develop a personalized treatment plan and to monitor their condition regularly. With prompt and appropriate treatment, some patients with cholangiocarcinoma may experience long-term survival and a good quality of life.

Fibroadenomas can be diagnosed through a physical examination, mammography or ultrasound. They are usually benign and do not spread to other parts of the body, but in rare cases, they may grow larger over time. Treatment for fibroadenoma is usually watchful waiting, as the tumors often do not change in size or shape over time. Surgical removal may be recommended if the tumor becomes larger or causes symptoms such as pain or discomfort.

Fibroadenomas are different from fibrocystic breast changes, which are common and benign changes that occur in the breasts. Fibrocystic breast changes can cause discomfort or pain, but they are not tumors and do not increase the risk of developing breast cancer.

Benign lip neoplasms include:

1. Lipoma: a benign tumor composed of fat cells that is usually slow-growing and painless.
2. Pyogenic granuloma: a benign growth caused by an overgrowth of capillaries and inflammatory cells in response to trauma or irritation.
3. Sebaceous gland hyperplasia: an enlargement of the sebaceous glands on the lips, which can cause a soft, keratinized nodule.

Malignant lip neoplasms include:

1. Squamous cell carcinoma: the most common type of malignant lip tumor, which arises from the squamous cells that line the surface of the lips.
2. Basal cell carcinoma: a slow-growing malignancy that originates in the basal cells of the epidermis.
3. Adenoid cystic carcinoma: a rare, aggressive malignancy that usually affects the minor salivary glands of the lips.
4. Melanoma: a rare and highly aggressive malignancy that arises from the pigment-producing cells (melanocytes) in the skin.

The diagnosis of lip neoplasms is based on a combination of clinical examination, imaging studies (such as ultrasound or MRI), and biopsy. Treatment options depend on the type and stage of the neoplasm, but may include surgical excision, radiation therapy, and/or chemotherapy. Early detection and treatment are important to prevent local tissue damage and potential metastasis.

There are several types of facial neoplasms, including:

1. Basal cell carcinoma: This is the most common type of skin cancer and typically appears as a small, fleshy bump or a flat, scaly patch on the face.
2. Squamous cell carcinoma: This type of skin cancer can appear as a firm, flat or raised bump on the face and can be more aggressive than basal cell carcinoma.
3. Melanoma: This is the most serious type of skin cancer and can appear as a dark spot or mole on the face.
4. Sebaceous gland carcinoma: This rare type of facial neoplasm develops in the oil-producing glands of the face.
5. Eyelid tumors: These can include basal cell carcinoma, squamous cell carcinoma, and melanoma, as well as other types of benign tumors such as papillomas and pyogenic granulomas.
6. Parotid gland tumors: These can include pleomorphic adenoma, a type of benign tumor that is the most common parotid gland tumor, and malignant tumors such as pleomorphic carcinoma.
7. Salivary gland tumors: These can include benign tumors such as pleomorphic adenoma and Warthin's tumor, as well as malignant tumors such as mucoepidermoid carcinoma and adenoid cystic carcinoma.
8. Osteosarcoma: This is a rare type of bone cancer that can affect the facial bones.
9. Chondrosarcoma: This is a type of cartilage cancer that can affect the facial bones and can be benign or malignant.
10. Lymphoma: This is a type of cancer that affects the immune system and can occur in various parts of the body, including the face.

Treatment for facial tumors depends on the type, location, and stage of the tumor, as well as the patient's overall health and preferences. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these. Early detection and treatment are important for achieving the best possible outcomes.

Example sentences:

1. The patient developed a radiation-induced neoplasm in their chest after undergoing radiation therapy for breast cancer.
2. The risk of radiation-induced neoplasms increases with higher doses of radiation exposure, making it crucial to minimize exposure during medical procedures.
3. The oncologist monitored the patient's health closely after their radiation therapy to detect any signs of radiation-induced neoplasms.

The most common types of palatal neoplasms include:

1. Ossifying fibroma: A benign tumor that is made up of immature bone cells and usually affects the maxilla (the bone that forms the upper jaw).
2. Malignant ossifying fibroma: A rare and aggressive type of ossifying fibroma that can be cancerous.
3. Benign migratory glossitis: A benign condition characterized by inflammation and ulceration of the tongue, which can sometimes lead to the formation of a tumor on the hard palate.
4. Squamous cell carcinoma: A type of skin cancer that can occur on the hard palate, usually in older adults.
5. Adenoid cystic carcinoma: A rare and slow-growing type of cancer that typically affects the salivary glands but can also occur on the hard palate.

The symptoms of palatal neoplasms can include:

1. Pain or tenderness in the mouth or jaw
2. Difficulty swallowing or speaking
3. Nasal congestion or obstruction
4. Facial pain or swelling
5. Unusual bleeding or discharge from the mouth

Palatal neoplasms are usually diagnosed through a combination of physical examination, imaging studies (such as X-rays or CT scans), and biopsy (the removal of a small sample of tissue for microscopic examination). Treatment options can vary depending on the type and stage of the tumor, but may include surgery, radiation therapy, chemotherapy, or a combination of these.

Prognosis for patients with palatal neoplasms depends on the specific diagnosis and stage of the tumor at the time of diagnosis. In general, early detection and treatment improve outcomes for these types of tumors.

Biliary tract neoplasms refer to abnormal growths or tumors that occur in the biliary tract, which includes the liver, gallbladder, and bile ducts. These tumors can be benign (non-cancerous) or malignant (cancerous).

There are several types of biliary tract neoplasms, including:

1. Cholangiocarcinoma: This is a rare type of cancer that originates in the cells lining the bile ducts. It can occur in the liver or outside the liver.
2. Gallbladder cancer: This type of cancer occurs in the gallbladder and is relatively rare.
3. Hepatocellular carcinoma (HCC): This is the most common type of primary liver cancer, which means it originates in the liver rather than spreading from another part of the body.
4. Bile duct cancer: This type of cancer occurs in the bile ducts that carry bile from the liver and gallbladder to the small intestine.

Biliary tract neoplasms can cause a variety of symptoms, including abdominal pain, jaundice (yellowing of the skin and eyes), weight loss, fatigue, and itching. These symptoms can be non-specific and may resemble those of other conditions, making diagnosis challenging.

Diagnosis of biliary tract neoplasms usually involves a combination of imaging tests such as ultrasound, CT scans, MRI, and PET scans, as well as biopsies to confirm the presence of cancer cells. Treatment options for biliary tract neoplasms depend on the type, size, location, and stage of the tumor, and may include surgery, chemotherapy, radiation therapy, or a combination of these.

Neuroectodermal tumors are relatively rare, accounting for only about 1-2% of all childhood cancers. However, they are a significant cause of morbidity and mortality in children and young adults. These tumors can be benign or malignant, and their behavior and clinical presentation can vary widely depending on the specific type and location of the tumor.

Some common types of neuroectodermal tumors include:

1. Medulloblastoma: This is a type of brain cancer that develops in the cerebellum, typically in children under the age of 10. It is the most common type of pediatric brain cancer and accounts for about 75% of all childhood brain tumors.
2. PNET (Primitive Neuroectodermal Tumor): This is a type of brain tumor that can occur in various parts of the central nervous system, including the brain, spinal cord, and peripheral nerves. PNETs are rare and tend to affect older children and young adults.
3. AT/RT (Askin Tumor/Rhabdoid Tumor): This is a type of brain tumor that typically occurs in infants and young children. It is a rare and aggressive form of cancer that can arise in various parts of the central nervous system.
4. Craniopharyngioma: This is a type of benign tumor that develops near the pituitary gland in the brain. It is relatively rare and tends to affect children and young adults.
5. Ganglioglioma: This is a type of brain tumor that arises from the fusion of ganglion cells and glial cells. It is a rare and benign tumor that can occur in various parts of the central nervous system.

The clinical presentation of neuroectodermal tumors can vary depending on their location, size, and type. Common symptoms include headaches, seizures, vomiting, and changes in behavior or cognitive function. Diagnosis is typically made through a combination of imaging studies (such as MRI or CT scans) and tissue biopsy.

Treatment for neuroectodermal tumors depends on the specific type and location of the tumor, as well as the age and overall health of the patient. Surgery is often the first line of treatment, followed by radiation therapy and/or chemotherapy. In some cases, a combination of these treatments may be necessary to achieve the best possible outcome.

The prognosis for neuroectodermal tumors can vary depending on the specific type and location of the tumor, as well as the age and overall health of the patient. In general, the prognosis for these types of tumors is generally better for children than for adults. With prompt and appropriate treatment, many patients with neuroectodermal tumors can achieve long-term survival and a good quality of life.

"A combined small cell carcinoma of the lung containing three components: small cell, spindle cell and squamous cell carcinoma ... Treatment is similar to small cell lung cancer, but survival rates are much higher than other small-cell carcinomas. Small-cell ... Small-cell carcinoma is most often more rapidly and widely metastatic than non-small-cell lung carcinoma (and hence staged ... Compared to non-small cell carcinoma, small cell carcinoma has a shorter doubling time, higher growth fraction, and earlier ...
Squamous cell carcinoma Small cell carcinoma Adenocarcinoma Large cell carcinoma Adenosquamous carcinoma Sarcomatoid carcinoma ... December 1982). "The clinical behavior of "mixed" small cell/large cell bronchogenic carcinoma compared to "pure" small cell ... combined small cell carcinoma of the lung has been long classified as a subset of small cell carcinoma, and not as a subset of ... reports the finding of small cell carcinoma, regardless of other components, because small cell carcinoma is considered the ...
... (LS-SCLC) is a type of small cell lung cancer (SCLC) that is confined to an area which ... 33% patients with small cell lung cancer are diagnosed with limited-stage small cell lung carcinoma when it is first found. ... can also be associated with small cell lung cancer. Unlike extensive-stage small cell lung cancer, limited-stage small cell ... Unlike extensive-stage small cell lung cancer, limited-stage small cell lung cancer is potentially curable. In limited small ...
Squamous-cell carcinoma (SCC) of the lung is a histologic type of non-small-cell lung carcinoma (NSCLC). It is the second most ... Early squamous-cell carcinoma of the lung (generally as squamous-cell carcinoma in situ) is asymptomatic and may only appear as ... A squamous-cell carcinoma is often preceded for years by squamous-cell metaplasia or dysplasia in the respiratory epithelium of ... Previous variants such as papillary, small-cell and clear-cell SCC were discarded from the current classification as these ...
... is a type of rare lung tumour under the category of poorly differentiated Non-small-cell lung carcinoma ( ... spindle cell carcinoma (almost completely consists of spindle cells), pleomorphic carcinoma (at least 10% spindle/giant cells ... Moran C, Saul S (2010). "Non Small Cell Carcinomas of the Lung". Tumors and Tumor-like Conditions of the Lung and Pleura. ... it can be classified into giant cell carcinoma (almost completely consists of giant cells), ...
It is currently considered to be a subtype of large cell lung carcinoma. LCNEC is often generically grouped among the non-small ... Large cell neuroendocrine carcinoma of the lung (LCNEC) is a highly malignant neoplasm arising from transformed epithelial ... "combined large cell neuroendocrine carcinoma" (c-LCNEC). Travis, William D; Brambilla, Elisabeth; Muller-Hermelink, H Konrad; ... cell lung carcinomas. The World Health Organization classification of lung tumors recognizes a variant of LCNEC, namely " ...
Small-cell carcinoma Squamous cell carcinoma Adenocarcinoma Large-cell carcinoma Adenosquamous carcinoma Sarcomatoid carcinoma ... Only small-cell carcinoma and large-cell carcinoma had shorter average survival.) Most GCCL have already grown and invaded ... By the definition of "large-vs.-small-cell carcinoma", the diameter of GCCL cells must be considerably greater than three times ... Giant-cell carcinoma of the lung (GCCL) is a rare histological form of large-cell lung carcinoma, a subtype of undifferentiated ...
There are two types of neuroendocrine carcinomas of the cervix: small-cell and large-cell. Small-cell carcinoma (SCC) of the ... Large-cell carcinoma (LCC), like small-cell carcinoma (SCC) is very rare and only accounts for about 5% of all cervical cancers ... It resembles small-cell cancer of the lungs and accounts for less than 3% of all cervical cancers. Like small-cell cancer in ... "Because of the distinct natural history of small cell carcinoma of the uterine cervix, and because patients with this condition ...
Squamous cell carcinoma Small cell carcinoma Adenocarcinoma Large cell carcinoma Adenosquamous carcinoma Sarcomatoid carcinoma ... Salivary gland-like carcinomas of the lung generally refers a class of rare cancers that arise from the uncontrolled cell ... Carcinoma is a term for malignant neoplasms derived from cells of epithelial lineage, and/or that exhibit cytological or tissue ... Rossi G, Marchioni A, Sartori1 G, Longo L, Piccinini S, Cavazza A (2007). "Histotype in non-small cell lung cancer therapy and ...
Squamous cell carcinoma Small cell carcinoma Adenocarcinoma Large cell carcinoma Adenosquamous carcinoma Sarcomatoid carcinoma ... In the 1960s, small cell lung carcinoma (SCLC) was recognized as a unique form of lung cancer, based both on its appearance ( ... by volume each of squamous cell carcinoma (SqCC) and adenocarcinoma (AdC) cells. Lung cancers have been historically classified ... Rossi G, Marchioni A, Sartori G, Longo L, Piccinini S, Cavazza A (2007). "Histotype in non-small cell lung cancer therapy and ...
Small, William; Teng, Nelson (1 May 2009). "Uterine Neoplasms". Journal of the National Comprehensive Cancer Network. 7 (5): ... Glassy cell carcinoma of the cervix, also glassy cell carcinoma, is a rare aggressive malignant tumour of the uterine cervix. ... glassy cell carcinoma tumours are composed of cells with a glass-like cytoplasm, typically associated with an inflammatory ... 2004). "Glassy cell carcinoma of the uterine cervix a rare histology. Report of three cases with a review of the literature". ...
... squamous cell carcinoma, malignant melanoma, lymphoma, and small cell carcinoma, or as a benign cyst. Merkel cell carcinomas ... It is also known as cutaneous APUDoma, primary neuroendocrine carcinoma of the skin, primary small cell carcinoma of the skin, ... Media related to Merkel cell carcinoma at Wikimedia Commons National Cancer Institute. "Merkel Cell Carcinoma". National ... "Immunotherapy for Merkel Cell Carcinoma , Merkel Cell Carcinoma". Retrieved 2020-05-14. Clinical trial number NCT01913691 for " ...
LCC is categorized as a type of NSCLC (non-small-cell lung carcinoma) which originates from epithelial cells of the lung. ... Giant-cell carcinoma of the lung Basaloid large cell carcinoma of the lung Clear cell carcinoma of the lung Lymphoepithelioma- ... like carcinoma of the lung Large-cell lung carcinoma with rhabdoid phenotype Large cell neuroendocrine carcinoma of the lung ... LCC is differentiated from small-cell lung carcinoma (SCLC) primarily by the larger size of the anaplastic cells, a higher ...
Small cell carcinoma is a rare (1%) type that cannot be diagnosed using PSA. As of 2009[update] researchers were investigating ... LNCaP cells express AR, but PC-3 and DU-145 cells express very little or no AR. The proliferation of LNCaP cells is androgen- ... Initially, small clumps of cancer cells remain within otherwise normal prostate glands, a condition known as carcinoma in situ ... Nutting C, Horwich A, Fisher C, Parsons C, Dearnaley DP (June 1997). "Small-cell carcinoma of the prostate". Journal of the ...
... classified as a small supernumerary marker chromosome (sSMC), in this malignancy's tumor cells. The sSMC has an isochromosome- ... Transitional cell carcinomas can be very difficult to treat. Treatment for localized stage transitional cell carcinomas is ... meaning a transitional cell carcinomas of the urinary system. Signs and symptoms of transitional cell carcinomas depend on the ... and high grade papillary carcinoma). Papillary transitional cell carcinoma, low grade Histopathology of urothelial carcinoma of ...
Celiac disease Ulcerative colitis Crohn's disease Hepatic cirrhosis Hepatocellular carcinoma Lung cancer, including small cell ... Mignogna MD, Fortuna G, Satriano AR (December 2008). "Small-cell lung cancer and necrolytic migratory erythema". The New ... Wilkinson DS (1973). "Necrolytic migratory erythema with carcinoma of the pancreas". Transactions of the St. John's Hospital ... swollen epidermal cells and necrosis of the superficial epidermis are most characteristic. Immunofluorescence is usually ...
... is typically a squamous cell carcinoma. Other types include adenocarcinoma, small cell carcinoma, and melanoma. ... Most anal cancers are squamous cell carcinomas (epidermoid carcinomas), that arises near the squamocolumnar junction. It may be ... Dewdney A, Rao S (2012). "Metastatic squamous cell carcinoma of the anus: time for a shift in the treatment paradigm?". ISRN ... Human papillomavirus: Examination of squamous cell carcinoma tumor tissues from patients in Denmark and Sweden showed a high ...
... basal cell skin carcinoma, extrapulmonary small cell carcinoma, and EGFR mutation-driven non-small cell lung cancer have been ... Merkel cell carcinomas. MCV can also be found in healthy tissues from people without Merkel cell carcinoma. A complete MCV ... "Merkel cell polyomavirus and extrapulmonary small cell carcinoma". Oncology Letters. 6 (4): 1049-1052. doi:10.3892/ol.2013.1483 ... "Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens". Journal of Virology. 84 ...
Small cell lung carcinoma (SCLC) (FDA Oct 2007). As of 2016, experiments were under way for Neuroblastoma, Brainstem glioma, ... Topotecan is often given in combination with paclitaxel as first line treatment for extensive-stage small-cell lung cancer. ... "FDA Rubber-Stamps APP Pharma's Generic Topotecan for Small Cell Lung and Cervical Cancers". 30 Nov 2010. DNA Topoisomerases and ... In addition, topotecan is experimentally treating Non-small cell lung cancer, Colorectal Cancer, Breast cancer, Non-Hodgkin ...
The two main types are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC). The most common symptoms are ... "Small Cell Lung Cancer Stages". American Cancer Society. 1 October 2019. Retrieved 2 December 2022. "Small Cell Lung Cancer ... In the middle airways, implicated stem cells include club cells and neuroepithelial cells that express club-cell secretory ... small cell lung cancer (SCLC; 15% of lung cancer diagnoses) and non-small-cell lung cancer (NSCLC; 85% of diagnoses). In SCLC, ...
NSE is produced by small-cell carcinomas, which are neuroendocrine in origin. NSE is therefore a useful tumor marker for ... "Molecular characterization of prostatic small-cell neuroendocrine carcinoma". Prostate. 55 (1): 55-64. doi:10.1002/pros.10217. ... distinguishing small-cell carcinomas from other tumors. GRCh38: Ensembl release 89: ENSG00000111674 - Ensembl, May 2017 GRCm38 ... Detection of NSE with antibodies can be used to identify neuronal cells and cells with neuroendocrine differentiation. ...
... being present in the malignant cells of most cases of this disease. Transitional cell bladder carcinomas associated with this ... smaller in size than one of the smaller human chromosomes, chromosome 20. They originate as copies of relatively small parts of ... sSMC i(5)(p10) is the single most common recurrent structural chromosomal abnormality in transitional cell carcinomas of the ... Fadl-Elmula I (August 2005). "Chromosomal changes in uroepithelial carcinomas". Cell & Chromosome. 4: 1. doi:10.1186/1475-9268- ...
Big Rude Jake, 57, Canadian musician, small-cell carcinoma. Tony Boskovic, 89, Australian soccer referee. John Sears Casey, 91 ... squamous cell carcinoma. Miryam Romero, 59, Spanish journalist and television presenter, leukemia. Jim Ryan, 76, American ...
... small cell carcinoma of the prostate, in turn, exhibit a universal type in that virtually all the constituent tumor cells ... June 2006). "Small cell carcinoma of the prostate: an immunohistochemical study". The American Journal of Surgical Pathology. ... Immunohistochemically, prostatic small cell carcinoma are positive for thyroid transcription factor 1 (TTF-1), CD56, ... These types of prostate cancer comprise true neuroendocrine cancers, such as small cell carcinoma, carcinoid and carcinoid-like ...
Ectopic ACTH syndrome, also known as small-cell carcinoma. Ectopic calcification, a pathologic deposition of calcium salts in ... such as small-cell carcinoma, can cause Cushing's syndrome Ectopia lentis, the displacement of the crystalline lens of the eye ...
Syrian hamsters are a model for researching Non-small-cell lung carcinoma, which is one of the types of human lung cancer. In ... "Current role of surgery in small cell lung carcinoma". Journal of Cardiothoracic Surgery. 4 (1): 30. doi:10.1186/1749-8090-4-30 ... Oral squamous-cell carcinoma is a common cancer in humans and difficult to treat. Scientists studying this disease broadly ... The scientist can take cell samples from the mouth of the hamster to measure the development of the cancer. This process has ...
Mary A. McClure, 77, American politician, small-cell carcinoma. Carlos Morocho Hernández, 76, Venezuelan WBA and WBC super ... desmoplastic small-round-cell tumor. Sheilla Lampkin, 70, American politician, member of the Arkansas House of Representatives ... Paddy Phelan, 78, English cricketer (Essex). Anita Reeves, 68, Irish actress (Dancing at Lughnasa, Little Gem), cancer. Wolfram ... sumo's small great 'Wolf,' dies Thomas Edward Danson Jr. Tributes paid to renowned poet and vicar Gwynn ap Gwilym Archived ...
... (NSCLC) is any type of epithelial lung cancer other than small-cell lung carcinoma (SCLC). NSCLC ... Non-Small Cell Lung Cancer at eMedicine "What Is Non-Small Cell Lung Cancer?". www.cancer.org. Smokers defined as current or ... "Non-Small Cell Lung Cancer Signs and Symptoms". www.cancer.org. Retrieved 4 December 2017. "Non-small cell lung cancer". ... "Non-Small Cell Lung Cancer Treatment". National Cancer Institute. 1 January 1980. Retrieved 4 December 2017. "Non-small cell ...
Gronowitz JS, Steinholtz L, Källander CF, Hagberg H, Bergh J (1986). "Serum deoxythymidine kinase in small cell carcinoma of ... is cell cycle-independent. TK1 is synthesized by the cell during the S phase of cell division. After cell division is completed ... Another reason is that lung cancer, particularly small cell lung cancer, is very aggressive with very low five-year survival ... Cells prepare for cell division by making some of the enzymes required during the division. They are not normally present in ...
Hietanen S, Lain S, Krausz E, Blattner C, Lane DP (2000). "Activation of p53 in cervical carcinoma cells by small molecules". ... However, recent data shows that leptomycin causes G1 cell cycle arrest in mammalian cells and is a potent anti-tumor agent ... Cell Res. 242 (2): 540-7. doi:10.1006/excr.1998.4136. PMID 9683540. Nishi K, Yoshida M, Fujiwara D, Nishikawa M, Horinouchi S, ... Leptomycin B was found to cause cell elongation of the fission yeast Schizosaccharomyces pombe. Since then this elongation ...
Cell Dev. Biol. 17 (5): 544-54. doi:10.1016/j.semcdb.2006.09.001. PMID 17071117. Minghetti L, Pocchiari M (2007). " ... small amounts of oxidation products are formed due to the oxygen trapping of an allylic radical intermediate at positions 13 ... "A new cyclo-oxygenase-2 gene variant in the Han Chinese population is associated with an increased risk of gastric carcinoma". ... PTGS2 (COX-2) is unexpressed under normal conditions in most cells, but elevated levels are found during inflammation. PTGS1 ( ...
... carcinoma Small cell carcinoma Neuroendocrine tumour Glassy cell carcinoma Villoglandular adenocarcinoma Though squamous cell ... About 90% of cervical cancer cases are squamous cell carcinomas, 10% are adenocarcinoma, and a small number are other types. ... Histologic subtypes of invasive cervical carcinoma include: Squamous cell carcinoma (about 80-85%) adenocarcinoma (about 15% of ... In medical research, the most famous immortalized cell line, known as HeLa, was developed from cervical cancer cells of a woman ...
... radial arrangements of neoplastic cells around small blood vessel) and nuclear palisading (i.e. parallel arrangements of the ... These cells, which are not myoepithelial cells, have been termed globoid cells. They have eosinophilic cytoplasm (i.e. pink or ... Rarely, invasive SPC occurs with nearby invasive carcinoma of NST, lobular carcinoma, cribriform carcinoma, or tubular ... mucinous carcinoma, or tubular carcinoma tumors. Immunohistochemical analyses of the tumors cells in most individuals with EPC ...
... non-small-cell lung carcinoma, renal cell carcinoma, and breast cancer. The forced over expression of CMTM5-v1 in Huh7 human ... Cai B, Xiao Y, Li Y, Zheng S (August 2017). "CMTM5 inhibits renal cancer cell growth through inducing cell-cycle arrest and ... hepatic cells also inhibited the ability of these cells to grow in a mouse model of cancer. Finally, various cancer human cell ... "Research Advances in CKLF-like MARVEL Transmembrane Domain-containing Family in Non-small Cell Lung Cancer". International ...
Vacuolated, or clear cells are common. Necrosis or cell death is normally observed to some extent in most of these tumors cells ... Since there is such a small number of cases that have been reported, the treatment guidelines have not been established. A ... and metastatic papillary carcinoma. Papillary tumors characteristically show a discrete, compressive border with adjacent ... If the abnormal cells continue to grow, divide, and produce more abnormal cells, the mass of abnormal cells may eventually ...
Cell. 176 (5): 952-965. doi:10.1016/j.cell.2019.01.043. PMID 30794780. Wood AJ, Oakey RJ (November 2006). "Genomic imprinting ... A small number of imprinted genes are fast evolving under positive Darwinian selection possibly due to antagonistic co- ... an imprinted putative tumor suppressor gene in ovarian and breast carcinomas". Proceedings of the National Academy of Sciences ... of the parents and are maintained through mitotic cell divisions in the somatic cells of an organism. Appropriate imprinting of ...
F9 embryonal carcinoma cells are similar to the P19 cells shown in Figure 1 and normally have cell-to-cell adhesion mediated by ... In F9 cells lacking both β-catenin and plakoglobin, very little E-cadherin and α-catenin accumulated at the cell surface. Mice ... A tumor cell line with defective δ-catenin, low levels of E-cadherin and poor cell-to-cell adhesion could be restored to normal ... Catenin and EMT interactions may also play a role in hepatocellular carcinoma. VEGF-B treatment of hepatoma carcinoma cells can ...
A virus-infected cell releases viral particles that can infect nearby cells. However, the infected cell can protect neighboring ... Control of chronic hepatitis C by IFN is associated with reduced hepatocellular carcinoma. Unconfirmed results suggested that ... clinical trials and the preparation of small amounts of interferon messenger RNA to clone the human alpha and beta interferon ... and its expression is restricted to immune cells such as T cells and NK cells. All interferons share several common effects: ...
... grades for esthesioneuroblastoma Esthesioneuroblastoma can resemble small blue cell tumors like squamous cell carcinoma, ... The olfactory epithelium consists of olfactory sensory cells, sustentacular cells and basal cells. Esthesioneuroblastoma ... sinonasal undifferentiated carcinoma, extranodal NK/T cell lymphoma, nasal type, rhabdomyosarcoma, Ewing/PNET, mucosal ... Radiotherapy alone is reserved only for small lesions not appropriate for either surgery or chemotherapy. Both photon and ...
... squamous cell carcinoma and melanoma via cell cycle control. Recent genome-wide association studies (GWAS) have provided ... June 2007). "A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing". Cell. 129 (7): 1401-14. doi:10.1016/ ... Analysis of promoter methylation in oral rinses of patients with squamous cell carcinoma of the head and neck showed that miR- ... miR-137 is shown to regulate neural stem cell proliferation and differentiation in mouse embryonic stem cells, and neuronal ...
... carcinoid Pulmonary Typical bronchial carcinoid Atypical bronchial carcinoid Large cell neuroendocrine carcinoma Small cell ... tumors Non-functioning endocrine pancreatic tumors Insulinoma Gastrinoma Glucagonoma VIPoma Adrenals Adrenocortical carcinoma ...
However, little is known about its exact function. CD34 is also an important adhesion molecule and is required for T cells to ... and papillary thyroid carcinoma. A negative CD34 may exclude Ewing's sarcoma/PNET, myofibrosarcoma of the breast, and ... as a cell surface glycoprotein and functions as a cell-cell adhesion factor. It may also mediate the attachment of ... Cells expressing CD34 (CD34+ cell) are normally found in the umbilical cord and bone marrow as haematopoietic cells, or in ...
The genes that currently have evidence to be associated with CMM disorder include DCC (deleted in colorectal carcinoma), DNAL4 ... The congenital mirror movements begin in infancy and persist throughout the patient's life, often with very little improvement ... "Non cell-autonomous role of DCC in the guidance of the corticospinal tract at the midline". Scientific Reports. 7 (1): 410. ... a protein thought to be responsible for axon guidance and neuronal cell migration during development. A mutation of this gene ( ...
... in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/ ... the first-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumors express PD-L1 with a ≥ 50% ... Results of a Phase II clinical trial in Merkel-cell carcinoma were reported in The New England Journal of Medicine in June 2016 ... the first-line treatment of advanced renal cell carcinoma (RCC) in adults in combination with axitinib. In June 2020, the U.S. ...
"Galectin-9 as a regulator of cellular adhesion in human oral squamous cell carcinoma cell lines". International Journal of ... "Expression profiles and clinical value of plasma exosomal Tim-3 and Galectin-9 in non-small cell lung cancer". Biochemical and ... Moreover, galectin-9 contributed to tumorigenesis by tumor cell transformation, cell-cycle regulation, angiogenesis, and cell ... and hepatocellular carcinoma. HAVCR2/ galectin-9 interaction attenuated T-cell expansion and effectors function in tumor ...
... suppresses the generation of blood vessels in tumors and slows down cancer cell growth. Years later, a small molecule inhibitor ... from which a derivative was approved in 2006 for the treatment of kidney carcinoma and gastro-intestinal stromal tumors. 2005 ... The simultaneous inhibition of these targets therefore leads to both reduced tumor vascularization and cancer cell death, and ... gene transcripts of a large number of tumor cell lines and primary tumors. The laboratory also focuses on functional ...
Even rarer neoplasms include sarcoma, squamous cell carcinoma, yolk sac tumor, neuroendocrine carcinoma, paraganglioma, ... via a small outpouching near the developing prostate, the seminal vesicles. Sertoli cells secrete anti-mullerian hormone, which ... The glands are lined with column-shaped and cuboidal cells. The vesicles are present in many groups of mammals, but not ... When viewed under a microscope, the cells are seen to have large bubbles in their interior. This is because their interior, ...
As the incidence of basal-cell carcinoma and squamous-cell carcinoma is rising and about 80% are located in the head and neck ... Small defects can be filled with morcellized bone, which will consolidate in some weeks. Because of the anatomy of the skull, ... As the incidence of basal cell carcinoma and squamous-cell carcinoma rises, so does the need for reconstructions after radical ... By using Mohs surgery the defect can be kept minimal, but nevertheless infiltrative basal cell carcinoma may have the need to ...
... most cells looked fairly normal and there was no evidence of mitosis which would indicate that cells were rapidly dividing), ... This will result in compression of organs and will destroy the function of the colon, small intestine, stomach, or other organs ... While the majority of these cases are associated with appendiceal carcinomas, other conditions may also be found, including ... irregular cells, evidence that cells were rapidly dividing, and other criteria), with or without an associated primary mucinous ...
Several cell types or tissues, e.g. osteoblasts, chondrocytes, cardiac tissue, gastrointestinal smooth muscle cells, and ... There Is too little experience on the treatment of LECT2 amyloidosis (ALECT2) to establish recommendations. There is no ... of individuals with Hepatocellular carcinoma. In the latter form of liver cancer, LECT2 levels increase with increasingly poor ... However, its expression in these cells is extremely low or undetectable even though these cells express very high levels of ...
Hemosiderosis is hemosiderin deposition within cells, while hemochromatosis is hemosiderin within cells and interstitium. ... Liver biopsy is the removal of small sample in order to be studied and can determine the cause of inflammation or cirrhosis. In ... The presence of cirrhosis increases the risk of hepatocellular carcinoma. HHC is most common in certain European populations ( ... A diet low in iron is generally recommended, but has little effect compared to venesection. The human diet contains iron in two ...
... there is still little conclusive data that explains the occurrence of spontaneous regression." Apoptosis (programmed cell death ... carcinoma). Frequency was estimated to be about 1 in 100,000 cancers; however, this proportion might be an under- or an ... It is likely that the frequency of spontaneous regression in small tumors has been drastically underrated. In a carefully ... Indeed, in many cancer cells apoptosis is defective, and angiogenesis is activated, both of these effects being caused by ...
... showed that small molecules can be used to cleave RNA targets in cells and also importantly demonstrated that designer small ... "Small Molecule Targeting of a MicroRNA Associated with Hepatocellular Carcinoma". ACS Chemical Biology. 11 (2): 375-80. doi: ... Guan, Lirui; Disney, Matthew D (2013). "Small-Molecule-Mediated Cleavage of RNA in Living Cells". Angewandte Chemie ... RNA-targeting small molecules represent a class of small molecules, organic compounds with traditional drug properties (e.g., ...
... , sold under the brand name Gilotrif among others, is a medication used to treat non-small cell lung carcinoma (NSCLC ... It has received regulatory approval for use as a treatment for non-small cell lung cancer, although there is emerging evidence ... Vavalà T (2017). "Role of afatinib in the treatment of advanced lung squamous cell carcinoma". Clinical Pharmacology. 9: 147- ... May 2012). "Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of ...
The small intestine consists of the duodenum, jejunum and ileum. Inflammation of the small intestine is called enteritis, which ... Congenital disorders of the stomach include pernicious anaemia, in which a targeted immune response against parietal cells ... "Epigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma: disease and treatments". World Journal of ... 848 The small and large intestines may be affected by infectious, autoimmune, and physiological states. Inflammation of the ...
Côté JF, Vuori K (August 2007). "GEF what? Dock180 and related proteins help Rac to polarize cells in new ways". Trends in Cell ... which function as activators of small G proteins. Dock11 activates the small G protein Cdc42. Dock11 was identified as a ... "Improved gene expression signature of testicular carcinoma in situ". International Journal of Andrology. 30 (4): 292-302, ... Meller N, Merlot S, Guda C (November 2005). "CZH proteins: a new family of Rho-GEFs". Journal of Cell Science. 118 (Pt 21): ...
Cell. 138 (1): 63-77. doi:10.1016/j.cell.2009.06.030. PMC 2720686. PMID 19596235. Denner J, Eschricht M, Lauck M, Semaan M, ... Heart-type Fatty Acid-Binding Protein (H-FABP) is a small cytoplasmic protein (15 kDa) released from cardiac myocytes following ... "Expression of heart-type fatty acid-binding protein in human gastric carcinoma and its association with tumor aggressiveness, ... Cell. 122 (6): 957-68. doi:10.1016/j.cell.2005.08.029. hdl:11858/00-001M-0000-0010-8592-0. PMID 16169070. S2CID 8235923. ...
... signaling and they are implicated as potent oncogenes in the embryonal carcinoma cell. The protein encoded by this gene ... However, the N-terminal part of human Gli2 is much smaller than its mouse or frog homologs, suggesting that it may lack ... "Expression of the GLI2 oncogene and its isoforms in human basal cell carcinoma". The British Journal of Dermatology. 148 (5): ... resembling those of basal cell carcinoma (BCC). Unlike Gli1 transgenic mice, Gli2 transgenic mice only developed BCC-like ...
... all-trans retinoic acid dependent expression of HOXB and HOXC homeogenes in human embryonal and small-cell lung carcinoma cell ... Scott MP (November 1992). "Vertebrate homeobox gene nomenclature". Cell. 71 (4): 551-3. doi:10.1016/0092-8674(92)90588-4. PMID ...
... s can be defined as an irregular neck mass or a lump which develops from cells and tissues left over after the ... In some individuals, portions of the duct remain behind, leaving small pockets, known as cysts. During a person's life, these ... Ali M.; Abussa A.; Hashmi H. (2007). "Papillary thyrpid carcinoma formation in a thyroglossal cyst. A case report". Libyan ... These tumors are generally papillary thyroid carcinomas, arising from the ectopic thyroid tissue within the cyst. Thyroglossal ...
... also called oat cell carcinoma, can create its own hormones, which alter body chemistry. ... Small cell carcinoma, also called oat cell carcinoma, can create its own hormones, which alter body chemistry. ...
... however most of non-small cell lung cancer tumours are not sensitive to this treatment. As an alternative to chemoterapy, ... Chemotherapy is the standard care for the treatment of non-small cell lung carcinoma (NSCLC) patients, ... Point-of-care blood device for fast and reliable prediction of drug response in non- small-cell lung carcinoma patients from ... Chemotherapy is the standard care for the treatment of non-small cell lung carcinoma (NSCLC) patients, however most of non- ...
Small cell carcinoma. Definition: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid ... Synonyms (terms occurring on more labels are shown first): small cell carcinoma, oat-cell carcinoma More information: PubMed ... cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. ( ...
As a skilled psychologist, she is always obsessed with her handsome husband, who has relationships beyond her control. While the whole day she was only busy with work and patients with psychological instability, her husband often goes back and forth on business trips away from the builders. Obsessed with the day he will lose him, so even after turning 40, she still tried to give birth to a son to suit his wishes. But unfortunately, the difficult birth led her to illness. And from there, she became increasingly stressed with baseless fantasies. She surrounded him everywhere with talented spies.. ...
X-ray irradiation induced Disabled-2 gene promoter de-methylation enhances radiosensitivity of non-small-cell lung carcinoma ... X-ray irradiation induced Disabled-2 gene promoter de-methylation enhances radiosensitivity of non-small-cell lung carcinoma ... DNMT3b and MeCP2 could be detected in both LK2 and SPC-A-1 cells compared to non-irradiated cells (P , 0.05). Both in vitro ... Bisulfite sequencing PCR (BSP) was used to evaluate the methylation status of lung cancer cells with or without X-ray treatment ...
Small cell neuroendocrine carcinoma of the endometrium]. [Small cell neuroendocrine carcinoma of the endometrium]. / ... The article describes a rare case of small cell neuroendocrine carcinoma of the endometrium in a 67-year-old woman. According ... Carcinoma de Células Pequenas/genética; Carcinoma de Células Pequenas/patologia; Endométrio/metabolismo; Carcinoma ... Histological examination revealed three necessary features the small-cell nature of the tumor, the presence of epithelial and ...
SMALL CELL CARCINOMA NRG-LU002. Study #LU002 Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus ... Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial ...
Long non-coding RNA dysregulation is a frequent event in non-small cell lung carcinoma pathogenesis. 05 February 2020 ... We excluded patients with microsatellite unstable tumours, because these are a small subset of sporadic CRCs with different ... Integrated whole transcriptome and small RNA analysis revealed multiple regulatory networks in colorectal cancer. 14 July 2021 ... earlier studies have reported that c-Myc has conflicting apoptosis-induction and cell proliferation roles in normal and tumour ...
Small cell carcinoma of the urinary bladder: virtual CT cystoscopic findings.. Authors: Tsili, A C. Giannakis, D. Sofikitis, N ... Tsili AC, Giannakis D, Sofikitis N, Tsampoulas K. Small cell carcinoma of the urinary bladder: virtual CT cystoscopic findings ... Radical cystectomy was performed and pathology reported pure small cell carcinoma of the urinary bladder. ...
Pathological examination of an excisional mediastinal lymph node biopsy showed thymic small cell carcinoma, supporting a ... A review of the literature reveals that this is the first case report of a patient with thymic small cell cancer presenting ... Repairing and Protecting Effects of Pneumatophorus japonicus heads peptides on GES-1 Cells Damaged by Alcohol. ... Caveolin-1 inhibits proliferation and migration of gastric cancer cell via inactivating BMI-1 ...
The preferred method of imaging renal cell carcinomas is dedicated renal computed tomography (CT). In most cases, this single ... Case 3. Small left renal cell carcinoma is subtle on this intravenous urographic image. View Media Gallery ... Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer Genome Atlas-Renal Cell Carcinoma (TCGA- ... Clear cell renal cell carcinoma: discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic ...
title = "Metastatic calcinosis in small cell ovarian carcinoma, hypercalcemic type",. abstract = "Small cell carcinoma of the ... Metastatic calcinosis in small cell ovarian carcinoma, hypercalcemic type. / Farukhi, Irfan M.; Erdman, William A. In: Clinical ... Small cell carcinoma of the ovary, hypercalcemic type, can lead to metastatic calcinosis - the deposition of calcium in the ... Metastatic calcinosis in small cell ovarian carcinoma, hypercalcemic type. Clinical Nuclear Medicine. 2005 Jun 1;30(6):429-430 ...
small cell carcinoma. *neuroendocrine tumors. *transitional cell carcinomas. Prostate cancer is the most common form of cancer ... Prostate cancer occurs when cells in the prostate gland start to grow uncontrollably. Some prostate nodules can be cancerous, ... There are different types of prostate cancer, depending on which cells they appear in. ...
Pathologic Findings in Small Cell Bladder Carcinoma * 2001/s/viewarticle/995278. How Newly Discovered Genes Might Fit Into ... Therapy for Patients With Non-Small Cell Lung Cancer in the Absence of Genomic Mutations ... "That said, many researchers have long been pointing out that the level of risk genetic information can convey is very small," ...
Carcinoma, Non-Small-Cell Lung. Respiratory Tract Neoplasms. Thoracic Neoplasms. Neoplasms by Site. Neoplasms. Lung Diseases. ... Non-small Cell Lung Cancer (NSCLC) Drug: Atezolizumab Drug: Tiragolumab Drug: Durvalumab Phase 3 ... Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03). The safety and scientific validity of this study is ... unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based ...
Carcinoma, Non-Small-Cell Lung. Respiratory Tract Neoplasms. Thoracic Neoplasms. Neoplasms by Site. Neoplasms. Lung Diseases. ... A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC). The safety and ... This is a phase 2 study of the HSP90 inhibitor, STA-9090 (ganetespib) in subjects with stage IIIB or IV non-small cell lung ... Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung ...
STK1p as a prognostic biomarker for overall survival in non-small cell lung carcinoma, based on real-world-data..docx ... Supplementary Data: STK1p as a prognostic biomarker for overall survival in non-small cell lung carcinoma, based on real-world- ... STK1p as a prognostic biomarker for overall survival in non-small cell lung carcinoma, based on real-world-data. ... STK1p as a prognostic biomarker for overall survival in non-small cell lung carcinoma, based on real-world-data. ...
Pathologic Findings in Small Cell Bladder Carcinoma * 2001/viewarticle/992689. Genes Dont Explain Worse Prostate Cancer ... No driver mutations were seen in a high proportion of patients with chromophobe renal cell carcinoma and pancreatic ... Driver point mutations played a major role in colorectal adenocarcinomas and mature B-cell lymphomas. Many driver mutations ... and it was able to identify mutations in roughly 20,000 protein-coding genes in the human cell. And in the next 10 years, the ...
However, a limitation of microscopy is that only a small number of biomarkers can typically be monitored simultaneously. Thus, ... Carcinoma, Non-Small-Cell Lung * Cell Line, Tumor * Computational Biology / methods * Flow Cytometry / methods ... How much information about a cells phenotypic state in one biomarker is gained by knowing its state in another biomarker? Here ... However, a limitation of microscopy is that only a small number of biomarkers can typically be monitored simultaneously. Thus, ...
Incorrect: The histology was small-cell carcinoma of the lung.. Correct: The histologic diagnosis was small-cell carcinoma of ... Morphology is not a synonym for shape, and such statements as "The cell showed a flat morphology" are wrong. In this example, ... For the term "large T-antigen," use a capital letter "T"; for the term "small t-antigen," use a lowercase letter "t." ... The procedure of removing and examining tissue, cells, or fluids from the living body. Observations are made on the biopsy ...
Pathologic Findings in Small Cell Bladder Carcinoma * Fast Five Quiz: Genomic Medicine - CRISPR Gene Editing ... Therapy for Patients With Non-Small Cell Lung Cancer in the Absence of Genomic Mutations ... Hepatocellular carcinoma complicating liver cirrhosis in type IIIa glycogen storage disease. J Clin Gastroenterol. 2000 Jul. 31 ... Glycogen storage disease type III-hepatocellular carcinoma a long-term complication?. J Hepatol. 2007 Mar. 46(3):492-8. [QxMD ...
lung non-small cell carcinoma. IDs. lung non-small cell carcinoma DOID:3908. EFO:0003060. KEGG:05223. MESH:D002289. NCI:C2926. ... Click on grid cells to view annotations.. *Blue cells = expressed in wild-type.. Gray triangles = other expression annotations ... hepatocellular carcinoma DOID:684. DOID:5005. EFO:0000182. ICD10CM:C22.0. MESH:D006528. NCI:C3099. OMIM:114550. ORDO:88673. ...
Carcinoma, Non-Small-Cell Lung. *Mesothelioma. Anatomical therapeutic chemical (ATC) code L01BA04 ... advanced non-small-cell lung cancer of the kind known as non-squamous, where it is used either in combination with cisplatin ... Non-small cell lung cancer. Ciambra in combination with cisplatin is indicated for the first line treatment of patients with ... Ciambra is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer ...
Adenocarcinomas and squamous cell carcinomas are two types of non-small cell lung cancer. A few (6% to 8%) are small cell lung ... are squamous cell carcinomas (cancer that forms in the thin, flat cells lining the inside of the lungs). ... cancer that begins in the cells that line the lungs tiny air sacs and make substances such as mucus). About 10% to 20% ...
Stage 0 (carcinoma in situ): Abnormal cells are found in the tiny tubules where sperm cells begin to develop. These abnormal ... Stage 0 is also called carcinoma in situ.. Stage IA: Cancer is in the testicle and epididymis (tube connecting ducts in rear of ... A tissue sample from the testicle is examined under a microscope to determine the presence of testicular cancer cells and the ... Lactate dehydrogenase (LDH): This enzyme is related to increased energy production by the bodys cells and tissues, which ...
Non-squamous non-small cell lung cancer. • Recurrent glioblastoma. • Renal cell carcinoma ... Reduction of allogeneic red blood cell transfusion in anemic patients undergoing surgery ...
... nine were small cell anaplastic carcinomas; six were adenocarcinoma, bronchogenic type; two were adenocarcinoma, bronchiolar ... and three were large cell undifferentiated carcinomas. Among the 25 lung cancer patients, 17 were smokers at the time of ... In 25 of the cases, the primary site of malignancy was the lung: five of these malignancies were epidermoid carcinomas; ... Histopathologic classification of bronchogenic carcinomas among a cohort of workers occupationally exposed to beryllium. ...
The small-molecule KIT inhibitor suntinib is approved as a treatment for renal cell carcinoma, as a second-line medication for ... especially hematopoietic stem cells, and serve to identify those cells to antibodies and to communicate with other cells. ... tiny.cc/zeou1, tiny.cc/pa0i3, tiny.cc/6wjgg ... non-small cell lung cancer; ER, estrogen receptor; PgR, ... Another antibody that inhibits KIT is pazopanib (Votrient), which was approved for the treatment of renal cell carcinoma 2 ...
Nivolumab for Small Cell Lung Cancer. Closing out 2020, Bristol Myers Squibb announced their decision to withdraw the ... Durvalumab for Urothelial Carcinoma. On February 22, 2021, AstraZeneca decided to withdraw the indication for durvalumab ( ... Pembrolizumab for Small Cell Lung Cancer. On March 1, 2021, Merck voluntarily withdrew the US indication for pembrolizumab ( ... for the treatment of patients with small cell lung cancer (SCLC) whose disease has progressed after platinum-based chemotherapy ...
... renal cell carcinoma (RCC; n = 23), non-small cell lung cancer (NSCLC; n = 21), or hepatocellular carcinoma (HCC; n = 30), ... Interleukin-8 (IL8) is a chemokine produced by malignant cells of multiple cancer types. It exerts various functions in shaping ... IL8 levels were monitored by sandwich ELISAs in cultured tumor cells supernatants, tumor-xenografted mice serum, and in samples ... IL8 concentrations correlated with the number of IL8-producing tumor cells in culture. In xenografted neoplasms, IL8 serum ...
  • Chemotherapy is the standard care for the treatment of non-small cell lung carcinoma (NSCLC) patients, however most of non-small cell lung cancer tumours are not sensitive to this treatment. (europa.eu)
  • Serum specimens from 51 patients with non-small cell lung cancer (NSCLC) and from 50 healthy volunteers were collected. (nih.gov)
  • The expression and genetic methylation patterns of NMDAR2B in non-small cell lung cancer (NSCLC) are unknown. (biomedcentral.com)
  • The relationship between gene methylation and expression of NMDAR2B was analyzed in NSCLC cell lines (N = 9) and clinical tissues (N = 216). (biomedcentral.com)
  • Although surgical techniques and perioperative managements have progressed, the prognosis of patients with non-small cell lung cancer (NSCLC) remains poor. (biomedcentral.com)
  • Pathologically, it is categorized into two types: Small cell lung cancer (SCLC) and non-SCLC (NSCLC). (spandidos-publications.com)
  • NSCLC consists of several types of cancer, including adenocarcinoma (the most common type), squamous carcinoma, large cell undifferentiated carcinoma, bronchioalveolar carcinoma and neuroendocrine tumors ( 2 ). (spandidos-publications.com)
  • The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression. (clinicaltrials.gov)
  • This is a phase 2 study of the HSP90 inhibitor, STA-9090 (ganetespib) in subjects with stage IIIB or IV non-small cell lung cancer (NSCLC). (clinicaltrials.gov)
  • Adults age 18 and older who had EGFR-mutated non-small-cell lung carcinoma (NSCLC) that was treated and now transformed to SCLC or another neuroendocrine tumor. (nih.gov)
  • Subjects with initial diagnosis of EGFR-mutated non-small-cell lung carcinoma (NSCLC) and histologically or cytologically confirmed transformation to small cell or neuroendocrine tumor following treatment with EGFR tyrosine kinase inhibitor. (nih.gov)
  • Also, 27,527 patients with squamous cell carcinoma of the cervix and 5,231 patients with adenocarcinoma of the cervix were identified for comparison. (nih.gov)
  • The mean annual incidence for small cell carcinoma was 0.06 per 100,000 women, compared with 6.6 and 1.2 for squamous cell carcinoma and adenocarcinoma, respectively. (nih.gov)
  • [ 5 ] and an elderly Czech patient with mantle cell lymphoma and prostate adenocarcinoma. (medscape.com)
  • However, aberrant methylation was an independent prognostic factor in squamous cell carcinoma cases. (biomedcentral.com)
  • The prognosis was significantly better for cases of squamous cell carcinoma in which NMDAR2B was methylated. (biomedcentral.com)
  • 9. Results of surgical salvage after failure of definitive radiation therapy for early-stage squamous cell carcinoma of the glottic larynx. (nih.gov)
  • 20. Level IIb lymph node metastasis in laryngeal squamous cell carcinoma. (nih.gov)
  • About 10% to 20% are squamous cell carcinomas (cancer that forms in the thin, flat cells lining the inside of the lungs). (cdc.gov)
  • Adenocarcinomas and squamous cell carcinomas are two types of non-small cell lung cancer. (cdc.gov)
  • An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. (embl.de)
  • The present study aimed to estimate the profile of patients with bronchogenic carcinoma and assess the cancer resectability in newly diagnosed patients. (spandidos-publications.com)
  • A total of 800 patients with bronchogenic carcinoma were included. (spandidos-publications.com)
  • In conclusion, bronchogenic carcinoma is rapidly increasing without a predilection for sex in the Iraqi population. (spandidos-publications.com)
  • Despite the significant increase in lung cancer incidence in recent decades in Iraq, there are only a few small sample-sized studies focused on the profile of bronchogenic carcinoma ( 1 , 7 ). (spandidos-publications.com)
  • Transarterial chemoembolization(TACE) is the suggested treatment for hepatocellular carcinoma (HCC) not amenable to curative treatments. (frontiersin.org)
  • Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third common cause of cancer deaths in 2020 ( 1 ). (frontiersin.org)
  • A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA). (nih.gov)
  • Small cell carcinoma is a rare histology of cervical cancer associated with a worse prognosis and a predilection for nodal and distant metastasis. (nih.gov)
  • Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. (scienceopen.com)
  • Prophylactic oophorectomy can prevent small cell carcinoma of the ovary, hypercalcemic type in carriers of germline SMARCA4 mutations. (nih.gov)
  • The dilemma of early preventive oophorectomy in familial small cell carcinoma of the ovary of hypercalcemic type. (nih.gov)
  • Small cell carcinoma of the ovary, hypercalcemic type, can lead to metastatic calcinosis - the deposition of calcium in the alkaline walls of acid-secreting organs. (elsevierpure.com)
  • Here, we aim to study if X-ray irradiation can induce de-methylation of the Dab2 gene and subsequently up-regulate its expression, and also to attempt to suppress the malignant biological behavior of and enhance the radiosensitivity in lung cancer cells with hypermethylation of the Dab2 gene. (duke.edu)
  • Colony Formation, matrigel invasion and xenograft experiment were performed to evaluate the malignant biological behavior of lung cancer cells with irradiation. (duke.edu)
  • A rapid screening process identified a two-drug combination that shrank small-cell lung tumors, which are often fatal within weeks of recurrence. (nih.gov)
  • The researchers also tested the drug combination in 10 people with related rare tumors called small-cell neuroendocrine cancers, which can arise in other organs such as the breast and bladder. (nih.gov)
  • Its specificity in differentiating between neuroendocrine and nonneuroendocrine tumors, its sensitivity to detect small tumors, and its clinical value, compared with other neuroendocrine markers, have not clearly been defined, however. (nih.gov)
  • Bisulfite sequencing PCR (BSP) was used to evaluate the methylation status of lung cancer cells with or without X-ray treatment. (duke.edu)
  • X-ray treatment significantly inhibits proliferation and invasion of lung cancer cells with hypermethylation of the Dab2 gene promoter, but is less effective in lung cancer cells with hypomethylation of the Dab2 gene promoter. (duke.edu)
  • These results indicate that the methylation status of the Dab2 gene promoter might be a potential predictor of the radiosensitivity of lung cancer cells. (duke.edu)
  • Small cell lung cancer (SCLC) is a recalcitrant cancer as defined by its five-year relative survival rate of less than seven percent and the loss of approximately 30,000 lives per year. (nih.gov)
  • U01), and PAR-16-051, Innovative Approaches to the Prevention and Early Detection of Small Cell Lung Cancer (U01). (nih.gov)
  • In a pilot clinical trial, almost two-thirds of people who received the combination to treat recurrent small-cell lung cancer lived for at least six months. (nih.gov)
  • About 13% of people with lung cancer have a type called small-cell lung cancer (SCLC). (nih.gov)
  • Results were published on April 12, 2021, in Cancer Cell . (nih.gov)
  • Cancer cells divide quickly, racing past the checkpoints that normal cells use to repair DNA damage. (nih.gov)
  • A review of the literature reveals that this is the first case report of a patient with thymic small cell cancer presenting with PLE. (siftdesk.org)
  • 13. Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. (nih.gov)
  • To compare M6620 plus topotecan to topotecan alone in people with small cell lung cancer (SCLC). (nih.gov)
  • Also, to test the effects of M6620 plus topotecan in people with small cell cancer outside the lungs. (nih.gov)
  • It is optional for those with small cell cancer outside the lungs. (nih.gov)
  • Outside of the lungs small cell cancer participants will be assigned to receive both drugs. (nih.gov)
  • However, few datasets are available for small cell lung cancer (SCLC) due to the scarcity of fresh tumor samples. (elsevierpure.com)
  • Prostate cancer occurs when cells in the prostate gland start to grow uncontrollably. (medicalnewstoday.com)
  • There are different types of prostate cancer, depending on which cells they appear in. (medicalnewstoday.com)
  • SCLC is known as oat cell cancer owing to the packed nature of the small dense cells. (spandidos-publications.com)
  • About 50% to 60% of lung cancers found in people who never smoked are adenocarcinomas (cancer that begins in the cells that line the lung's tiny air sacs and make substances such as mucus). (cdc.gov)
  • A few (6% to 8%) are small cell lung cancers, and the rest are other types of lung cancer. (cdc.gov)
  • 16. Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. (nih.gov)
  • X-ray irradiation induced Disabled-2 gene promoter de-methylation enhances radiosensitivity of non-small-cell lung carcinoma cells. (duke.edu)
  • The cell lines were studied using RT-PCR and 5-aza-2'-deoxycytidine treatment, while the clinical tissues were examined by methylation specific real-time quantitative PCR and immunohistochemistry. (biomedcentral.com)
  • Methylation is closely involved in the development of various carcinomas. (elsevierpure.com)
  • Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. (nih.gov)
  • Small cell cancers are aggressive and grow fast. (nih.gov)
  • Lung cancers with EGFR mutations may develop resistance to therapies targeting this protein by evolving/being transformed into small cell or neuroendocrine cancers. (nih.gov)
  • 17. [Primary large cell neuroendocrine carcinoma of the kidney: morphologic and immunohistochemical features of two cases]. (nih.gov)
  • I guess Metastatic Poorly Differentiated small cell neuroendocrine Carcinoma, multiple liver mets. (mayoclinic.org)
  • From 1977 to 2003, 290 women with small cell carcinoma of the cervix uteri were identified from the Surveillance, Epidemiology, and End Results database. (nih.gov)
  • Supplementary Data: STK1p as a prognostic biomarker for overall survival in non-small cell lung carcinoma, based on real-world-data. (figshare.com)
  • GABABR-Mediated Paraneoplastic Limbic Encephalitis Due To Thymic Small Cell Carcinoma. (siftdesk.org)
  • Pathological examination of an excisional mediastinal lymph node biopsy showed thymic small cell carcinoma, supporting a diagnosis of paraneoplastic limbic encephalitis (PLE). (siftdesk.org)
  • To compare the incidence, mortality, and presentation of small cell carcinoma of the cervix with other histologies. (nih.gov)
  • Subjects should have received platinum-based chemotherapy with or without immunotherapy for small cell/neuroendocrine transformation or refused such therapy. (nih.gov)
  • In addition, paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis. (nih.gov)
  • In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving paclitaxel. (nih.gov)
  • IMSEAR at SEARO: Small cell carcinoma of the urinary bladder: virtual CT cystoscopic findings. (who.int)
  • Tsili AC, Giannakis D, Sofikitis N, Tsampoulas K. Small cell carcinoma of the urinary bladder: virtual CT cystoscopic findings. (who.int)
  • Radical cystectomy was performed and pathology reported pure small cell carcinoma of the urinary bladder. (who.int)
  • These results strongly suggest that H2O2 production by PAO has a role in CPENSpm cytotoxicity in sensitive cells via PCD and demonstrate a potential basis for differential sensitivity to this promising new class of antineoplastic agents. (nih.gov)
  • Histological examination revealed three necessary features the small- cell nature of the tumor , the presence of epithelial and neuroendocrine markers. (bvsalud.org)
  • The major goals of this project are to define the biochemistry of chloride and sodium transport in airway epithelial cells and clone the gene(s) involved in transport. (nih.gov)
  • The major goals of this project are to identify and isolate airway epithelium progenitor cells and express human CFTR in airway epithelial cells. (nih.gov)
  • The coordinating center grant was awarded in February 2017 and has a hub for models and molecular profiling, an extensive number of cell lines, and a clinical correlates database. (nih.gov)
  • Since this effect was seen at concentrations of the drugs known to be safe in people, the team rapidly moved the combination into a small clinical trial. (nih.gov)
  • The major goals of this project are to use viral strategies to express the normal p53 gene in human SCLC cell lines and to study the effect on growth and invasiveness of the lines. (nih.gov)
  • A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. (nih.gov)
  • [ 10 ] The majority of primary cases in this series (12 cases) were DLBCLs, with smaller numbers of SLL (4 cases), follicular lymphoma (4 cases), and Burkitt lymphoma (2 cases). (medscape.com)
  • 15. Primary small cell neuroendocrine carcinoma of the larynx. (nih.gov)
  • [ 1 ] They found 1.2% of cases involved leukemia or lymphoma: nine chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLLs), three Hodgkin lymphomas, and one hairy cell leukemia. (medscape.com)
  • [ 2 ] They found that 29 (0.6%) cases demonstrated involvement by leukemia or lymphoma: 17 CLL/SLLs, three marginal-zone lymphomas, three mantle cell lymphomas, one diffuse large B-cell lymphoma (DLBCL), and four follicular lymphomas. (medscape.com)
  • CPENSpm treatment results in the superinduction of the polyamine catabolic enzyme spermidine/spermine N1-acetyltransferase (SSAT) in sensitive cell types and has been demonstrated to induce programmed cell death (PCD). (nih.gov)
  • Small cell esophageal carcinoma is a type of small cell neuroendocrine carcinoma (SCNEC). (elsevier.com)
  • A MEDLINE search was done, using the terms 'small cell carcinoma' or 'oat cell carcinoma' combined with 'gastrointestinal' or with any of the GI sites, for the period 1970 to 2003. (scienceopen.com)
  • These cell lines were established and kindly provided by Dr. Adi Gazdar of the University of Texas Southwestern Medical Center. (biomedcentral.com)
  • This award supports the PI's program to map and clone the gene(s) implicated in the development of Alzheimer's disease and to target expression of the cloned gene(s) to relevant cells. (nih.gov)
  • Sixty-seven cases of small cell lung carcinoma (SCLA) in Tri-Service General Hospital (TSGH) during the past 16 years were studied. (tmu.edu.tw)
  • 12. Large cell neuroendocrine carcinoma of the larynx: a case report and a review of the classification of this neoplasm. (nih.gov)